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Challenges in the Discovery and Optimization of Metabotropic Glutamate 2/4 
Heterodimer Positive Allosteric Modulators 
Introduction 
 
 
Metabotropic Glutamate Receptor Structure and Function 
The metabotropic glutamate (mGlu) receptors are G protein-coupled 
receptors (GPCRs) that are widely distributed throughout the central nervous system 
(CNS). While the exact number varies, more than 800 GPCRs have been identified 
in humans and comprise ~4% of our genome1-4. GPCRs also comprise a large 
portion of targets for Food and Drug administration (FDA) approved drugs; 475 
drugs approved by the FDA target 108 different GPCRs5,6. Additionally, 
approximately 20% of ongoing clinical trials also target GPCRs7, emphasizing their 
prevalence and importance in the field of medicine. This is due to the fact that 
GPCRs play a number of key, and diverse, roles in human biology. Activation of 
GPCRs elicit hundreds, if not thousands, of secondary messaging cascades that 
result in a myriad of different cellular effects8,9, but broadly play roles in our senses 
(smell, sight, taste)10, behavior9, homeostasis11, hormonal signaling12, and immune 
system regulation13. GPCRs are split into 6 classes, based on sequence homology 
and function, of which mGlus are a member of Class C.  This family is characterized 
by a large extracellular, N-terminus domain, which is termed the Venus flytrap 
domain (VFD) for mGlus (Figure 1.114). This name arises from the way that its two 
lobes “bite” down on glutamate to induce receptor activation. When the VFD 
activates, a large conformational change occurs which is propagated through the 
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structurally rigid cysteine-rich domain (CRD), comprised of 9 cysteine residues, of 
which 8 form disulfide bridges with the other protomer of the mGlu obligate dimer15. 
The 9th cysteine forms a disulfide bridge with the 
VFD, which allows for it to propagate the 
structural changes in the VFD upon glutamate 
binding down through to the seven-
transmembrane domain (7TD)15. Structural 
rearrangement of the transmembrane domains 
results in the heterotrimeric G protein breaking apart 
into Gβγ and Gα subunits, which then can participate 
in secondary messenger cascades and exert a number of intracellular changes15. 
The mGlus are also constitutive dimers, in which a disulfide bridge between cysteine 
residues in unstructured loops near the VFD between the two monomers covalently 
links the two protomers15. However, recent studies have shown that this disulfide 
bond is relatively unimportant for dimerization, as mutations of the cysteine residues 
to other amino acids only results in a small reduction in receptor function16. Further 
mutational studies indicate that the main energetic impetus for dimerization lies on 
the back (non-ligand binding portion) side of the upper lobe of the VFD, which 
contains hydrophobic residues that form a hydrophobic pocket with the hinge region 
of a second mGlu monomer16. Mutations of any of these hydrophobic residues to 
more polar amino acids results in severe reductions in receptor activation16. In 
addition, mutations that weaken this hydrophobic interface resulted in a receptor 
with a higher affinity for glutamate and more spontaneous activation in the absence 
of agonist as compared to the wild-type, suggesting that this interface is important 
Figure 1.114 Structural and 
schematic representation of a 
generic mGlu monomer with 
structural features labeled.  
VFD 
CRD 
7TD 
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for stabilizing the receptor in its non-active state16.  
There are 8 members of the mGlu family, mGlu1-8, that are separated based 
on sequence homology, G protein signaling, and ligand binding. Group 1 consists of 
mGlu1,5, group 2 consists of mGlu2,3, and group 3 is made up of mGlu4,6,7,8, mGlu6 is 
localized to the retina of the eye, whereas the other group III receptors are widely 
expressed in the CNS. Group 1 is coupled to Gαq, wherein activation of the receptor 
results in the release of the Gαq subunit from the heterotrimeric G protein. Gαq 
activates phospholipase C (PLC), which cleaves phosphatidylinositol 4,5-
biphosphate (PIP2) into diacyl glycerol (DAG) and isolitol 1,4,5-triphosphate (IP3), 
the latter of which is cytosolic and activates a number of receptors15,17. Importantly, 
it activates endoplasmic reticulum (ER) bound calcium channels, which allows for 
influx of calcium ions into the cytosol18. Assays for Gαq coupled receptors can take 
advantage of this signaling cascade by loading the cell with calcium sensitive dyes, 
which allows measure of the release of calcium ions as a proxy for measurement of 
receptor activation19.  Group 2 and 3 are both coupled to Gαi, where the interaction 
of the G protein with adenylate cyclase (AC) results in a reduced activation of AC, 
which converts adenosine triphosphate (ATP) into cyclic adenosine monophosphate 
(cAMP). This reduction in cellular CAMP can have a myriad of intracellular effects, 
including impacts on cellular ion channels and the ser/thr-speific protein kinase A 
(PKA) family of protein kinases20-22. Gi/o GPCRs can also directly affect ion channels 
via the βγ subunits and this may be even more important in modulating synaptic 
transmission than changes in cAMP. 
mGlus and Schizophrenia 
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Schizophrenia is a mental disorder that affects approximately 1% of the US 
population and the cost of this disease was estimated to be $25-102 billion in 
201323,24. Symptoms of schizophrenia are separated into three main clusters: 
positive symptoms are those commonly associated with this disease, including 
hallucinations, delusions, and paranoia; negative symptoms are those that affect 
mood and behavior, including reduced expression of emotions and reduced 
pleasure from everyday life; and finally, cognitive symptoms include difficulty taking 
information and applying it to various situations. Today, numerous antipsychotics 
are on the market for treating this disease25. However, most are only able to treat 
the positive symptoms and have deleterious side effects that can cause difficulties 
with patient compliance26-30. Negative and cognitive symptoms represent a large 
unmet need for this patient population, and addressing these symptoms could 
greatly improve the quality of life for those who suffer from this condition.   
Schizophrenia is associated with genetic mutations across a number of 
proteins, and the direct causes and pathology of the disease are not well 
understood31,32. However, a correlation with glutamatergic signaling was observed 
in the 1960s when recreational phencyclidine (PCP) users were admitted into clinics 
exhibiting symptoms similar to those observed in schizophrenic patients33-37. PCP is 
an N-methyl-D-aspartate (NMDA) receptor antagonist, which is an ionotropic 
glutamate receptor that allows flux of positive ions in response to ligand binding 
(glutamate, glycine, and/or aspartate). Additionally, NMDA knockdown mice (~5-
10% expression level, knockouts are non-viable) exhibit increased hyperlocomotion 
and stereotypies, which are behaviors correlated with the positive symptoms of 
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schizophrenia38,39. This phenotype could be rescued by gene therapy in mouse 
models40, which means that potentiation of signaling at NMDA receptors could 
provide a therapeutic benefit. While direct NMDA agonists can cause excitotoxicity41-
43, which led to the hypothesis that modulation of upstream signaling pathways for 
NMDA receptors could have therapeutic potential for this disease.  
Numerous studies have shown the efficacy of molecules that potentiate group 
II mGlu receptor activity in animal models of schizophrenia, including a number of 
tool compounds and clinical trials. It has been shown that group II non-selective 
agonists had efficacy in models of this disease in mGlu3 knockout mice, but not in 
mGlu2 knockouts, indicating that the efficacy of these agonists lies in their activity at 
mGlu2.  
Orthosteric and Allosteric Ligands 
 Most commercial drugs are act through an orthosteric mechanism, which 
means that they target the same binding site as the endogenous ligand for the 
targeted receptor44-48. The nature of endogenous ligands can vary vastly in nature 
and size, from small neurotransmitters for CNS receptors to large peptides, such as 
hormones. However, synthetic orthosteric ligands come with a number of caveats 
that can require rigorous medicinal chemistry efforts to overcome. Because 
orthosteric ligands result in sustained receptor activation or deactivation, chronic 
dosing can result in diminishing results as receptors become desensitized and 
internalized49-52. This means that the orthosteric drug can lose efficacy over time. 
For example, a number of drugs of abuse, such as heroin, hydrocodone, oxycodone 
and morphine are opioid receptor agonists that require increasing doses to achieve 
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the same effect over chronic administration due to receptor desensitization53-55. 
Additionally, as orthosteric binding sites are highly conserved within receptor 
families, subtype selectivity can be elusive, which can complicate the interpretation 
of pharmacology if multiple receptors are being simultaneously activated or 
inhibited56,57. Finally, for CNS drug discovery, many orthosteric ligands are very 
polar (L-glutamate, gamma-aminobutyric acid (GABA), etc) or charged 
(acetylcholine) and mimics of these molecules must overcome this polarity for them 
to be sufficiently able to cross the blood brain barrier (BBB) for CNS indications58.  
 Because of these challenges in orthosteric drug discovery, allosteric 
modulation has become a burgeoning 
area for medicinal chemistry efforts44-
47,56,57. Allosteric pockets are located in 
areas of the protein outside of the 
orthosteric ligand binding pocket and 
molecules that interact with these 
allosteric sites can have a myriad of 
effects (Figure 1.2). Pure positive 
allosteric modulators (PAMs) can 
increase the potency and efficacy of the endogenous ligand, but do not result in 
signaling in the absence of agonist. Potentiation is accomplished by stabilizing an 
active conformation of the receptor, which can improve affinity, efficacy, or both. 
Agonist-PAMs (or ago-PAMs) are capable of activating the target in the absence of 
the orthosteric agonist, but also potentiates the receptor activation upon interaction 
with the orthosteric ligand. Negative allosteric modulators (NAMs) reduce the effect 
Figure 1.259 Location of orthosteric and allosteric 
binding sites, along with the effects of allosteric 
modulators on orthosteric affinity and efficacy.  
Orthosteric 
Binding 
Site 
Allosteric 
Binding 
Site 
Cellular Effects 
Modulation 
of Cellular 
Response 
Modulation of 
Orthosteric 
Affinity 
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of the receptors orthosteric ligand by stabilizing an inactive conformation of the 
target. Additionally, neutral allosteric ligands (NALs) have no impact on signaling 
through the orthosteric site, but can block the effect of other allosteric ligands that 
bind in the same pocket.  
 The first major group of allosteric drugs was the benzodiazepine class, which 
have sedative, anxiolytic, and amnesic effects, and act by enhancing the effect of 
(GABA) at GABA receptors60-62. Recent drug discovery campaigns have had 
success in the clinic with allosteric modulators, first with cincacalcet, a calcium-
sensing receptor PAM that was approved in 200463 (Figure 1.3). This was followed 
by the CCR5 NAM maraviroc, which is used in HIV treatment to help prevent entry 
of the virus into human cells64,65. The relatively low number of allosteric modulators 
in the clinic may have several explanations. Structure-activity relationships (SAR) in 
allosteric modulation can often be very complicated; subtle changes can completely 
ablate activity, or even result in mode switches (i.e-from PAM to NAM)66. The 
structure of allosteric pockets can also be vastly different between species, which 
can complicate the translation of data from animal models to human disease and 
the clinic67. Finally, allosteric modulators are typically extremely lipophilic, relying on 
hydrophobic interactions within the allosteric pocket, which can cause the drug to 
Figure 1.3 Structures and targets of commercially available allosteric drugs. 
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deposit into fatty tissues, along with other undesired pharmacokinetic effects68. 
Driving down the lipophilicity of these allosteric modulators can be very challenging. 
However, despite these challenges, allosteric compounds can function as invaluable 
tool compounds for achieving subtype selectivity and teasing apart complicated 
pharmacology within a family of receptors.  
Metabotropic Glutamate Receptor Heterodimers 
 As mentioned previously, mGlus exist as constitutive dimers and were 
historically thought to exist exclusively as homodimeric receptors. However, 
heterodimeric receptors are known throughout the family of GPCRs, including GABA 
receptors, sweet taste receptors, and umami taste receptors69-71. Additionally, a 
number of mGlus are colocalized in certain brain regions, which suggests that 
heterodimerization is possible72-75. The first evidence for formation of these 
heteromers was shown by Doumezane et al in 2011, in which SNAP and CLIP tags 
were genetically fused to the extracellular N-terminus of all of the mGlus, with the 
exception of mGlu676. These tags are suicide inhibitors, meaning they covalently 
bind to the SNAP and CLIP enzymes and can be linked to specific substrates to 
label cysteines in the CLIP/SNAP active site. This allows for direction of Lumi4, a 
Förster resonance energy transfer (FRET) donor, and Green, a FRET acceptor, 
specifically to different mGlu monomers. Using this technology, heterodimer 
signaling can be specifically isolated by expressing the FRET donor and acceptor 
on different mGlus. In this study, each of the 49 possible SNAP/CLIP tagged proteins 
were expressed and it was determined that Group I mGlus are able to 
heterodimerize with each other, while Group II and III mGlus are capable of 
  
9  
heterodimerizing in both an intra- and intergroup manner. Logically, this makes 
sense as it prevents monomers with different G-protein coupling from 
heterodimerizing. Additionally, Group I mGlus are almost always located 
postsynaptically, whereas Group II and Group III are typically presynaptic, meaning 
that the cellular localization of these proteins potentially plays a role in their 
heterodimerization77.   
Metabotropic Glutamate 2/4 Heterodimers in Vitro 
Using the knowledge that functional heterodimers can form between group II 
and group III mGlus, the mGlu2/mGlu4 (denoted from here on as mGlu2/4) 
heterodimer was explored as a means of better understanding the functional and 
pharmacological characteristics of this receptor. This combination was chosen in 
part due to the ability to pharmacologically manipulate each monomer of the 
heterodimer separately, using the group II selective orthosteric agonist DCGIV and 
the group III selective agonist L-AP4. It was discovered that selective agonists alone 
were unable to activate the heterodimer, but administration of both selective 
agonists, or use of glutamate, allowed for full receptor response by activating both 
monomers of the heterodimer78.  
However, these initial studies were performed in vitro via heterologous 
expression in neurons from rat superior cervical ganglion (SCG), which do not 
express mGlu receptors. Additionally, the heterodimer was formed by expression of 
both mGlu2 and mGlu4, which means there are likely three cell populations 
expressed in the cell: mGlu2 and mGlu4 homodimers, along with the desired 
heterodimer. The presence of the two homodimer populations complicates the 
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interpretations derived from these studies. The use of means to selectively isolate 
signaling from the heterodimer alone also complicate interpretation, as alterations 
to the native proteins make relevance to living systems more complicated. While 
strong evidence was shown to support the existence of mGlu2/4 heterodimers under 
these conditions, the relevance of this receptor in living systems had not yet been 
shown. 
Metabotropic Glutamate 2/4 Heterodimers in Vivo 
An interesting dichotomy has been observed with regards to mGlu4 PAMs in 
which some scaffolds have efficacy in models of anxiety disorders, while other PAMs 
have no effect in these assays78-81. Anxiolytic type activity is typically associated with 
mGlu2 potentiation82-84, leading to the hypothesis that mGlu2 and mGlu4 may form a 
functional heterodimeric complex. Using 
co-immunoprecipitation with antibodies 
against mGlu2 and mGlu4 respectively, 
the Niswender lab showed that anti-
mGlu4 antibodies were capable of 
precipitating mGlu2 protein (and vice 
versa) both in cell lines expressing the heterodimer and in native tissues, indicating 
that there is a physical interaction between the two proteins85. Additionally, using 
two structurally distinct mGlu4 PAMs, it was observed that the effects of glutamate 
in mGlu2/4 cell lines were potentiated by VU0155041, but not by N-phenyl-7-
(hydroxyamino)cyclopropa[b]chromen-1a-carboxamide (PHCCC) (Figure 1.4).  
Through electrophysiology and co-immunoprecipitation studies, the mGlu2/4 
Figure 1.4 Structures of dual PAM 
VU0155041 and selective mGlu4 PAM 
PHCCC. 
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heterodimer has been shown to be localized presynaptically to corticostriatal 
synapses, where cortical signaling is converted into changes in synaptic plasticity 
across the striatum86-89. These changes can have impacts on motor learning, habit 
formation, and cognition87-90. Additionally, this region of the basal ganglia is 
associated with numerous psychiatric diseases, such as schizophrenia, autism 
spectrum disorder, obsessive-compulsive disorder, and major depressive 
disorder91. A selective mGlu2/4 PAM could allow one to selectively modulate 
glutamatergic signaling in this region and give great insight into the role(s) of this 
receptor under both normal physiological conditions and in models of schizophrenia.  
However, the lack of a selective mGlu2/4 PAM has prevented more detailed studies 
into the specific roles that these heterodimeric complexes play in modulating 
neuronal signaling.  
mGlu2/4 Heterodimer Ligand Selectivity 
 As mentioned above, PHCCC is active at mGlu4 homodimers, but not at the 
mGlu2/4 heterodimer. This indicates that there are structural differences between the 
heterodimer and homodimer that could be exploited to potentially synthesize a 
selective mGlu2/4 PAM. Though no modeling or structural work has been done 
specifically at the heterodimer, potentially due to the complexity that would be 
involved in trying to model the effects of the protein-protein interactions on the shape 
of the allosteric pocket, previous modeling studies indicate that there are two binding 
pockets within the mGlu4 allosteric pocket92. One pocket lies higher in the protein, 
occupying a region that is closer to the extracellular space. The second pocket 
extends deeper into the protein, and these modeling studies indicate that this deeper 
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pocket is more amenable to more linear, planar molecules like PHCCC. Modeling 
with VU041, which has a cyclohexane ring that can exist in a chair conformation and 
occupy a larger conformational space, showed that it was restricted to the shallow 
mGlu2/4 allosteric pocket. These modeling studies indicate that flexible, sterically 
encumbered mGlu4 PAMs are likely to be active at both the mGlu4 homodimer and 
mGlu2/4 heterodimer, while planar, linear, aromatic PAMs are more likely to be 
selective for mGlu4 homodimers.  
Conclusion 
 There is ample evidence for the existence of an mGlu2/4 heterodimer both in 
vitro and in vivo. Electrophysiology and co-immunoprecipitation assays indicate that 
this receptor may be localized to corticostriatal synapses, an area of the brain 
strongly associated with behavior gating. Additionally, potentiation of mGlu2 is 
associated with anxiolytic type activity, meaning that potentiation of mGlu2 in this 
region of the brain may be efficacious in ameliorating symptoms of schizophrenia. A 
potent, selective, and CNS penetrant PAM targeting the mGlu2/4 heterodimer would 
be vital for furthering the evidence toward the existence of these heterodimeric 
receptors and to help tease out the exact role(s) that this receptor performs in 
biological symptoms. One of the goals of this thesis was to use medicinal chemistry 
techniques to synthesize a selective mGlu2/4 heterodimer PAM to enhance the study 
of this unique receptor.  
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Materials and Methods 
 
General synthetic methods and instrumentation 
All NMR spectra were recorded on a 400 MHz AMX Bruker NMR 
spectrometer. 1H and 13C chemical shifts are reported in δ values in ppm downfield 
with the deuterated solvent as the internal standard. Data are reported as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, b = broad, 
m = multiplet), integration, coupling constant (Hz). Low-resolution mass spectra 
were obtained on an Agilent 6120 or 6150 with ESI source. Method A: MS 
parameters were as follows: fragmentor: 70, capillary voltage: 3000 V, nebulizer 
pressure: 30 psig, drying gas flow: 13 L/min, drying gas temperature: 350 ºC. 
Samples were introduced via an Agilent 1290 UHPLC comprised of a G4220A binary 
pump, G4226A ALS, G1316C TCC, and G4212A DAD with ULD flow cell. UV 
absorption was generally observed at 215 nm and 254 nm with a 4 nm bandwidth. 
Column: Waters Acquity BEH C18, 1.0 x 50 mm, 1.7 um. Gradient conditions: 5% 
to 95% CH3CN in H2O (0.1% TFA) over 1.4 min, hold at 95% CH3CN for 0.1 min, 
0.5 mL/min, 55ºC. Method B: MS parameters were as follows: fragmentor: 100, 
capillary voltage: 3000 V, nebulizer pressure: 40 psig, drying gas flow: 11 L/min, 
drying gas temperature: 350 ºC. Samples were introduced via an Agilent 1200 HPLC 
comprised of a degasser, G1312A binary pump, G1367B HP-ALS, G1316A TCC, 
G1315D DAD, and a Varian 380 ELSD (if applicable). UV absorption was generally 
observed at 215 nm and 254 nm with a 4 nm bandwidth. Column: Thermo Accucore 
C18, 2.1 x 30 mm, 2.6 µm. Gradient conditions: 7% to 95% CH3CN in H2O (0.1% 
TFA) over 1.6 min, hold at 95% CH3CN for 0.35 min, 1.5 mL/min, 45 ºC. High-
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resolution mass spectra were obtained on an Agilent 6540 UHD Q-TOF with ESI 
source. MS parameters were as follows: fragmentor: 150, capillary voltage: 3500 V, 
nebulizer pressure: 60 psig, drying gas flow: 13 L/min, drying gas temperature: 275 
ºC. Samples were introduced via an Agilent 1200 UHPLC comprised of a G4220A 
binary pump, G4226A ALS, G1316C TCC, and G4212A DAD with ULD flow cell. UV 
absorption was observed at 215 nm and 254 nm with a 4 nm bandwidth. Column: 
Agilent Zorbax Extend C18, 1.8 µm, 2.1 x 50 mm. Gradient conditions: 5% to 95% 
CH3CN in H2O (0.1% formic acid) over 1 min, hold at 95% CH3CN for 0.1 min, 0.5 
mL/min, 40 ºC. For compounds that were purified on a Gilson preparative reversed-
phase HPLC, the system comprised of a 333 aqueous pump with solvent selection 
valve, 334 organic pump, GX-271 or GX-281 liquid handler, two column switching 
valves, and a 155 UV detector. UV wavelength for fraction collection was 
userdefined, with absorbance at 254 nm always monitored. Method: Phenomenex 
Axia-packed Luna C18, 30 x 50 mm, 5 µm column. Mobile phase: CH3CN in H2O 
(0.1% TFA). Gradient conditions: 0.75 min equilibration, followed by user-defined 
gradient (starting organic percentage, ending organic percentage, duration), hold at 
95% CH3CN in H2O (0.1% TFA) for 1 min, 50 mL/min, 23 ºC. Solvents for extraction, 
washing and chromatography were HPLC grade. All reagents were purchased from 
Aldrich Chemical Co. and were used without purification. 
mGlu Receptor Thallium Flux Assays 
Cell lines: Polyclonal rat mGlu2/HEK/GIRK, rat mGlu4/HEK/GIRK and rat 
mGlu4/mGlu2 HEK/GIRK cells were used for these studies. For dye loading, media 
was exchanged with Assay Buffer (HBSS containing 20 mM HEPES, pH 7.4) using 
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an ELX405 microplate washer (BioTek), leaving 20 µL/well, followed by addition of 
20 µL/ well 2× FluoZin-2 AM (164 nM final) indicator dye (Life Technologies, 
prepared as a DMSO stock and mixed in a 1:1 ratio with pluronic acid F-127) in 
Assay Buffer. After a 1 h incubation at room temperature, dye was exchanged with 
Assay Buffer, leaving 20 µL/well, and allowed to sit for 15 minutes. Thallium flux was 
measured at room temperature using a Functional Drug Screening System 7000 
(FDSS 7000, Hamamatsu). Baseline readings were taken (2 images at 1 Hz; 
excitation, 470 ± 20 nm; emission, 540 ± 30 nm), and test compounds (2×) were 
added in a 20µL volume and incubated for 140 s before the addition of 10 µL of 
Thallium Buffer with or without agonist (5×). Data were collected for an additional 
2.5 min and analyzed using using Dotmatics software (Bishops Stortford, Hertz, UK) 
using a four parameter logistical curve fit. For direct GIRK assays, methods were 
performed as described previously.93 
In-Vitro DMPK Methods- Intrinsic Clearance in Liver Microsomes 
Hepatic microsomes (0.5 mg/mL) and 1 µM test compound were incubated 
in 100 mM potassium phosphate pH 7.4 buffer with 3 mM MgCl2 at 37 ºC with 
constant shaking. After a 5 min preincubation, the reaction was initiated by addition 
of NADPH (1 mM). At selected time intervals (0, 3, 7, 15, 25, and 45 min), 50 µL 
aliquots were taken and subsequently placed into a 96-well plate containing 150 µL 
of cold acetonitrile with internal standard (50 ng/mL carbamazepine). Plates were 
then centrifuged at 3000 rcf (4 ºC) for 10 min, and the supernatant was transferred 
to a separate 96-well plate and diluted 1:1 with water for LC/MS/MS analysis. The 
in vitro half-life (T1/2, min, Eq. 1), intrinsic clearance (CLINT, mL/min/kg, Eq. 2) and 
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subsequent predicted hepatic clearance (CLHEP, mL/min/kg, Eq. 3) were determined 
employing the following equations:  
(1)                   𝑇1/2 =  
𝐿𝑛(2)
𝑘
 
where k represents the slope from linear regression analysis of the natural log 
percent remaining of test compound as a function of incubation time  
(2)                   𝐶𝐿𝑖𝑛𝑡 =  
0.693
𝑖𝑛 𝑣𝑖𝑡𝑟𝑜 𝑇1/2
𝑥 
𝑚𝐿 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛
𝑚𝑔 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑒𝑠
 𝑥 
45 𝑚𝑔 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑒𝑠
𝑔𝑟𝑎𝑚 𝑙𝑖𝑣𝑒𝑟
 𝑥 
45𝑎  𝑔𝑟𝑎𝑚 𝑙𝑖𝑣𝑒𝑟
𝑘𝑔 𝑏𝑜𝑑𝑦 𝑤𝑡
 
a species specific scale up factors  
(3)                         𝐶𝐿ℎ𝑒𝑝 =  
𝑄ℎ∙𝐶𝐿 𝑖𝑛𝑡
𝑄ℎ+𝐶𝐿 𝑖𝑛𝑡
 
where Qh = hepatic blood flow in each species.  
Plasma Protein Binding 
  The protein binding of each compound was determined in plasma via 
equilibrium dialysis employing HTDialysis Teflon dialysis chamber and cellulose 
membranes (MWCO 12-14 K) (HTDialysis LLC, Gales Ferry, CT). Plasma was 
added to the 96-well plate containing test compound and mixed thoroughly for a final 
concentration of 5 µM. Subsequently, 150 µL of the plasma-compound mixture was 
transferred to the dialysis chamber, with an accompanying 150 µL of phosphate 
buffer (25 mM, pH 7.4) on the other side of the membrane. The device plate was 
sealed and incubated for 4 hours at 37 ºC with shaking. At completion, aliquots from 
each chamber were diluted 1:1 with either plasma (for the buffer sample) or buffer 
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(for the plasma sample) and transferred to a new 96-well plate, at which time ice-
cold acetonitrile containing internal standard (50 ng/mL carbamazepine) (2 volumes) 
was added to extract the matrices. The plate was centrifuged (3000 rcf, 10 min) and 
supernatants transferred and diluted 1:1 (supernatant: water) into a new 96 well 
plate, which was then sealed in preparation for LC/MS/MS analysis. Each compound 
was assayed in triplicate within the same 96-well plate. Fraction unbound was 
determined using the following equation:  
𝐹𝑢 =  
𝐶𝑜𝑛𝑐𝑏𝑢𝑓𝑓𝑒𝑟
𝐶𝑜𝑛𝑐𝑝𝑙𝑎𝑠𝑚𝑎
 
Brain Homogenate Binding  
The binding of each compound was determined in brain homogenate via 
equilibrium dialysis employing HTDialysis Teflon dialysis chamber and cellulose 
membranes (MWCO 12-14 K) (HTDialysis LLC, Gales Ferry, CT). Brain tissue 
homogenate was prepared by diluting one volume whole brain tissue with three 
volumes of phosphate buffer (25 mM, pH 7.4). The mixture was then subjected to 
mechanical homogenization employing a Mini-Beadbeater™ and 1.0 mm 
Zirconia/Silica Beads (BioSpec Products). Brain homogenate spiked with test 
compound and mixed thoroughly for a final concentration of 5 µM. Subsequently, 
150 µL of the brain homogenate-compound mixture was transferred to the dialysis 
chamber with an accompanying 150 µL of phosphate buffer (25 mM, pH 7.4) on the 
other side of the membrane. The block was sealed and incubated for 6 hours at 37 
ºC with shaking. At completion, aliquots from each side of the chamber were diluted 
1:1 with either brain homogenate (to the buffer side) or buffer (to the brain 
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homogenate side) in a new 96 well plate, at which time ice-cold acetonitrile 
containing internal standard (50 ng/mL carbamazepine) was added to extract the 
matrices. The plate was centrifuged (3000 rcf, 10 min) and supernatants transferred 
and diluted 1:1 (supernatant: water) into a new 96 well plate, which was then sealed 
in preparation for LC/MS/MS analysis. Each compound was assayed in triplicate 
within the same 96-well plate. Fraction unbound was determined using the following 
equation:  
𝐹𝑢,𝑡𝑖𝑠𝑠𝑢𝑒 =
1/𝐷𝑓
(
1
𝐹𝑢,ℎ𝑜𝑚
− 1) + 1/𝐷𝑓
 
Where Fu,hom represent the measured fraction unbound in the diluted homogenate 
and Df represents dilution factor.  
LC/MS/MS Analysis of Samples from In Vitro Assays  
Samples were analyzed via electrospray ionization (ESI) on an AB Sciex API-
4000 (Foster City, CA) triple-quadrupole instrument that was coupled with Shimadzu 
LC-10AD pumps (Columbia, MD) and a Leap Technologies CTC PAL auto-sampler 
(Carrboro, NC). Analytes were separated by gradient elution using a Fortis C18 3.0 
x 50 mm, 3 µm column (Fortis Technologies Ltd, Cheshire, UK) thermostated at 40 
ºC. HPLC mobile phase A was 0.1% formic acid in water (pH unadjusted), mobile 
phase B was 0.1% formic acid in acetonitrile (pH unadjusted). The gradient started 
at 10% B after a 0.2 min hold and was linearly increased to 90% B over 1.2 min; 
held at 90% B for 0.1 min and returned to 10% B in 0.1 min followed by a re-
equilibration (0.9 min). The total run time was 2.5 min and the HPLC flow rate was 
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0.5 mL/min. The source temperature was set at 500 ºC and mass spectral analyses 
were performed using multiple reaction monitoring (MRM), with transitions specific 
for each compound utilizing a Turbo-Ionspray® source in positive ionization mode 
(5.0 kV spray voltage). 
In-Vivo PK Methods 
 All rodent PK experiments were conducted in accordance with the National 
Institute of Health regulations of animal care covered in Principles of Laboratory 
Animal Care (National Institutes of Health publication 85-23, revised 1985) and were 
approved by the Institutional Animal Care and Use Committee. 
Discrete Rat PK and Tissue Distribution Studies  
For discrete rat pharmacokinetic experiments, compounds were formulated 
in 10% EtOH/60% PEG400/30% saline (IV, 0.2 mg/kg) and in 10% Tween 80 in 
0.5% MC (PO, 10 mg/kg) and dosed via the jugular vein to two dual-cannulated 
(carotid artery and jugular vein) adult male Sprague– Dawley rats (IV) or by oral 
gavage (PO). Whole blood collections via the carotid artery were performed at 0.033, 
0.117, 0.25, 0.5, 1, 2, 4, 7, and 24 hours post dose and plasma samples prepared 
for bioanalysis. Tissue distribution studies were performed by formulating the 
compound in 10% Tween 80 in 0.5% MC and dosing via intraperitoneal injection (30 
mg/kg) to male SD rats (n = S36 3-4 per time point). At 1 hr post dose, animals were 
euthanized and decapitated, blood was collected via cardiac puncture, CSF was 
obtained, and the brains were removed, thoroughly washed in cold phosphate-
buffered saline, and immediately frozen on dry ice. 
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Plasma and Brain Sample Preparation  
Plasma was separated by centrifugation (4000 rcf, 4 ºC) and stored at –80 ºC 
until analysis. On the day of analysis, frozen whole brains were weighed and diluted 
with 1:3 (w/w) parts of 70:30 isopropanol:water. The mixture was then subjected to 
mechanical homogenation employing a Mini-Beadbeater™ and 1.0 mm 
Zirconia/Silica Beads (BioSpec Products) followed by centrifugation. The sample 
extraction of plasma (20 μL), brain homogenate (20 μL), or CSF (where appropriate, 
20 μL) was performed by a method based on protein precipitation using three 
volumes of ice-cold acetonitrile containing an internal standard (50 ng/mL 
carbamazepine). The samples were centrifuged (3000 rcf, 5 min) and supernatants 
transferred and diluted 1:1 (supernatant: water) into a new 96-well plate, which was 
then sealed in preparation for LC/MS/MS analysis. 
LC/MS/MS Bioanalysis of Samples from In Vivo Assays  
In vivo samples were analyzed via electrospray ionization (ESI) on an AB 
Sciex API-4000 (Foster City, CA) triple-quadrupole instrument that was coupled with 
Shimadzu LC-10AD pumps (Columbia, MD) and a Leap Technologies CTC PAL 
auto-sampler (Carrboro, NC). Analytes were separated by gradient elution using a 
Fortis C18 3.0 x 50 mm, 3 µm column (Fortis Technologies Ltd, Cheshire, UK) 
thermostated at 40 ºC. HPLC mobile phase A was 0.1% formic acid in water (pH 
unadjusted), mobile phase B was 0.1% formic acid in acetonitrile (pH unadjusted). 
The source temperature was set at 500 ºC and mass spectral analyses were 
performed using multiple reaction monitoring (MRM), with transitions specific for 
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each compound utilizing a Turbo-Ionspray® source in positive ionization mode (5.0 
kV spray voltage). The calibration curves were constructed, and linear response was 
obtained by spiking known amounts of test compound in blank brain homogenate or 
plasma. All data were analyzed using AB Sciex Analyst software v1.5.1. The final 
PK parameters were calculated by noncompartmental analysis using Phoenix 
(version 6.2) (Pharsight Inc., Mountain View, CA). 
 
Challenges in the Development of a Selective mGlu2/4 Heterodimer PAM 
 
Initial Screen of mGlu4 PAMs 
A catalog of ~2,000 internally synthesized mGlu4 PAMs was screened 
against the heterodimer receptor, with counter-screens against both mGlu2 and 
mGlu4 homodimers to probe scaffold selectivity. mGlu4 PAMs were chosen, as 
opposed to mGlu2 PAMs, due to the fact that we were able to measure the amount 
of mGlu4 homodimer transfected in our cell lines by use of PHCCC. Adjustment of 
the amount of mGlu4 transfected into the cell lines allowed for expression of a 
majority amount of heterodimer with a minimal expression of mGlu4 homodimer. In 
contrast, we were unable to reduce the level of mGlu2 homomers, limiting our ability 
to probe the activity of mGlu2 PAMs due to a contaminating signal.   
From numerous active compounds, VU0155041 (1.1) was chosen as a 
preliminary lead due to its similar potencies at both the heterodimer and mGlu4 
homodimer. This compound was first reported several years ago94,95, and showed 
efficacy in in vivo models of Parkinson’s disease, which is typical of mGlu4 
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activation96. Soon after this report, Lundbeck published data on their work on Lu 
AF2193497, which is the primary 
carboxamide congener of 
VU041. Though the potency 
and efficacy remain relatively 
unchanged, the replacement of 
the carboxylic acid with an 
uncharged congener in physiological systems allowed for a large improvement in 
brain penetrance, making it a more useful tool compound. Though the initial report 
indicated that SAR around this scaffold was steep, we hypothesized that the fact 
that the heterodimer exhibits different ligand selectivity relative to mGlu4 
homodimers means that the allosteric pocket must be different in shape. Because 
the allosteric pocket is different, it was worth treating it as a new receptor and fully 
interrogating the SAR.   
SAR of VU041 
Analogs of VU041 were synthesized in a rapid fashion from commercially 
available anhydrides following scheme 1.1. Briefly, the anhydride and 
Figure 1.5 Initial screening hit (1.1) and structurally 
similar scaffold (1.3) with superior brain penetration. 
Scheme 1.1: Route to synthesis of VU0155041 analogs.  
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corresponding amine were refluxed overnight in THF to give the carboxylic acid-
amide intermediate. This compound proved somewhat non-trivial to convert to the 
corresponding amide, due to the propensity for this molecule to cyclize upon itself 
to form an imide if the acid was too activated or the initial amine nucleophile was too 
electron rich. Screening of several amide coupling reagents led to the discovery that 
formation of a mixed anhydride using isobutyl chloroformate and Hunig’s base, 
followed by quenching with concentrated ammonium hydroxide for primary 
carboxamide congeners, or another amine nucleophile for further analogs. This 
resulted in a mixture of carboxylic acid and primary carboxamide, which was ideal 
as both analogs could be submitted for testing in our assay. Over 100 analogs were 
synthesized around the VU041 scaffold, revealing steep SAR that was observed in 
previous medicinal chemistry efforts.  Initial modifications focused on changes to the 
substituents on the aniline ring used in the anhydride opening. No changes made to 
the aniline ring provided compounds that were superior in potency to the original hit, 
though some trends could be teased out from the data found. Halogens in the 3 and 
4 positions of the aniline provided compounds that were active, with chlorine (1.9, 
1.10) and bromine (1.60) being the most favorable. Converting from the 3,4-
dichloroaniline to either the 2-amino-4,5-dichloropyridine (1.58) or 5-amino-2,3-
dichloropyridine (1.59) also did not improve potency. The N-methyl analog of 
LUAF21934 also completely ablated activity, indicating that the secondary amide 
protons may play important roles in the activity of these compounds.  
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Ar OH/NH2 
Compound 
Number 
VUID 
mGlu2/4 
EC50 
(µM) 
mGlu2/4 
%Glu 
Max 
3,5-Cl, 4-F OH 1.6 VU6006812 >10 58 
3-Me, 4-F OH 1.7 VU6006829 Inactive 
3-Cl NH2 1.8 VU6008057 2.9 31 
4-Cl NH2 1.9 VU6008058 >10 58 
3,5-Cl NH2 1.10 VU6008059 4.01 52 
2,4-Cl NH2 1.11 VU6008061 Inactive 
3,4,5-F NH2 1.12 VU6008206 >10 30 
     
Table 1.1. Structure for aryl analogs of VU0155041 1.6-1.59 and associated potency and 
efficacy data from 10-point CRC-format screen at rat mGlu2/4 cell lines. Tl+ flux responses for 
each compound are reported as a percentage of the maximum response. VU number denotes 
the compound identifier assigned by Vanderbilt University. Data represent the mean of at least 
3 replicate experiments with similar results.  
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3-Me, 4-F 
 
NH2 
 
1.13 
 
VU6008208 
 
Inactive 
3-Cl, 4-CF3 NH2 1.14 VU6008924 >10 48 
3-Me, 4-Cl NH2 1.15 VU6008926 Inactive 
3-Me, 4-Cl NH2 1.16 VU6008927 >10 33 
3-Me, 4-OMe NH2 1.17 VU6008928 Inactive 
3-F, 4-CF3 NH2 1.18 VU6008930 >10 28 
3-CF3, 4-Cl  NH2 1.19 VU6008931 Inactive 
3-CF3, 4-Cl  OH 1.20 VU6008932 >10 35 
3-F, 4-Cl NH2 1.21 VU6008933 >10 49 
3-F, 4-Cl OH 1.22 VU6008934 Inactive 
3-OMe, 4-CN NH2 1.23 VU6008935 Inactive 
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3-OMe, 4-CN OH 1.24 VU6008936 Inactive 
3-F, 4-F OH 1.25 VU6008937 Inactive 
3-Cl, 4-OCF3 NH2 1.26 VU6008938 Inactive 
3-Cl, 4-OCF3 OH 1.27 VU6008939 >10 40 
3-F, 4-Me OH 1.28 VU6008940 Inactive 
3-OMe, 4-Cl NH2 1.29 VU6008941 >10 33 
3-OMe, 4-Cl OH 1.30 VU6008942 Inactive 
3-CF3, 4-Me NH2 1.31 VU6008944 Inactive 
3-CF3, 4-Me OH 1.32 VU6008945 Inactive 
3-Cl, 4-Me NH2 1.33 VU6008946 >10 28 
3-Cl, 4-Me OH 1.34 VU6008947 Inactive 
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3-F, 4-OCF3 NH2 1.35 VU6008948 >10 23 
3-F, 4-OCF3 OH 1.36 VU60084949 Inactive 
3-CN, 4-Me NH2 1.37 VU6008951 Inactive 
3-Me, 4-CN NH2 1.38 VU6008954 Inactive 
3-CF3, 5-CF3 OH 1.39 VU6008955 Inactive 
3-Cl, 5-CF3 OH 1.40 VU6008957 Inactive 
3-Cl, 5-CN OH 1.41 VU6008959 Inactive 
3-CF3, 5-CF3 NH2 1.42 VU6008955 Inactive 
3-OMe, 4-CF3 OH 1.43 VU6008966 Inactive 
3-CN, 4-OMe OH 1.44 VU6008967 Inactive 
3-CF3, 4-F NH2 1.45 VU6008968 Inactive 
  
28  
3-CF3, 4-F OH 1.47 VU6008969 Inactive 
3-OMe, 4-Me NH2 1.48 VU6008970 Inactive 
3-OMe, 4-Me OH 1.49 VU6008971 Inactive 
3-CN, 4-Cl OH 1.50 VU6008972 Inactive 
2,2-difluoro, 1,3-
dioxole 
NH2 1.51 VU6008973 Inactive 
2,2-difluoro, 1,3-
dioxole 
OH 1.52 VU6008974 Inactive 
3-CF3, 4-OMe NH2 1.53 VU6008975 Inactive 
3-CF3, 4-OMe OH 1.54 VU6008976 Inactive 
3-CN, 4-F NH2 1.55 VU6008977 Inactive 
3-CN, 4-F OH 1.56 VU6008978 Inactive 
3-OMe, 4-F OH 1.57 VU6008979 Inactive 
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2-N, 4,5-Cl OH 1.58 VU6009645 Inactive 
3-N, 4,5-Cl OH 1.59 VU6014324 >10 33 
3-Br NH2 1.60 VU6014329 5.27 79 
 
The modeling studies on mGlu4 indicated the potential presence of some 
space in the binding pocket that was unoccupied by VU041 extending from the 
carboxylic acid portion of the molecule. Attempts to occupy this space through 
synthesis of substituted amides on the northern portion of the molecule proved 
ineffective, though the reason for the discrepancy between the modeling studies and 
obtained information is unknown. 
 
 
 
 
 
 
Table 1.2. Structure for amide analogs of VU0155041 1.60-1.71 and associated potency and 
efficacy data from 10-point CRC-format screen at rat mGlu2/4 cell lines. Tl+ flux responses for 
each compound are reported as a percentage of the maximum response. VU number denotes 
the compound identifier assigned by Vanderbilt University. Data represent the mean of at least 
3 replicate experiments with similar results.  
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HNR1R2 Compound Number VUID 
mGlu2/4 
EC50 (µM) 
mGlu2/4 
%Glu Max 
 
  
 
1.60 VU6009633 Inactive 
 
 
 
 
 
1.61 
 
 
VU6009634 
 
 
Inactive 
 
 
 
1.62 VU6009635 Inactive 
 
 
 
1.63 VU6009636 Inactive 
 
 
 
1.64 VU6008637 Inactive 
 
 
 
1.65 VU6009640 Inactive 
 
 
 
1.66 VU6009643 Inactive 
  
1.67 VU6009644 Inactive 
 
 
 
1.68 VU6009647 Inactive 
 
 
 
1.69 VU6009648 Inactive 
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1.70 
 
VU6009649 
 
Inactive 
 
 
 
1.71 VU60014326 Inactive 
 With changes to the aniline ring and different amide substitutions proving 
ineffective in inducing potency or efficacy at the heterodimer, alterations were then 
made to the central core. Conversion of the cis-cyclohexane to the cyclohexene 
(1.78), trans-cyclohexane (1.73), or smaller ring sizes (1.77) resulted in a complete 
ablation of activity. We hypothesize that this is due to an induced fit model, where 
the conformation of the protein and the PAM may change such that they conform to 
fit each other and stabilize the active conformation. Restriction of this compound, 
either by rendering the ring less flexible with unsaturation or by changing the 
conformation with a trans-substitution, wherein both substituents can lie equatorial 
and the barrier to inversion is higher, resulted in ablation of activity. Additionally, we 
were able to confirm that the heterodimer also displayed an enantiomeric preference 
(1.79, 1.80) by separation of racemic VU041 into the pure enantiomers using 
supercritical fluid chromatography (SFC).  
 
 
 
 
Table 1.3. Structures for core analogs of VU0155041 1.72-1.79 and associated potency and 
efficacy data from 10-point CRC-format screen at rat mGlu2/4 cell lines. Stereocenters 
designated with * were resolved via chiral SFC separation and tested as single enantiomers of 
unknown configuration. Tl+ flux responses for each compound are reported as a percentage of 
the maximum response. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean of at least 3 replicate experiments with similar results. 
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Structure 
Compound 
Number 
VUID 
mGlu2/4 
EC50 
(µM) 
mGlu2/4 
%Glu 
Max 
 
  
 
1.72 VU6009632 >10 51 
 
 
  
 
 
 
1.73 
 
 
 
 
VU6007206 
 
 
 
 
Inactive 
 
 
 
1.74 VU6008221 Inactive 
 
 
 
1.75 VU6007810 Inactive 
 
 
 
 
  
 
 
1.76  VU6009630 Inactive 
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1.77 VU6009631 >10 44 
 
 
 
1.78 VU6008952 Inactive 
 
 
 
1.79 VU6008953 1.89 84 
 
Screen of FDA Approved Drugs 
Having determined that VU041 was an unproductive path towards 
synthesizing a selective mGlu2/4 PAM, we decided to embark on a screening 
campaign in an 
attempt to discover a 
scaffold that was 
inherently selective 
for the heterodimer. A 
pilot screen was performed using a library of 1,152 structurally diverse drugs. 
Approved drugs make an ideal starting point for an SAR campaign due to the fact 
that they inherently have a good DMPK profile. This screening effort resulted in the 
Figure 1.6. Initial hit (1.80) from a screen of FDA approved drugs 
and initial analog (1.81) with improved KP.  
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discovery that Febuxostat (1.80), a xanthine-oxidase inhibitor used for the treatment 
of gout, had a weak activity of 3.38 μM, and displayed no activity against mGlu4 in a 
Gqi5 calcium assay. Unfortunately, this compound exhibited poor brain penetrance 
(Kp = 0.03), which was hypothesized to be due to the presence of the carboxylic acid 
moiety, which was a focus of our initial analog synthesis 
Analogs were synthesized by a HATU-mediated coupling of commercially 
available Febuxostat (1.80) with various amines (Scheme 1.2). Conversion from the 
carboxylic acid to the primary carboxamide (VU6009638, 1.181) proved to be a large 
improvement over the parent compound, increasing the potency to 2.2 μM and 
resulting in an ~100 fold improvement to the brain penetration (Kp = 3.44). Excitingly, 
when VU638 was screened against mGlu4 in a calcium mobilization assay, it had no 
potentiation, which indicated that this chemotype had potential to be a selective 2/4 
heterodimer PAM. However, when screened against HEK293 cell lines with a GIRK 
readout, this selectivity was lost. Next, this compound was screened against 
HEK293 cells that were not transfected with mGlu4, mGlu2, or mGlu2/4, and activity 
was observed, which indicated that these compounds were direct GIRK activators. 
While VU638 was inactive in cell lines expressing GIRK2 homodimers, it was 
efficacious against GIRK1 containing cells lines (GIRK1/2, GIRK1/4).  
Despite this setback, a small library of amide analogs was synthesized and 
Scheme 1.2: Route to synthesis of Febuxostat analogs.  
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screened to determine their activity against the 2/4 heterodimer and to determine if 
we were able to modulate activity between GIRK and mGlu receptors. Excitingly, 
three compounds were found to be active against the heterodimer, VU6009964, 
VU6009958, and VU6009967, with corresponding activities of 5.2, 2.3, and 0.76 μM 
(35, 24 and 28% Glu max, Table 1.4). Initial screen against GIRK expressing cell 
lines proved promising, with indication of direct GIRK activation. However, these 
analogs proved to be weak potentiators of mGlu2/4, and additionally, were not 
selective due to comparable activity at mGlu2 homodimers (4.8 μM 73% Glu max, 
2.4 μM 53% Glu max, 0.77 μM 57% Glu max). Due to our inability to determine the 
amount of mGlu2 homodimer in our cell lines, and comparable activities between the 
mGlu2/4 and mGlu2 cell lines, it is likely that this activity is mostly driven by mGlu2 
homodimers. With this in mind, the secondary and tertiary amides of 1.80 are better 
characterized as mGlu2 PAMs. In addition, the elimination of the carboxylic acid from 
these compounds proved detrimental to the favorable DMPK properties of these 
compounds, with high predicted hepatic clearance in both human and rat liver 
microsomes (human CLhep >14 mL/min/kg, rat CLhep >62 mL/min/kg). Due to these 
complications, the further development of this chemotype as mGlu2/4 heterodimer 
PAMs was not pursued. 
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NR1R2 
Compound 
Number 
VUID 
mGlu2/4 
EC50 
mGlu2/4 % Glu 
max 
  
1.82 VU6009940 Inactive 
 
 
 
 
  
 
1.83 VU6009942 Inactive 
 
 
 
 
 
1.84 VU6009944 Inactive 
 
 
 
 
 
 
1.85 VU6009953 5.29 35 
 
 
 
 
 
 
1.86 VU6009958 2.03 24 
 
 
 
 
 
 
1.87 VU6009962 Inactive  
 
 
      
Table 1.4. Structures for amide analogs of Febuxostat 1.82-1.89 focused on amide synthesis 
for improvement of brain penetration and potency/efficacy over the original hit. Associated 
potency and efficacy data from 10-point CRC-format screen at rat mGlu2/4 cell lines. Tl+ flux 
responses for each compound are reported as a percentage of the maximum response. VU 
number denotes the compound identifier assigned by Vanderbilt University. Data represent 
the mean of at least 3 replicate experiments with similar results. 
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1.88 
 
VU6009964 
 
>10 
 
57 
 
 
 
 
 
1.89 VU6009967 0.76 28 
 
 
 
 
 
 
High-Throughput Screening Campaign 
 
 In order to discover new chemical matter that could result in a selective PAM 
for the mGlu2/4 heterodimer, a high-throughput screening (HTS) campaign was 
commenced. This was run using the VICB collection of ~100,000 compounds and 
were run a single-point format, meaning a single 10 μM concentration of compound 
was tested to determine efficacy. First, compounds were screened against the 
heterodimer, then active compounds were tested in cell lines expressing either 
mGlu2 or mGlu4 homodimers to determine the selectivity of these compounds. 
However, due to the length of time that is required for an HTS campaign, active hits 
in the heterodimer cell line with attractive scaffolds for medicinal chemistry were 
resynthesized along with small libraries of analogs to both determine the selectivity 
and if there was any SAR around the new chemotype. The results of this work are 
detailed below.  
VU6010417 
 The first hit explored was azetidinyl 1,2,4-oxadiazole VU6010417, which was 
an attractive scaffold for medicinal chemistry due to the ease of access to diverse 
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analogs. It was synthesized by a one pot microwave mediated condensation 
reaction between commercially available benzamidoximes (1.90-1.91, Scheme 1.3) 
with 1-Boc-azetidine-3-carboxylic acid to yield Boc-protected 1,2,4-oxadiazole 
(1.93-1.94). Next, Boc-deprotection with trifluoroacetic acid gave the free amine in 
45% over the two steps. Finally, HATU-mediated amide coupling with thiophene-2-
carboxylic acid gave VU6010417 in 17% yield.  Using this synthetic strategy, a 
diverse library of compounds was synthesized by varying the substituent on the 
Eastern arene (3-Cl and 3-CF3), utilizing various 5-membered heterocyclic acids in 
the HATU-coupling reaction with the intermediate azetidine, and by varying the 
nature of the central ring to determine the necessity of the azetidine for activity. 
  
The initial hit exhibited a potency of 2.11 μM and 99% Glu max, which was a 
promising start for analog synthesis and optimization. Moving the thiophene 
substitution from the 2- to the 3-position resulted in a similar potency of 2.02 μM, but 
Scheme 1.3: Route for rapid synthesis of analogs of VU6010417 focusing on aryl amide 
analogs of the Eastern aryl ring. 
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a drastic decrease in efficacy to 60% Glu max. Surprisingly, conversion of the 5-
membered heterocycle to an oxazole, thiazole, and furan provided compounds that 
were either greater than 10 μM or exhibited diminished activity in comparison to the 
original hit. Because thiophenes are considered to be bioisosteres of phenyl rings, 
the thiophene was replaced with a phenyl ring to determine if this analog had better 
interactions with the target protein. However, this strategy also proved inefficacious, 
with both the chloro and trifluoromethyl analogs exhibiting potencies greater than 10 
μM, though they did exhibit good efficacy at 108% Glu max for the chloro analog 
and 101% Glu max for the trifluoromethyl. Replacement of the chlorine of the aryl 
ring to the trifluoromethyl group resulted in an increase in potency to 1.10 μM and a 
massive increase in efficacy, 156% Glu max. Excitingly, an additional 4 analogs 
exhibited activities greater than the parent compound. Addition of a fluorine atom to 
the three position of the thiophene proved favorable, almost doubling the potency to 
1.14 μM and 103% Glu max. Interestingly, a 2-carboxy-3-methly furan substituent 
gave the best overall potency of 1.02 μM and 94% Glu max. A 2-cyclopropyl-3-
carboxyl substituted furan exhibited a potency of 1.28 μM and 85% Glu max, which 
corresponds with analogs seen before wherein the 3-substituted furan was superior 
to the 2-substitution. Finally, 3-carboxy-5-methyl thiophene resulted in a potency of 
1.13 μM and 56% Glu max. Of special focus in these analogs was substituents in 
the 2 and 5 positions of these heterocycles, as these are hot spots for metabolism, 
and substituting these positions can block this metabolism and give a better DMPK 
profile.   
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Unfortunately, analysis of these compounds in cell lines expressing mGlu2 
homodimer revealed that these analogs were also able to potentiate activity at these 
receptors. Additionally, the potency and efficacy at the homodimer were much better 
than at the 
heterodimer, typically 
being twice as potent 
at the homodimeric 
receptor and with 
improved efficacy as 
well. The two best 
analogs, 
VU6017122 and 
VU6017139, were submitted for DMPK analysis, and exhibited moderate clearance 
in both human and rat. Both analogs exhibited poor free fraction, at less than 1% 
(0.4% and 0.5% respectively). Surprisingly, there was a drastic difference in the 
brain penetration for these two analogs, with VU122 having a moderate Kp of 0.99 
and VU139 having a favorable distribution into the brain of 2.44.  
 
 
 
Figure 1.7. DMPK properties of two of the best analogs synthesized 
around the VU6010417 scaffold. These compound exhibited 
moderate clearance, poor free fraction, and moderate to good brain 
penetration. 
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R Cl/CF3 
Compound 
Number 
VUID 
mGlu2/4 
EC50 
(μM) 
mGlu2/4 
%Glu 
Max 
mGlu2 
EC50 
(μM) 
mGlu2 
%Glu 
Max 
 
  
 
Cl 1.97 VU0531026 Inactive Inactive 
 
 
Cl 1.98 VU0531042 2.02 60 1.16 92 
 
 
CF3 1.99 VU0531089 >10 48 >10 60 
 
 
CF3 1.100 VU0531090 >10 44 >10 82 
 
 
 
 
 
CF3 
 
 
 
1.101 
 
 
 
VU0531097 
 
 
 
>10 
 
 
 
50 
 
 
 
>10 
 
 
 
84 
 
 
Cl 1.102 VU6010417 2.50 55 1.89 123 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.5. Structures for azetidinyl amide analogs 1.97-1.134 of VU6010417 focused on 
amide synthesis for improvement of potency and efficacy, along with analysis of selectivity for 
mGlu2/4. Asociated potency and efficacy data from 10-point CRC-format screen at rat mGlu2/4 
cell lines. Tl+ flux responses for each compound are reported as a percentage of the 
maximum response. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean of at least 3 replicate experiments with similar results. 
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 Cl 1.103 VU6010418 >10 40 4.85 65 
 
 
 
Cl 1.104 VU6010419 2.31 75 1.95 112 
 
 
 
Cl 1.105 VU6010420 6.94 36 2.85 59 
 
 
Cl 1.106 VU6010421 9.01 62 2.63 91 
 
 
Cl 1.107 VU6010422 >10 30 3.09 54 
 
 
Cl 1.108 VU6010423 >10 26 6.68 47 
 
 
Cl 1.109 VU6010424 >10 30 3.33 55 
 
 
Cl 1.110 VU6010754 5.63 46 5.19 62 
 
 
Cl 1.111 VU6010755 >10 29 >10 45 
 
 
Cl 1.112 VU6010756 >10 34 4.77 47 
 
 
Cl 1.113 VU6010757 Inactive Inactive 
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Cl 1.114 VU6010758 Inactive Inactive 
 
 
Cl 1.115 VU6010759 5.37 48 4.40 87 
 
 
Cl 1.116 VU6010760 >10 36 >10 46 
 
 
Cl 1.117 VU6010761 >10 52 >10 73 
 
 
Cl 1.118 VU6010762 7.41 44 4.15 55 
 
 
Cl 1.119 VU6010763 >10 23 4.09 39 
 
 
Cl 1.120 VU6010764 1.13 56 0.91 71 
 
 
Cl 1.121 VU6010765 >10 30 >10 58 
 
 
Cl 1.122 VU6010766 >10 33 >10 51 
 
 
 
Cl 1.123 VU6010767 5.21 55 3.59 58 
 
 
 
Cl 1.124 VU6010768 >10 50 8.64 62 
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Cl 1.125 VU6010769 >10 55 >10 90 
 
 
Cl 1.126 VU6010770 Inactive Inactive 
 
 
Cl 1.127 VU6010771 >10 48 6.42 69 
 
 
Cl 1.128 VU6017115 8.81 43 6.25 108 
 
 
CF3 1.129 VU6017116 4.92 37 2.42 84 
 
 
Cl 1.130 VU6017122 0.71 35 0.90 81 
 
 
Cl 1.131 VU6017126 1.43 56 1.02 94 
 
 
Cl 1.132 VU6017127 2.94 54 1.28 85 
 
 
 
 
Cl 
 
1.133 
 
VU6017138 
 
3.33 
 
43 
 
2.64 
 
93 
 
 
CF3 1.134 VU6017139 0.496 85 1.10 156 
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Despite these setbacks for this chemotype as mGlu2/4 heterodimer PAMs, 
further analog synthesis was pursued to explore its potential as an mGlu2 PAM. 
Though these analogs exhibited moderate DMPK values, the subnanomolar 
potency of some analogs led us to want to pursue further analog synthesis. It was 
hypothesized that the azetidine moiety may potentially be a source of metabolic 
liability due to its relatively low chemical stability, especially under acidic conditions. 
Replacement of the azetidine with a pyrrolidine (1.130) and piperidine (1.131) 
moieties resulted in complete ablation of activity. Additionally, changing from the 3-
substituted azetidine to the 2-substituted analog (1.132) resulted in inactive 
compounds. Synthesis of uncyclized analogs, both with 1 (1.133) and 2 (1.134) 
carbons between the 1,2,4-oxadiazole and the amine, resulted in compounds that 
were low potency, though exhibited moderate efficacy at 56% Glu max.  
 
 
Core 
Compound 
Number 
VUID 
mGlu2/4 mGlu2/4 mGlu2 mGlu2 
EC50 
(μM) 
%Glu 
Max 
EC50 
(μM) 
%Glu 
Max 
 
 
 
1.135 VU6017144 2.44 56 3.09 83 
 
 
 
 
 
1.136 VU6017145 >10 39 >10 78  
Table 1.6. Structures for azetidine replacement analogs 1.135-1.139 of VU6010417 for the 
improvement of clearance, free fraction, and selectivity. Associated potency and efficacy data 
from 10-point CRC-format screen at rat mGlu2/4 cell lines. Tl+ flux responses for each 
compound are reported as a percentage of the maximum response. VU number denotes the 
compound identifier assigned by Vanderbilt University. Data represent the mean of at least 3 
replicate experiments with similar results. 
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1.137 VU6017146 >10 37 >10 44 
 
 
 
 
 
 
1.138 VU6017147 >10 60 >10 57 
 
 
 
 
 
 
1.139 VU6017149 >10 63 >10 69 
 
 
 
VU6010427 
The next hit of interest was 1,3,4-oxadiazole VU6010427 (VU427), which 
again had a scaffold amenable to rapid analog synthesis and was a novel 
chemotype for potentiation of mGlu receptors. First, condensation of commercially 
available 4-methyl-benzhydrazide with cyanogen bromide gave known intermediate 
amino-1,3,4-oxadiazole (1.142)98,99. Next, amide formation with substituted benzoic 
acids via a HATU-mediated amide coupling gave the final compound (1.143-1.153). 
Using this synthetic route, a small library of 11 analogs of the aryl carboxylic was 
synthesized to explore the selectivity of this scaffold. Interestingly, as observed in 
the work around VU041, this scaffold also was most potent with a chlorine 
substituent (1.145), which may indicate that these two scaffolds bind in a similar 
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manner. Unfortunately, it was more potent at the mGlu4 homodimer than at the 
mGlu2/4 heterodimer (259 nM, 102% Glu max vs 386 nM 120% Glu max, 
respectively). Of interest, however, is that this was the first scaffold we observed 
that was active in cells expressing all three receptor populations, though the potency 
and efficacy were diminished at mGlu2. From the data we have obtained, it is difficult 
to determine if this is due to off-target potentiation of GIRK proteins, as seen in 
Febuxostat, or if this compound is able to potentiate mGlu2, mGlu4, and mGlu2/4. 
These compounds are currently being studied in the Weaver lab, where it has been 
determined that there is an off-target effect that is causing a false positive in our 
assays. Though the exact identity of the target is not yet known, we know that it is a 
protein that allows for thallium flux outside of GIRK activation.  
 
 
Scheme 1.4: Synthetic route for the synthesis of Eastern aryl 
replacements for VU6010427. 
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R 
Compound 
Number 
VUID 
mGlu2/4 
EC50 
(μM) 
mGlu2/4 
%Glu 
Max 
mGlu2 
EC50 
(μM) 
mGlu2 
%Glu 
Max 
mGlu4 
EC50 
(μM) 
mGlu4 
%Glu 
Max 
F 1.143 VU6010425 2.04 113 1.52 96 2.65 96 
CF3 1.144 VU6010426 >10 73 >10 67 >10 42 
Cl 1.145 VU6010427 1.60 87 1.80 83 3.76 83 
OCF3 1.146 VU6010428 >10 77 >10 86 >10 52 
 
 
 
1.147 VU6010429 Inactive Inactive Inactive 
 
 
 
1.148 VU6010430 >10 55 >10 55 >10 25 
CN 1.149 VU6010431 >10 23 >10 32 >10 18 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.7. Varied aryl substitution analogs of the Eastern ring on scaffold VU6010427, along 
with selectivity data across all three cell lines (both homodimers and heterodimer). Associated 
potency and efficacy data from 10-point CRC-format screen at rat mGlu2/4 cell lines. Tl+ flux 
responses for each compound are reported as a percentage of the maximum response. VU 
number denotes the compound identifier assigned by Vanderbilt University. Data represent 
the mean of at least 3 replicate experiments with similar results. 
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1.150 
 
VU6010432 
 
Inactive 
 
Inactive 
 
Inactive 
 
 
 
1.151 VU6010433 Inactive Inactive Inactive 
CHF2 1.152 VU6010434 >10 57 >10 63 >10 35 
H 1.153 VU6010435 >10 48 >10 60 >10 20 
VU0495443 
The next hit synthesized was aryl pyridone scaffold VU0495443. Synthesis 
began with methyl 6-hydroxynicotinate, which was alkylated with 3-
(trifluoromethyl)benzyl bromide in DMF provided the desired N-alkylated material in  
 
 
64% yield (Scheme 1.5). Saponification gave the necessary acid in 33% yield, which 
Scheme 1.5: Synthesis of southern aryl analogs of VU0495443 1.157-1.181. 
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was followed by HATU-mediated amide couplings with varying substituted benzoic 
acids gave analogs (1.157-1.181). As seen with previous heterodimer scaffolds, 
VU443 exhibited very steep SAR, with most structural modifications exhibiting no 
activity altogether. The initial hit, the 2-methyl carboxylate (1.159), exhibited modest 
activity at 8.5 μM and 42% Glu max. Keeping with electron withdrawing groups in 
the 2-position, the 2-trifluoromethoxybenzene analog (1.162) was synthesized, 
which almost doubled the potency to 5.38 μM and 43% Glu max. Interestingly, 
cyclization of the amide onto the benzene ring by amide coupling with indoline 
(1.161) was the most potent analog synthesized at 3.50 μM and 40% Glu max at the 
heterodimer. Unfortunately, this scaffold was equally or more potent at the mGlu2 
homodimer, which precluded it from further optimization.  
 
NR1R2 
 
Compound 
Number 
VUID 
mGlu2/4 
EC50 
(μM) 
mGlu2/4 
%Glu 
Max 
mGlu2 
EC50 
(μM) 
mGlu2 
%Glu 
Max  
 
 
 
  
1.157 VU0495433 Inactive Inactive 
  
 
 
 
 
   1.158 VU0495439 Inactive Inactive 
Table 1.8. Southern amide analogs 1.157-1.181 of VU0429553 focused on understanding 
potency/efficacy at mGlu2/4 and selectivity against a mGlu2 homodimer cell line. Associated 
potency and efficacy data from 10-point CRC-format screen at rat mGlu2/4 cell lines. Tl+ flux 
responses for each compound are reported as a percentage of the maximum response. VU 
number denotes the compound identifier assigned by Vanderbilt University. Data represent 
the mean of at least 3 replicate experiments with similar results. 
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1.159 VU0495443 4.48 65 8.48 42 
  
  
 
 
 
 
  
1.16 VU0495445 Inactive Inactive 
  
  
 
 
  
1.161 VU0495454 3.5 40 3.44 61 
  
 
  
 
 
 
 
  
1.162 VU6010548 5.38 43 4.5 66 
  
  
 
 
 
 
  
1.163 VU6010549 Inactive Inactive 
  
  
 
 
 
 
  
1.164 VU6010552 Inactive Inactive 
  
  
 
 
 
 
  
1.165 VU6010553 Inactive Inactive 
  
  
 
 
  
1.166 VU6010554 Inactive Inactive 
  
 
  
 
       
  
52  
 
 
 
 
 
  
 
1.167 
 
 
VU6010555 
 
 
Inactive 
 
 
Inactive 
  
 
 
 
 
  
1.168 VU6010556 Inactive Inactive 
  
  
 
 
 
 
  
1.169 VU6010557 Inactive Inactive 
  
  
 
 
 
 
  
1.170 VU6010558 Inactive Inactive 
  
  
 
 
 
 
  
1.171 VU6010560 Inactive Inactive 
  
  
 
 
 
 
  
1.172 VU6010561 Inactive Inactive 
  
  
 
 
 
 
  
1.173 VU6010562 Inactive Inactive 
  
  
 
 
 
 
  
1.174 VU6010563 Inactive Inactive 
  
  
 
 
 
 
  
1.175 VU6010564 Inactive Inactive 
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1.176 VU6010565 Inactive Inactive 
  
 
  
 
 
 
 
  
1.177 VU6010566 Inactive Inactive 
  
  
 
 
 
 
  
1.178 VU6010567 Inactive Inactive 
  
  
 
 
 
 
  
 
 
1.179 
 
 
VU6010568 
 
 
Inactive 
 
 
Inactive 
  
  
 
 
 
 
  
1.180 VU6010569 Inactive Inactive 
  
  
 
 
 
 
  
1.181 VU6010570 Inactive >10 55 
  
  
 
 
VU6009122 
Due to its exceptional potency and interesting chemical structure, the positive 
control used in mGlu2 screening, N-(4′-cyano[1,1′-biphenyl]-3-yl)-N-(3-
pyridinylmethyl)-ethanesulfonamide hydrochloride (CBiPES), was explored for its 
selectivity. Analogs were synthesized according to the route shown in scheme 1.6. 
Briefly, Suzuki cross-coupling between 3-iodoaniline and 4-cyanobenzene boronic 
accomplished by first refluxing the intermediate aniline and varying benzaldehydes 
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in methanol, followed by cooling and reduction via addition of sodium borohydride. 
Quench and workup of this material gave the crude product in sufficient purity to 
accomplish sulfonamide formation by addition of pyridine and ethanesulfonyl acid 
gave known intermediate (1.184) in 70% yield100. Next, reductive amination was  
chloride to the crude 
residue in DCE, giving 
desired materials in 5-
20% yield. We 
primarily focused on 
the pyridine portion of 
this molecule to 
determine if there was SAR around this molecule and if there was any inherent 
selectivity. There was some texture to the SAR around the pyridine ring, with 
addition of a fluorine and methoxy group to this position being tolerated, though the 
fluorine was superior. Conversion of the pyridine ring to a pyrimidine was done to 
allow for any rotational conformational of the ring to have a nitrogen present in the 
meta position, which would hypothetically mean that there are more rotations of that 
ring in which favorable interactions with the protein are present.  However, the 
pyrimidine analog did not prove to be superior to the original hit. Replacement of the 
pyridine ring with a thiazole resulted in a compound ~2 weaker than the original hit. 
Finally, replacement of the pyridine nitrogen with a fluorine atom, to mimic the 
electron withdrawing nature of the pyridine while removing the hydrogen bond 
acceptor, resulted in a completely inefficacious compound in either cell line. This 
combined with the good potency of the thiazole gives strong evidence that a basic 
Scheme 1.6: Synthesis of benzylamine analogs of mGlu2 PAM 
CBiPES 1.185-1.208. 
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nitrogen on this portion of the molecule was required for activity.  
 
 
 
 
 
R 
Compound 
Number 
VUID 
mGlu2/4 
EC50 
(nM) 
mGlu2/4 
%Glu 
Max 
mGlu2 
EC50 
(nM) 
mGlu2 
%Glu 
Max 
 
 
 
 
1.185 VU6012561 Inactive Inactive 
 
 
 
 
 
 
 
1.186 VU6012571 Inactive Inactive 
 
 
 
 
 
1.187 VU6012573 Inactive Inactive 
 
 
 
 
 
1.188 VU6012574 Inactive Inactive 
 
 
 
 
 
1.189 VU6012577 Inactive Inactive 
 
 
 
 
1.19 VU6012578 Inactive Inactive 
 
  
  
Table 1.9. Structures of benzylamine analogs of VU6009122 for the determination of scaffold 
selectivity against mGlu2 and initial analysis of potency and efficacy. Associated potency and 
efficacy data from 10-point CRC-format screen at rat mGlu2/4 cell lines. Tl+ flux responses for 
each compound are reported as a percentage of the maximum response. VU number denotes 
the compound identifier assigned by Vanderbilt University. Data represent the mean of at least 
3 replicate experiments with similar results.  
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1.191 VU6012579 Inactive Inactive 
 
 
 
 
1.192 VU6012583 Inactive Inactive 
 
 
 
 
 
 
 
1.193 VU6012584 424 66 230 83 
 
 
 
 
 
1.194 VU6012586 157 74 108 92 
 
 
 
 
 
 
 
1.195 VU6012588 >10,000 50 4,490 73 
 
 
 
 
 
1.196 VU6012589 246 69 148 89 
 
 
 
   
 
 
 
1.197 VU6012590 Inactive Inactive 
 
 
 
1.198 VU6012591 Inactive Inactive 
 
 
 
 
 
1.199 VU6012592 Inactive Inactive 
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1.200 VU6012593 Inactive Inactive 
 
 
 
 
1.201 
 
 
VU6012594 
 
 
Inactive 
 
 
Inactive 
 
 
 
 
 
 
 
1.202 
 
VU6012595 
 
Inactive 
 
Inactive 
 
 
 
 
1.203 VU6012596 Inactive Inactive 
 
 
 
 
 
 
1.204 VU6012597 Inactive Inactive 
 
 
 
 
 
1.205 VU6012598 Inactive Inactive 
 
 
 
 
 
 
 
1.206 VU6012599 Inactive Inactive 
 
 
 
 
1.207 VU6012600 Inactive Inactive 
 
 
 
 
 
1.208 VU6012601 Inactive Inactive 
 
 
 
 
 Using the same chemistry as shown in scheme 1.6, but replacing 
ethanesulfonyl chloride with trifluoroethylsulfonyl chloride allowed for synthesis of 
compounds 1.209-1.210. While these analogs retained the good potency of the 
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parent compound (1.194), the conversion to the trifluoroethyl sulfonamide resulted 
in a large decrease in the efficacy for this scaffold.  
 
R 
Compound 
Number 
VUID 
mGlu2/4 
EC50 (nM) 
mGlu2/4 
%Glu Max 
 
 
 
1.209 VU6013343 126 44 
 
 
 
1.210 VU6013344 413 35 
 
Despite the poor selectivity of this scaffold, several of the best compounds 
were taken on for DMPK analysis. All three compounds exhibited high predicted 
hepatic clearance in both rat and human. While VU6012584 showed good free 
fraction in both human and rat, the other two showed an undesirable very high 
fraction unbound, which can allow for higher metabolism and clearance. This 
chemotype also exhibited moderate Kp values of 0.57 and 0.44 (1.196 was not run 
in the Kp study). However, due to the unselective nature of this compound and no 
evidence of the SAR being able to engender selectivity, we moved on to a new 
chemotype.  
 
 
Table 1.10. Structures of two trifluoroethyl sulfonamide analogs, wherein the conversion from 
ethyl to trifluoroethyl caused a drastic drop in efficacy. Associated potency and efficacy data 
from 10-point CRC-format screen at rat mGlu2/4 cell lines. Tl+ flux responses for each 
compound are reported as a percentage of the maximum response. VU number denotes the 
compound identifier assigned by Vanderbilt University. Data represent the mean of at least 3 
replicate experiments with similar results.  
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Completion of HTS Screen 
 
Met with disappointment with our initial efforts towards synthesizing a 
selective PAM for the mGlu2/4 heterodimer, we elected to allow the HTS screen to 
complete. Compounds were initially 
screened in cells expressing the 
heterodimer, and then active 
compounds were counterscreened in 
cells expressing mGlu2 or mGlu4 
homodimers to determine the selectivity of the hits. The screen found 216 active 
compounds, which were then distributed into 4 categories: pan-activators (61) 
compounds, mGlu2 and mGlu2/4 potentiators (141), mGlu4 and mGlu2/4 potentiators 
(12) and compounds selective for mGlu2/4 (2) (Figure 1.9). Due to the chemical 
liability of acyl thioureas (especially to hydrolysis), our initial interest focused on 
VU0503424. 
 
 
Figure 1.8. DMPK properties of analogs 1.193, 1.194, and 1.196. 1.193 exhibited good free 
fraction, and both 1.193 and 1.194 had moderate KP values (there was insufficient material to 
test 1.196). However, both 1.194 and 1.195 had very high free fractions, which can allow for 
higher metabolism. This may contribute to the very high clearance across all three analogs.  
Figure 1.9. Structures of two hits from the HTS 
screen that exhibited some selectivity of the 
mGlu2/4 heterodimer over mGlu2 and mGlu4 
with single point screening at 10 μM. 
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VU0503424 
 The single-point data for compounds 
VU0503424 can be seen in Figure 1.10. Screening this 
compound at 10 µM revealed that this compound 
seemed to be moderately selective at 36% Glu max, as 
compared to 21% at mGlu2 and 26% at mGlu4, although 
the efficacy was noted as weak. However, a preference 
in activity at high concentrations led us to explore this 
scaffold to determine if the potency and efficacy could be improved to yield selective 
PAMs.   
 Modular synthesis of this scaffold allowed for rapid access to diversity on both 
ends of this chemotype. Starting from 2,6-dichloropyridazine, SNAr with the sodium 
salt of ethanolamine formed by sodium hydride allowed access to known 
intermediate (1.213) in 48% yield101. From here, the synthesis was split into two 
parts depending on which part of the molecule was the focus. For diversifying the 
sulfonamide, microwave-mediated Suzuki coupling with phenylboronic acid gave 
intermediate (1.217) in 35% yield. Finally, sulfonamide formation with diverse 
sulfonyl chlorides gave desired analogs (1.218-1.243) in good yields. For access to 
diversity on the aryl pyridazine substituent, again from intermediate (1.213), 
sulfonamide formation with 2-fluorosulfonyl chloride gave intermediate (1.215) in 
90% yield. Next, Suzuki-coupling with diverse boronic acids gave analogs (1.244- 
Figure 1.10. Structure 
of 1.211 and related 
single-point efficacy 
from the HTS screen. 
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1.265) in 10-30% yield.  
 
Using this this divergent synthesis, a series of 56 analogs was synthesized. 
SAR around this scaffold was exceptionally steep (Table 1.11). On the sulfonamide 
moiety, fluorines were tolerated in both the 2 and 4 position. Around the aryl 
pyridazine, electron withdrawing groups were best tolerated, with the 3-chloro 
analog being the most potent compound (5.31 µM and 37% Glu max). Though the 
potency was measurable, the efficacy was still below the threshold for what is 
typically considered a PAM. Efficacy was improved in analogs 1.263 and 1.242 to 
64 and 52% respectively, though this resulted in compounds that had potencies of 
10 µM or greater.  
 
Scheme 1.7: Divergent routes for synthesis of pyridazine analogs 1.218-1.265. 
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R 
Compound 
Number 
VUID 
mGlu2/4 EC50 
(µM) 
mGlu2/4 %Glu 
Max 
3-Me 1.218 VU0503417 Inactive 
3,4-OMe 1.219 VU0503421 Inactive 
2-F 1.220 VU0503424 >10 41 
3-Cl 1.221 VU0503432 Inactive 
3,4-Cl 1.222 VU6013362 Inactive 
3,5-Cl 1.223 VU6013363 Inactive 
4-CF3 1.224 VU6014106 Inactive 
4-Cl 1.225 VU6014107 Inactive 
Table 1.11. Structures of VU0503424 analogs focusing on sulfonamide substitutions to 
determine selectivity and establish requirements for potency and efficacy. Associated potency 
and efficacy data from 10-point CRC-format screen at rat mGlu2/4 cell lines. Tl+ flux responses 
for each compound are reported as a percentage of the maximum response. VU number 
denotes the compound identifier assigned by Vanderbilt University. Data represent the mean 
of at least 3 replicate experiments with similar results.  
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3-OMe 1.226 VU6014108 Inactive 
2-OCF3 1.227 VU6014109 Inactive 
H 1.228 VU6014110 >10 39 
3-Me, 4-Cl 1.229 VU6014111 Inactive 
4-Me 1.230 VU6014112 Inactive 
3,4-F 1.231 VU6014113 Inactive 
2-CN 1.232 VU6014114 Inactive 
2-OMe 1.233 VU6014115 Inactive 
2-CF3 1.234 VU6014116 >10 52 
2-Me 1.235 VU6014117 >10 44 
2-Cl 1.236 VU6014118 >10 35 
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3-CN 1.237 VU6014120 Inactive 
4-CN 1.238 VU6014121 Inactive 
3-OCF3 1.239 VU6014122 Inactive 
3-CF3 1.240 VU6014123 Inactive 
3-F 1.241 VU6014124 >10 42 
4-F 1.242 VU6014125 9.67 52 
4-OCF3 1.243 VU6014126 Inactive 
 
 
 
 
 
Table 1.12. Structures of VU0503424 analogs of the Eastern aryl ring substitution. Associated 
potency and efficacy data from 10-point CRC-format screen at rat mGlu2/4 cell lines. Tl+ flux 
responses for each compound are reported as a percentage of the maximum response. VU 
number denotes the compound identifier assigned by Vanderbilt University. Data represent 
the mean of at least 3 replicate experiments with similar results.  
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R 
Compound 
Number 
VUID 
mGlu2/4 EC50 
(µM) 
mGlu2/4 %Glu 
Max 
4-OMe 1.244 VU0503458 Inactive 
2-F 1.245 VU6013118 Inactive 
2-Cl 1.246 VU6013119 Inactive 
2-Me 1.247 VU6013120 Inactive 
2-CF3 1.248 VU6013121 Inactive 
2-OMe 1.249 VU6013122 Inactive 
2-OCF3 1.250 VU6013123 Inactive 
3-F 1.251 VU6013124 Inactive 
3-Cl 1.252 VU6013125 5.31 37 
3-Me 1.253 VU6013126 >10 37 
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3-CF3 1.254 VU6013127 Inactive 
3-OMe 1.255 VU6013128 Inactive 
3-OCF3 1.256 VU6013129 Inactive 
3-CN 1.257 VU6013130 Inactive 
3-N 1.258 VU6013131 Inactive 
4-F 1.259 VU6013132 Inactive 
4-Cl 1.260 VU6013133 Inactive 
4-Me 1.261 VU6013134 1.57 31 
4-CF3 1.262 VU6013135 Inactive 
4-OCF3 1.263 VU6013136 >10 64 
4-CN 1.264 VU6013137 Inactive 
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4-N 1.265 VU6013138 Inactive 
 
In an effort to improve the potency of the most efficacious compound, VU136, 
a series of poly-fluorinated sulfonamides was synthesized both to determine if the 
potency of this scaffold could be improved and to measure the selectivity of this 
scaffold. From the poly-fluorine walk, the 2,4-fluorosulfonamide (VU6014334, 1.271, 
EC50 mGlu2/4= 2.77 µM, 52% Glu max) was the most optimal analog synthesized in 
this effort, with moderate potencies and efficacy. However, when screening against 
both homodimer cell lines, it was discovered that this compound was active at both 
homodimeric receptors (EC50 mGlu2= 618 nM, 38% Glu max; EC50 mGlu4= 1.13 µM, 
55% Glu max). However, due to the lack of selectivity of this scaffold and the steep 
SAR encountered in our efforts to optimize it, work on this scaffold was terminated.  
 
 
 
 
R 
Compound 
Number 
VUID 
mGlu2/4 
EC50 
(μM) 
mGlu2/4 
%Glu 
Max 
mGlu2 
EC50 
(μM) 
mGlu2 
%Glu 
Max 
mGlu4 
EC50 
(μM) 
mGlu4 
%Glu 
Max 
3,5-F 1.266 VU6014323 Inactive Inactive Inactive 
2,5-F 1.267 VU6014330 Inactive Inactive Inactive 
Table 1.13. Polyfluorinated analogs of VU0503424 synthesized in an effort to improve 
potency. Associated potency and efficacy data from 10-point CRC-format screen at rat 
mGlu2/4 cell lines. Tl+ flux responses for each compound are reported as a percentage of the 
maximum response. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean of at least 3 replicate experiments with similar results.  
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2,6-F 1.268 VU6014331 >10 41 Inactive Inactive 
3,4-F 1.269 VU6014332 Inactive Inactive Inactive 
3,4,5-F 1.270 VU6014333 Inactive Inactive Inactive 
2,4-F 1.271 VU6014334 2.77 46 0.618 38 1.13 55 
VU0507341 
Our attention next turned to the second hit, VU0507341, which had a less 
ideal scaffold for medicinal chemistry efforts due to the potential reactivity of the 
core. Indeed, looking through literature precedent around acylthioureas of this type, 
a number of studies are observed to have this moiety central to the core of their 
molecules. However, these studies also have the goal of cytotoxicity (breast cancer 
cell lines, insecticides), which would mean that the toxicity of this core would need 
to be dialed out before in vivo studies could be performed. Additionally, it is possible 
that the potential cytotoxicity of this core could interfere with the in vitro assays used 
to measure potency and efficacy in our lab. Nonetheless, due to it being one of the 
two somewhat selective hits from our HTS screening campaign, it was determined 
that it was worth exploring this scaffold briefly.  
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 Synthesis of analogs of VU0507341 was accomplished by addition of 
potassium thiocyanate to commercial 4-methylbenzoyl chloride to form the acyl 
thiocyanate. This was 
then followed by 
addition of the 
desired amine to form 
the thiourea in 4-35% yield (scheme 1.8). Initial SAR focused around modifications 
to the pyrrolidine ring. Cleavage of the pyrollidine to the diethylamide resulted in a 
good increase in potency. Additionally, switching to the primary amine using 
cyclopropylamine resulted in a compound with low potency, suggesting that the 
tertiary amide is better for activity. Aromatization to the pyrrole resulted in a slight 
decrease in potency at the mGlu4 homodimer, but an increase at the heterodimer. 
While ring expansion to the 6-membered piperidine ring resulted in an inactive 
compound, a phenyl piperazine motif showed good efficacy (1.274, EC50 mGlu4=825 
nM, Glu Max=112%, EC50 mGlu2/4= 804 nM, Glu max=88%). Surprisingly, the urea 
formed from R-2-methylpiperidine was highly potent (1.281, EC50 mGlu4=268 nM, 
Glu Max=106%, EC50 mGlu2/4= 185 nM, Glu max=91%), which was especially 
interesting in comparison to the inactivity of piperidine itself. This phenomenon is a 
good display of the so-called “magic methyl” effect in medicinal chemistry, which 
corresponds to a number of chiral moieties (i.e- fluorine, amino, etc) can have a 
drastic effect on the potency of a molecule. This can be due to a number of factors, 
including changing the rotational energy around bonds and disturbing the planarity 
of a biaryl system by substitution of the 2-position of either ring. In this case, the 
methyl group is likely locking the conformation of the piperidine ring into a shape 
Scheme 1.8: 1-pot synthetic scheme for the synthesis of diverse 
thiourea analogs of VU0507341. 
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that is ideal for interaction with a hydrophobic region of the molecules target. 
Additionally, the methyl group protruding from the ring can have additional non-polar 
interactions. Though there was interesting SAR surrounding this structure, the 
similarity in the potencies between mGlu4 and mGlu2/4 (this series has not yet been 
tested on mGlu2 homomers) and the nature of this scaffold has led us to believe that 
this chemotype is likely a GIRK-activator, or some similar ion channel that can allow 
for non-selective thallium flux, and thus, efforts around this scaffold have been 
terminated until mGlu2 and GIRK screening can be performed.  
 
 
 
 
HNR1R2 
Compound 
Number 
VUID 
mGlu2/4 
EC50 
(nM) 
mGlu2/4 
%Glu 
Max 
mGlu4 
EC50 
(nM) 
mGlu4 
%Glu 
Max 
 
 
 
1.273 VU6019677 8,280 77 4,370 95 
 
 
 
 
1.274 VU6019678 804 88 825 112 
 
 
 
 
 
 
 
1.275 VU6019687 Inactive Inactive 
 
 
 
 
 
 
 
1.276 VU6019688 >10,000 66 >10,000 90  
Table 1.14. Thiourea analogs of acyl thiourea VU0507341. Associated potency and efficacy 
data from 10-point CRC-format screen at rat mGlu2/4 cell lines. Tl+ flux responses for each 
compound are reported as a percentage of the maximum response. VU number denotes the 
compound identifier assigned by Vanderbilt University. Data represent the mean of at least 3 
replicate experiments with similar results.  
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1.277 VU6019689 >10,000 33 >10,000 52 
 
 
 
 
 
 
 
1.278 VU6019691 3,180 73 6,080 103 
 
 
 
 
 
 
 
1.279 VU6019692 Inactive >10,000 31 
 
 
 
 
 
 
 
1.28 VU6019694 4,300 73 6,200 89 
 
 
 
 
 
 
 
1.281 VU6019695 268 106 185 91 
 
 
 
 
 
 
 
1.282 VU6019696 >10,000 83 >10,000 101 
 
 
 
VU0544412 
 Turning our attention back to the mGlu4/mGlu2/4 dual activating hits, we were 
intrigued by the structure of thiazepane VU0544412. Additionally, there were 3 
different aryl analogs of this scaffold that showed up as hits from the HTS screen, 
which was exciting because it gave strong evidence that this scaffold was a true hit 
instead of a false positive (though this does not rule out it being a GIRK activator). 
Finally, we believed that VU0544412 could potentially occupy a similar chemical 
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space to the earlier VU041 scaffold, as both have flexible core structures and prefer 
halogens in the three position. 
Synthesis of VU412 was performed according to a procedure reported in the 
literature. First, Michael addition of L-cysteine onto methyl acrylate using 
triethylamine as a base gave the Michael adduct in good yields. Next, intramolecular 
cyclization was accomplished by diluting the intermediate in 7M ammonia/methanol 
for 7 days. Workup of this reaction by acid base extraction gave the known 
thiazepane carboxylic acid core102. Analogs were then synthesized by a HATU 
mediated amide coupling reaction with various anilines (Scheme 1.9).  
  
 
 
 
 
 
The initial hit, VU0544412 (1.288), had a potency of 772 nM and 106% Glu 
max, making it the most active compound synthesized in this project. Further 
halogen analogs showed that chlorines were favored in the three and in both the 
three and five positions (1.299 and 1.313), but the 3,4-dichloroaniline analog (1.291) 
was devoid of activity. Addition of a fluorine to the 4-position of the 3,5-
dichloroaniline (1.314) resulted in a slight boost in potency.  
Scheme 1.9: Synthesis of thiazepine VU0544412 analogs from L-cysteine and methyl acrylate. 
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HNAr 
Compound 
Number 
VUID 
mGlu2/4 
EC50 (nM) 
mGlu2/4 
%Glu Max 
  
1.287 VU0544376 Inactive 
  
1.288 VU0544412 772 106 
  
1.289 VU0544413 >10,000 37 
  
1.290 VU0544414 Inactive 
  
 
 
 
1.291 
 
 
 
VU0544423 
 
 
 
>10,000 
 
 
 
57 
    
Table 1.15. Amide analogs of thiazepine VU0544412 focused on understanding necessities 
for activity and similarities to favorable activity for VU0544841. Associated potency and 
efficacy data from 10-point CRC-format screen at rat mGlu2/4 cell lines. Tl+ flux responses for 
each compound are reported as a percentage of the maximum response. VU number denotes 
the compound identifier assigned by Vanderbilt University. Data represent the mean of at least 
3 replicate experiments with similar results.  
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1.292 
 
 
VU0544478 
 
 
Inactive 
  
1.293 VU6014291 Inactive 
  
1.294 VU6014292 Inactive 
  
1.295 VU6014293 Inactive 
  
1.296 VU6014294 Inactive 
  
 
 
 
 
1.297 
 
 
 
 
VU6014295 
 
 
 
 
Inactive 
  
 
 
 
 
 
1.298 
 
 
 
 
 
VU6014296 
 
 
 
 
 
>10,000 
 
 
 
 
 
84 
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1.299 
 
 
VU6014297 
 
 
518 
 
 
111 
  
1.300 VU6014298 >10,000 63 
  
1.301 VU6014336 Inactive 
  
1.302 VU6014337 >10,000 55 
  
1.303 VU6014338 >10,000 51 
  
1.304 VU6014339 >10,000 52 
  
1.305 VU6014340 Inactive 
  
1.306 VU6014341 Inactive 
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1.307 
 
 
VU6014342 
 
 
Inactive 
  
1.308 VU6014343 Inactive 
  
1.309 VU6014344 Inactive 
  
1.310 VU6014345 Inactive 
 
 
1.311 VU6015336 Inactive 
  
1.312 VU6015337 Inactive 
  
 
 
 
 
1.313 
 
 
 
 
VU6015338 
 
 
 
 
632 
 
 
 
 
112 
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1.314 
 
VU6015340 
 
580 
 
95 
  
1.315 VU6018804 Inactive 
 
 
1.316 VU6018806 Inactive 
  
1.317 VU6018807 Inactive 
  
1.318 VU6022296 638 105 
  
1.319 VU6022297 Inactive 
  
1.320 VU6022298 2,090 55 
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1.321 
 
VU6022792 
 
Inactive 
  
1.322 VU6022793 1,790 37 
  
1.323 VU6022794 3,170 174 
  
1.324 VU6022795 >10,000 156 
  
1.325 VU6022796 Inactive 
  
1.326 VU6022797 3,550 90 
  
1.327 VU6022798 Inactive 
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1.328 
 
 
VU6022699 
 
 
>10,000 
 
 
53 
 
Next, all possible combinations of 3,5-dihaloamides were synthesized to 
determine what the ideal combination of halogen substitutions was for this scaffold 
(1.329-1.334). As can be seen with analogs 1.318 and 1.333, the addition of a 
bromine to the arene ring resulted in a massive boost to potency, with both the 3-
bromo-5-chloro and 3,5-dibromo analogs resulting in compounds that were in the 
double-digit nanomolar range.  
 
 
 
 
 
Compound 
Number 
VUID 
mGlu2/4 
EC50 
(nM) 
mGlu2/4 
%Glu 
Max 
mGlu4 
EC50 
(nM) 
mGlu4 
%Glu 
Max 
3,5-F 1.329 VU6023806 8,400 138 8,920 119 
3-Cl, 5-F 1.330 VU6023811 904 144 278 114 
3-Br, 5-F 1.331 VU6023808 992 118 351 119 
Table 1.16. 3,5-dihalogenated aniline analogs were explored to understand the most ideal 
halogen combination for potency and efficacy, and to better understand the trends in this 
series. Associated potency and efficacy data from 10-point CRC-format screen at rat mGlu2/4 
cell lines. Tl+ flux responses for each compound are reported as a percentage of the 
maximum response. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean of at least 3 replicate experiments with similar results.  
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3-I, 5-F 1.332 VU6023809 1,410 99 558 100 
3,5-Cl 1.313 VU6015338 632 112   
3-Br, 5-Cl 1.318 VU6022296 63.8 105 32.8 109 
3,5-Br 1.333 VU6023810 78.2 107 35.3 114 
3-I, 5-Br 1.334 VU6023812 274 75 115 100 
 
This trend in halogen potency tracks well with the one observed in halogen 
bonding, where the ability to halogen bond increases with the size of the halogen. 
Halogen bonding is a phenomenon where a heteroatom’s (typically oxygen) lone 
pairs can interact with and stabilize the σ* orbital from the halogen-carbon bond on 
the arene. This LUMO becomes lower in energy as the halogen size increases and 
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the bonds get longer and weaker. However, the iodo-analog exhibits poor potency 
even though it is the best halogen at hydrogen-bonding, but this can be explained 
by the fact that the iodine atom is susceptible to oxidation or other means of 
decomposition, and is also extremely large and can disrupt favorable interactions 
with the protein through steric clashing.  
 Because of the high potency of this molecule, it was tested for DMPK 
properties to determine if this chemotype 
could potentially be a good tool compound as 
a dual mGlu4/mGlu2/4 activator. However, this 
molecule displays poor pharmacological 
characteristics (Figure 1.11). The 3-chloro 
analog (1.299) was moderately cleared in 
human (9.4 mL/min/kg), but highly cleared in 
rat (63.6 mL/min/kg). Additionally, the amount 
of this compound crossing the blood brain 
barrier into the brain was below the limit of 
quantitation (BLQ) in our system. Therefore, there is no quantifiable KP, which is a 
major liability for this scaffold. This is partially believed to be due to the amino-acid 
like nature of this chemotype, in which the two amides are spaced such that they 
mimic the same spacing seen in proteins. This is likely making this a target of a P-
glycoprotein (PGP) transporter, which are transporters that have evolved to move 
molecules across cell membranes. PGP in the BBB plays a large role in keeping 
substrates out of the brain, which is part of the reason that CNS targets can be 
difficult to target.  
Figure 1.11. DMPK properties of 
VU6014297, exhibiting moderate to 
high clearance and no brain 
penetration. 
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To date, the enantiomer of several of the most active compounds has been 
synthesized to determine the optimal stereochemistry for activity. In addition, the 
azapine analog of the thiazepane, with removal of the sulphur from the seven-
membered core, has been synthesized to determine if the oxygen atom from the 
sulphoxide impeded activity and the sulphur can be removed with a less bulky 
equivalent. Future work should be focused on replacing the sulphur atom with an 
oxygen, which would be a more metabolically stable and less potentially reactive. 
For ameliorating the PGP substrate liability, inverse amides could prevent 
recognition by the efflux protein, though synthesis of the reverse amide is difficult 
due to the thermal instability of this compound, preventing Curtius rearrangements, 
and the potential instability of the hemiaminal species.  
Conclusions 
 This subchapter has detailed our initial efforts towards synthesizing a small 
molecule PAM that was selective for the mGlu2/4 heterodimer over both the mGlu2 
and mGlu4 homodimers and the challenges that came along during this effort. The 
initial scaffold, VU041, faced very steep SAR and we were not able to improve the 
potency, efficacy, or selectivity over the hit compound. Work on scaffolds derived 
from HTS efforts resulted in a number of novel scaffold chemotypes, which resulted 
in the discovery of several compounds that showed activity at the mGlu2/4 
heterodimer and either mGlu2, mGlu4, or all three receptor populations. This last 
category of compounds were investigated as direct GIRK activators, or for activation 
of a separate protein altogether that allowed for non-mGlu receptor mediated 
thallium flux in our assays. Faced with these selectivity challenges, and, after the 
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synthesis of over 400 compounds and no evidence of sufficient differentiation 
between the allosteric binding pocket in the heterodimer over the homodimer, we 
decided that a new approach would be necessary.  
 
Tethering Strategy 
 
Background 
 While it is theoretically possible to synthesize small molecules that are 
selective for a heterodimer of interest, selectivity is reliant on a structural change in 
the binding pocket upon heterodimerization. Additionally, without robust structural 
information, it can be difficult to determine if there is such a change in the binding 
pocket, and if selectivity is achievable at all. Finally, as shown by numerous studies 
into mGlu heterodimers, activation of only one monomer of an mGlu heteromer is 
insufficient for full receptor activation, which means that it may be difficult to obtain 
a robust signal from a heteromer with a monovalent ligand16,55,57,65,71,. One method 
for solving these issues is the synthesis of a bivalent ligand, which contains a ligand 
that can each individually bind to one half of the monomer103,104. Beginning with the 
pioneering work of Portoghese et al on bivalent ligands for the mGlu5/Mu-opioid 
heterodimer3, the synthesis of heterodimeric probes for the selective targeting of 
heterodimer receptors has become a burgeoning field in the realm of medicinal 
chemistry105-118.  These ligands rely on a phenomenon known as avidity, the additive 
effect of multiple affinities119. One molecule binding to half of the receptor results in 
a local environment in which the other ligand has a very high concentration, which 
results in a high probability of activation of both monomers simultaneously.  
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 These bivalent ligands do suffer from some limitations, mainly that they are 
often very large in size (>1,000 Da), which results in very non-drug like 
pharmacology. For example, the Portoghuese lab found it necessary to use an 
intrathecal (into the spinal column) injection to administer their mGlu5/Mu-opioid 
tethered ligand in mice. Additionally, while these tethered ligands are designed with 
the intent of delivering both molecules simultaneously, there is the potential of 
negative allosteric interactions resulting in decreased affinity for the second ligand. 
Finally, these ligands are non-trivial to design and synthesize. They require high 
structural knowledge of the monovalent ligands, as it is required that either a 
functional group already on the molecule is utilized to attach the linker or the 
molecule must be functionally modified in such a way to allow for attachment of this 
linker. The linker must also be attached in such a location such that it minimally 
impacts the receptor-ligand interactions. Next, a number of linker lengths must be 
synthesized to determine the ideal spacing between the two ligands such that they 
can interact with the protein simultaneously. This can also result in some issues, as 
longer linker lengths can result in long hydrophobic chains that can impact aqueous 
solubility.  
 Despite these limitations and difficulties, the successful synthesis of a 
bivalent ligand can provide crucial information about receptor activation. An ideal 
bivalent ligand will produce a concentration response curve (CRC) that exhibits two 
EC/IC50s: a low concentration one in which one molecule interacts with each 
receptor and a second, higher concentration curve in which two separate molecules 
bind simultaneously (Figure 1.12). Operating in concentrations that elicit the low 
concentration response, one can potentially selectively elicit a response from a 
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heterodimeric receptor population. This information can provide strong evidence of 
the existence of these heterodimeric receptors in vivo, as it is hard to prove a 
heterodimer exists without a crystal structure, which is very difficult given the size 
and flexibility of GPCRs.  
 
 
 
 
 
 
 
 
 
mGlu2/4 Tethered Ligand 
 The inspiration for synthesizing a tethered ligand for this receptor stemmed 
from data reported by Pin et al121. In this report, they used a FRET based assay in 
which the FRET donor and acceptor were placed on mGlu2 and mGlu4, respectively. 
The VFDs of each 
receptor shift away 
from one other, 
resulting in a quenching 
of the FRET signal. 
Using a concentration 
Figure 1.13. Structures of PAMs VU0415374 and BINA that 
exhibited enhanced activation at mGlu2/4 cell lines in the presence 
of a submaximal concentration of glutamate.  
Figure 1.12. CRC of a tethered antagonist 
exhibiting a biphasic curve due to 
bisactivation with one molecule in low 
concentrations (IC50HIGH) and two molecules 
bidning simultaneously (IC50LOW)120. 
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of PAM to elicit a submaximal receptor response, they showed that co-administration 
of the mGlu2 PAM biphenyl-indanone A (BINA) and mGlu4 PAM VU374 resulted in 
a more than additive receptor response, suggesting that both PAMs acting 
simultaneously results in superior receptor activation (Figure 1.13). This finding is 
especially interesting given that VU374 has previously been shown to be inactive at 
the heterodimer alone. It has a long, linear, planar structure that makes it amenable 
to the deep pocket in mGlu4 that is hypothesized to be inaccessible in the 
heterodimer. Though the authors make note of this interesting phenomenon, they 
do not offer an explanation or thoughts as to why VU374 is active upon co-
administration with an mGlu2 PAM. It is possible that upon full activation of mGlu2 in 
the presence of BINA that the movement of the mGlu2 monomer can effect changes 
that allow for opening of the deep pocket in mGlu4. More studies need to be done to 
rationalize this phenomenon, but the evidence that the two PAMs have an additive 
effect was sufficient for us to move forward in synthesizing bivalent ligands derived 
from them.The initial SAR around BINA showed that changes to the aryl carboxylic 
acid region of the molecule were tolerated, whereas few modifications to the 
indanone core were tolerated120. While the carboxylic acid could theoretically be 
converted to an ester or amide as a means of attaching a linker, the high 
conservation of this group in the 3 and 4 positions of the arene suggested that it 
plays a role in this molecule’s potency. Fortunately, the initial report also gave strong 
evidence for a good location for the location of the linker. A BINA analog in which 
the carboxylic acid is moved to the three position (1.337) had an activity of 69 nM 
and 118% Glu max as compared to the parent compound with 111 nM and 114% 
Glu max (Figure 1.14). With the acid in this position, changing the hydrogen in the 
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4 position to a hydroxyl group (1.338) resulted in little change in potency (62 nM and 
113% Glu max). Alkylating the alcohol to a methoxy group (1.339) resulted in only a 
slight decrease in potency, meaning that placing a linker on a hydroxy in the 4 
position may allow for the molecule to maintain potency while also having the second 
ligand attached. 
 
  
 
 
 
 
 
 
 
 
 
Unfortunately, the SAR for VU374 was less helpful for ligand design than for 
BINA. The changes made to VU374 indicate that the pyridine ring tolerated very little 
change, which means that it is likely important for protein interactions. SAR on the 
far arene ring was much more tolerated, indicating that this side of the molecule may 
be solvent facing. Additionally, computational 
studies also modeled the pyridine ring binding 
deep into the allosteric pocket, while the 
chlorobenzene ring was closer to the top of 
Figure 1.14. BINA analogs from the published report indicate that 
a 4-OH group may be amenable for attachment of a linker122.  
Figure 1.15. Structure of VU374 analog 
modified for linker attachment. 
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the protein. However, there was no indication of what functional group could be 
appended without large changes to the compound’s potency. Based off of the 
computational studies, the 4 position was chosen to attach an amine that could be 
acylated to attach the linker (Figure 1.15).  
 With the design of both PAMs in hand, focus was next shifted to the design 
of the linker portion. While no dual allosteric bivalent ligand for two family C GPCRs 
has been synthesized to date, the mGlu5/Mu-opioid tether contains an mGlu5 NAM. 
While there is not necessarily an overlap between the location of the allosteric 
pocket between mGlus, especially between families where there is little sequence 
homology, the tether length used in their study was thought to be potentially the 
most similar to our system. Thus, a library of tethers was designed using diamines 
of various lengths to establish tethered ligands that were centered around the tether 
length of 22 atoms. To achieve this, it was decided that VU374 would be extended 
by reaction with glycolic anhydride, which extends this portion of the molecule by 6 
atoms and also adds an ether linkage that will help with aqueous solubility. For BINA, 
it was decided that the hydroxyl group would be alkylated with tert-butyl 
bromoacetate to extend this linker by 3 atoms and also add a functional handle to 
Figure 1.16. Design of mGlu2/4 linked compounds utilizing homologated diamines to modulate 
the spacing between the two PAMs.  
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add boc-protected diamines to before boc-deprotection and addition of the second 
PAM.  
Tether Synthesis- BINA 
 Though the synthesis of BINA is reported in the literature, there are no 
spectra or experimentals included in the report. Therefore, the synthesis of BINA 
was performed mostly according to this route, with changes made to accommodate 
the tether. First, Friedal-Crafts acylation with the acyl chloride derived from 
cyclopentylacetic acid provided the desired adduct in 85% yield. Mannich reaction 
of the resulting ketone with dimethylamine hydrochloride and para-formaldehyde in 
acetic acid followed by dilution in DMF and reflux gave the enone in 96% yield.  
Nazarov cyclization in concentrated sulfuric acid resulted in the desired cyclization 
product in 78% yield. Next, demethylation of the methoxy group was mediated by 
aluminum chloride in refluxing toluene for 1 hour, which gave the phenol, which was 
taken on crude for an SN2 reaction with 3-pinacolboranebenzyl bromide and Suzuki 
coupling with methyl 5-bromosalicylate gave 1.350 in 47% yield over the three steps. 
Alkylation of the resulting phenol with tert-butyl bromoacetate gave the desired 
adduct in 89% yield, which allowed for selective deprotection of the tert-
butylcarboxylate with TFA in 90% yield. This route gives the desired adduct in good 
yields in a very scalable 9 step synthesis.  
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Scheme 1.10: Route for synthesis of BINA analog 1.351. 
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Tether- VU374 
 The synthesis of the VU374 portion of the tether began with bis Boc-
protection of 2-methoxy-4-nitro aniline in quantitative yield. While reversing the nitro 
and amino group in the central core to achieve the synthesis would be simpler, the 
cost of this compound was prohibitive (100x more expensive) for scaling up and 
made the Boc-protection route more efficient. Reduction of the nitro group with 
hydrogen and palladium on carbon allowed for amide coupling with the HCl salt of 
2-pyridinecarbonyl chloride in 14% yield over the three steps. Boc-deprotection with 
TFA resulted in the free aniline in 65%, which was followed by the addition of 2-
chloro-4-nitrolcarbonyl chloride. This gave the VU374 core in 92% yield, and then 
was followed by an iron mediated nitro reduction. This helped avoid 
hydrodehalogenation that occurred when palladium on carbon and hydrogen were 
used. Finally, acylation of the resulting aniline using glycolic anhydride gave the 
extended VU374 analog in 20% yield over 2 steps.  
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Scheme 1.11: Synthetic scheme used to achieve the synthesis of VU374 analog 1.362. 
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Tether- Synthesis 
To achieve the synthesis of the final tethered ligands, monoprotected boc- 
diamines were required to connect the BINA and VU374 analogs. These were 
synthesized according to known procedures using excess diamine in the presence 
of Boc anhydride in chloroform. Workup of this crude reaction and water washes 
resulted in crude Boc-diamines that were sufficiently pure for further transformations. 
First, HATU-mediated amide coupling between Boc- diamine gave the crude BINA 
amide with the linker chain attached. Saponification to reveal the free carboxylic acid 
was followed by Boc-deprotection using HCl in dioxanes to precipitate the HCl salt 
of the primary amine. These steps were performed without purification. Amide 
coupling of this amine with the VU374 analog in DMF using HATU followed by 
preparative reverse-phase HPLC gave the desired tethered ligands in 2-12% yields, 
which gave sufficient quantities for biological testing.  
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Scheme 1.12: Final steps utilized to achieve the synthesis of 9 linkers of varying spacing. 
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Tether-Pharmacology 
The screening of these tethered ligands resulted in very complicated, 
somewhat opaque data. The tethered ligands were active across all three cell 
populations used in this study, both homomers and the heterodimer. This was 
actually very exciting because it indicates that the modifications made to each PAM 
did not render the PAMs inactive, which means that the tether of ideal length should 
work with our ligand design. When these compounds were screened in just the 
heterodimer cell line, some very interesting results were observed. As can be seen 
in Figure 1.17, there are some trends that can be observed. The intermediate linker 
lengths of 3-7 show a flattened CRC, whereas the linker lengths of 2, 8, 10, and 12 
seem to display curves that are more typical in these assays. The steepness of the 
CRC is measured by the Hill coefficient for these assays, where numbers of 1 or 
greater are typical for standard CRCs. However, the flattened CRCs exhibit 
diminished Hill coefficients, from which one can at least determine that there is some 
differential effects in the heterodimer cell line versus each homodimer. 
Unfortunately, due to the presence of homomer populations in the heterodimer cell 
line, it is difficult to definitively determine if this flattening is due to our tethered ligand 
acting as desired, or if there is some role that the heteromer populations are playing 
in making these curves different. One thing that is interesting to note is that the 
curves for the 7 and 8 carbon linkers seem to display the biphasic curve that is 
indicative of a functioning tethered ligand. However, due to the complications arising 
from the population of homomers and heteromers in our heterodimer cell line, few 
conclusions that can be derived from our assay results. For this reason, we 
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collaborated with the lab of Jonathan Javitch at Columbia, who utilized an assay 
developed in their lab for measuring signaling from heterodimeric receptors123. This 
assay is called complemented donor-acceptor resonance energy transfer (CODA-
RET) and, per the name, relies on complementation between the two monomers in 
a heterodimeric protein. In this assay, a C or N-terminal fragment of luciferase is 
fused to the C-terminus of each monomer of the desired heterodimer. Thus, the 
protein is only functional in a heterodimeric complex, wherein the complementary 
fragments can come together and isolating the signal to heterodimers over the 
respective homomers. This luciferase protein acts as a bioluminescence resonance 
energy transfer (BRET) donor for a BRET acceptor protein, mVenus, fused to the 
Gα subunit of the GPCR. Receptor activation results in a conformational change that 
brings the BRET acceptor and donor together in space, resulting in a high BRET 
state. Thus, BRET signaling in this assay can be used to quantify receptor activation 
specifically from heterodimeric proteins.  
Using the linkers of length n= 5, 10, 12 (1.373, 1.377, 1.378, Figure 1.18), it 
was shown that these PAMs were functional at homodimeric cell lines, but showed 
no significant potentiation versus vehicle in cell lines expressing the mGlu2/4 
heterodimer. These data highlight the fact that, while our cell line is perhaps the 
most biologically relevant compared to assays that utilize modified proteins to isolate 
heterodimer signaling, the lack of selectivity in signaling has greatly complicated 
data interpretation and clarity.  
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Figure 1.17. CRCs of each tethered ligand screened in cells expressing the mGlu2/4 
heterodimer exhibiting varying potencies and hill coefficients.  Carbon spacers 3-7 have 
reduced Hill slopes, which was thought to be potentially indicative of dimeric interaction.  
A B 
C 
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n 
Compound 
Number 
VUID 
mGlu2/4 
EC50 
(nM) 
mGlu2/4 
% Glu 
max 
mGlu2 
EC50 
(nM) 
mGlu2 
% Glu 
max 
mGlu4 
EC50 
(nM) 
mGlu4 
% Glu 
max 
2 1.370 VU6023797 210 70 281 92 657 104 
3 1.371 VU6023798 93 102 54 100 38 114 
4 1.372 VU6023800 50 93 98 98 33 113 
5 1.373 VU6023799 72 89 92 102 35 110 
Table 1.17. 3,5-dihalogenated aniline analogs were explored to understand the most ideal 
halogen combination for potency and efficacy, and to better understand the trends in this 
series. Associated potency and efficacy data from 10-point CRC-format screen at rat mGlu2/4 
cell lines. Tl+ flux responses for each compound are reported as a percentage of the 
maximum response. VU number denotes the compound identifier assigned by Vanderbilt 
University. Data represent the mean of at least 3 replicate experiments with similar results.  
Figure 1.18. Data courtesy of the Javitch lab using DCG-IV, an agonist selective for mGlu2 in 
this assay, and L-AP4, selective for mGlu4 activation. A. VU6023800 (VU800) acts as a PAM 
at mGlu4 homodimers, while VU6023804 (VU804) and VU6023805 (VU805) do not. B. All 3 
tethered ligands potentiate at mGlu2 homodimers. C,D. None of the tested compounds show 
significant efficacy versus vehicle in mGlu2/4 cell lines, indicating that there is no significant 
heterodimeric activation using these ligands.  
  
100  
6 1.374 VU6023801 384 88 62 102 79 86 
7 1.375 VU6023802 408 90 122 101 772 82 
8 1.376 VU6023803 245 80 94 97 642 90 
10 1.377 VU6023804 247 85 134 102 372 89 
12 1.378 VU60023805 2,050 70 1,180 102 1,850 80 
 Summary, Conclusions, and Future Directions 
 In summary, 9 tethered ligands were synthesized utilizing mGlu2 and mGlu4 
PAMs, with varying linker lengths to probe the distance between the allosteric 
pockets in the mGlu2/4 heterodimer. These ligands were then tested in our GIRK cell-
based assay which resulted in complex and opaque pharmacology. The data 
derived from these studies is hard to interpret due to the presence of mGlu2 and 
mGlu4 heteromers present in the heterodimer cell lines. However, differential 
pharmacology within the series hints at some difference between the tether lengths, 
where the extreme short and long lengths exhibited behavior that would indicate the 
two PAMs in the tether were acting as if they were monovalent. The intermediate 
lengths exhibited flattened CRCs, though it is again hard to discern why due to the 
multiple factors at hand. Due to these difficulties and concerns, the ligands were 
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sent to the Javitch lab at Columbia University. Using their assay which is selective 
for heterodimer signaling, it was determined that the three compounds we sent for 
testing did not function as a heterodimeric ligand using agonists selective for each 
monomer of the heterodimer. This assay will be retried in the future with glutamate 
as an agonist, due to the fact that the literature reports that activation of both sides 
of the heterodimer are necessary for activity. These data highlight the difficulties that 
were incurred due to the nature of how we were expressing the mGlu2/4 heterodimer. 
While our system was the most native in terms of its signaling pathways, the 
presence of mGlu2 and mGlu4 homodimers convolutes the data discovered in these 
assays. Assay optimization could be done to utilize cell lines that can isolate 
heterodimer signaling (i.e- FRET or CODA-RET based complimentarity assays), 
which would allow for a clearer picture of what receptor(s) PAMs are interacting with. 
Future directions for this project would be to test the remaining linker lengths to 
determine if any of them are an ideal length for bivalent activity. Additionally, the 
PAMs could be further modulated to test shorter and longer linker lengths to 
determine the ideal spacer length for use in this system. In terms of the discovery of 
a single small molecule PAM that may have more ideal DMPK properties than a 
tethered ligand, an HTS screen utilizing a cell line selective for mGlu2/4 signaling (i.e- 
FRET or BRET) could be utilized to discover scaffolds that may be inherently 
selective for the heterodimer. Introducing selectivity to a scaffold is an inherently 
difficult task, further complicated by the lack of understanding of the mGlu2/4 
allosteric pocket, on either the mGlu2 or mGlu4 PAM, so starting with a scaffold that 
is selective would be ideal. 
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Experimental Methods 
 
 
General synthetic methods and instrumentation 
All NMR spectra were recorded on a 400 MHz AMX or 600 MHz AV-II Bruker 
NMR spectrometer. 1 H and 13C chemical shifts are reported in δ values in ppm 
downfield with the deuterated solvent as the internal standard. Data are reported as 
follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, b 
= broad, m = multiplet), integration, coupling constant (Hz). Low-resolution mass 
spectra were obtained on an Agilent 6120 or 6150 with ESI source. Method A: MS 
parameters were as follows: fragmentor: 70, capillary voltage: 3000 V, nebulizer 
pressure: 30 psig, drying gas flow: 13 L/min, drying gas temperature: 350ºC. 
Samples were introduced via an Agilent 1290 UHPLC comprised of a G4220A binary 
pump, G4226A ALS, G1316C TCC, and G4212A DAD with ULD flow cell. UV 
absorption was generally observed at 215 nm and 254 nm with a 4 nm bandwidth. 
Column: Waters Acquity BEH C18, 1.0 x 50 mm, 1.7 um. Gradient conditions: 5% 
to 95% CH3CN in H2O (0.1% TFA) over 1.4 min, hold at 95% CH3CN for 0.1 min, 
0.5 mL/min, 55ºC. Method B: MS parameters were as follows: fragmentor: 100, 
capillary voltage: 3000 V, nebulizer pressure: 40 psig, drying gas flow: 11 L/min, 
drying gas temperature: 350ºC. Samples were introduced via an Agilent 1200 HPLC 
comprised of a degasser, G1312A binary pump, G1367B HP-ALS, G1316A TCC, 
G1315D DAD, and a Varian 380 ELSD (if applicable). UV absorption was generally 
observed at 215 nm and 254 nm with a 4 nm bandwidth. Column: Thermo Accucore 
C18, 2.1 x 30 mm, 2.6 um. Gradient conditions: 7% to 95% CH3CN in H2O (0.1% 
TFA) over 1.6 min, hold at 95% CH3CN for 0.35 min, 1.5 mL/min, 45ºC. High-
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resolution mass spectra were obtained on an Agilent 6540 UHD Q-TOF with ESI 
source. MS parameters were as follows: fragmentor: 150, capillary voltage: 3500 V, 
nebulizer pressure: 60 psig, drying gas flow: 13 L/min, drying gas temperature: 275 
ºC. Samples were introduced via an Agilent 1200 UHPLC comprised of a G4220A 
binary pump, G4226A ALS, G1316C TCC, and G4212A DAD with ULD flow cell. UV 
absorption was observed at 215 nm and 254 nm with a 4 nm bandwidth. Column: 
Agilent Zorbax Extend C18, 1.8 µm, 2.1 x 50 mm. Gradient conditions: 5% to 95% 
CH3CN in H2O (0.1% formic acid) over 1 min, hold at 95% CH3CN for 0.1 min, 0.5 
mL/min, 40ºC. For compounds that were purified on a Gilson preparative reversed-
phase HPLC, the system comprised of a 333 aqueous pump with solvent selection 
valve, 334 organic pump, GX-271 or GX-281 liquid handler, two column switching 
valves, and a 155 UV detector. UV wavelength for fraction collection was user 
defined, with absorbance at 254 nm always monitored. Method: Phenomenex Axia-
packed Luna C18, 30 x 50 mm, 5 µm column. Mobile phase: CH3CN in H2O (0.1% 
TFA). Gradient conditions: 0.75 min equilibration, followed by user-defined gradient 
(starting organic percentage, ending organic percentage, duration), hold at 95% 
CH3CN in H2O (0.1% TFA) for 1 min, 50 mL/min, 23ºC. Solvents for extraction, 
washing and chromatography were HPLC grade. All reagents were purchased from 
Aldrich Chemical Co. and were used without purification.  
 
General Procedure for Compounds 1.5-1.79. 
To a solution of 6 (0.13 mmol, 1 eq) in THF (0.5 mL, 0.26M) in a 1-dram vial at room 
temperature aniline/ heterocyclic amine (0.13 mmol, 1 eq) was added in one portion. 
The vial was sealed and the mixture heated to reflux for 16 hours to yield crude 1.5. 
  
104  
For compounds 1.6-1.79, after cooling to room temperature, N,N-
Diisopropylethylamine (0.143 mmol, 1.1 eq) and isobutyl chloroformate (0.143 
mmol, 1.1 eq) were added and the reaction was stirred for 30 minutes at room 
temperature. For primary carboxamide congeners, ammonium hydroxide (1mL) was 
added and the reaction was stirred for an additional hour at room temperature. For 
substituted amide analogs, desired amine (0.26, 2 eq) was added instead of 
ammonium hydroxide and stirring was continued for an additional 2 hours. The 
reaction was then diluted with ether (1mL), the layers were separated and the 
aqueous layer was extracted with ether (3x2mL). The organic layers were passed 
through a phase separator and concentrated in vacuo, and then crude product was 
purified using preparative HPLC (30x50mm column, MeCN/0.1% TFA:Water, 4 min 
gradient) to yield desired compounds 1.6-1.79 
 
 
 
 
(1S,2R)-N1-(4-chloro-4-fluorophenyl)cyclohexane1,2-dicarboxamide (1.21). 
White solid, 24% yield. 1H NMR (400 MHz, DMSO) δ 10.0 (s, 1H), 7.82 (dd, J = 12.5, 
2.0 Hz, 1H), 7.49 (t, J = 9.1 Hz, 1H), 7.35 (dd, J = 9.1, 2.0 Hz, 1H), 7.09 (bs, 1H), 
6.75 (bs, 1H), 2.85 (m, 1H), 2.51 (m, 1H), 2.21-2.10 (m, 1H), 2.09-2.00 (m, 1H), 
1.77-1.64 (m, 3H), 1.61-1.50 (m, 1H), 1.46-1.29 (m, 2H); 13C NMR (100 MHz, 
DMSO) δ 175.5, 173.5, 156.9 (d, JCF = 243.5 Hz), 140.3 (d, JCF = 10.2 Hz), 130.2, 
115.9 (JCF = 3.1), 112.0 (d, JCF = 17.8), 107.0 (d, JCF = 26.2 Hz), 43.3, 42.6, 27.4, 
25.8, 24.0, 22.2. LCMS: 0.867 min; M+H= 299.2; >99% at 215 and 254 nm. 
  
105  
 
General Procedure for Compounds 1.82-1.89. 
To a solution of 9 (0.06 mmol, 1 eq) in DMF (0.5 mL) in a 1-dram vial, HATU (0.126 
mmol, 2 eq) and N,NDiisopropylethylamine (0.190 mmol, 3 eq) were added. The 
reaction was stirred for 10 minutes, then amine (0.076 mmol, 1.2 eq) was added and 
the reaction was stirred for 8 hours at room temperature. The crude reaction mixture 
was diluted with water (1.5mL) and extracted with DCM (3x2mL) and the organics 
were passed through a phase separator and concentrated in vacuo. Crude product 
was purified using preparative HPLC (30x50mm column, MeCN/0.1% TFA:Water, 4 
min gradient) to yield desired compounds 1.82-1.89. 
 
 
 
2-(3-cyano-4-iosbutoxyphenyl)-4-methyl-N-(tetrahydro-2H-pyran-4-
yl)thiazole-5-carboxamide (1.85).  
Yellow solid, 63% yield. 1H NMR (400MHz, CDCl3) δ 8.11 (d, J = 2.2 Hz, 1H), 8.04 
(dd, J = 8.6, 2.2 Hz, 1H), 6.99 (d, J = 8.6 Hz,  1H), 5.72 (d, J = 7.5 Hz, 1H), 4.16 (m, 
1H), 4.00 (m, 2H), 3.89 (d, J = 6.6 Hz, 2H), 3.52 (td, J = 11.6, 1.5 Hz, 2H), 2.71 (s, 
3H), 2.19 (sep, J = 6.6 Hz, 1H), 1.97-2.05 (m, 2H), 1.58 (qd, J = 11.6, 4.1 Hz, 2H), 
1.08 (d, J = 6.6 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 164.6, 162.5, 161.1, 132.6, 
132.1, 126.1, 125.9, 115.6, 112.8, 103.1, 75.9, 66.9, 46.7, 33.3, 28.3, 19.2, 17.6. 
LCMS: 1.043 min; M+H= 400.2; >99% at 215 and 254 nm. 
 
General Procedure for tert-butyl 3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-
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yl]azetidine-1-carboxylate and tert-butyl 3-[3-[3-(trifluoromethyl)phenyl]-1,2,4-
oxadiazol-5-yl]azetidine-1-carboxylate (1.93-1.94). 
To a solution of 3-chloro-N'-hydroxybenzenecarboximidamide or 3-
(trifluoromethyl)benzamidoxime (1 eq), T3P (2.5 eq), and triethylamine (3 eq) in ethyl 
acetate (0.2 M) in a microwave vial was added 1-Boc-azetidine-3-carboxylic acid (1 
eq). The vial was capped and the reaction was heated to 150 °C via microwave 
irradiation for 30 minutes. After cooling to room temperature, the reaction was 
washed with saturated ammonium chloride, then extracted with EtOAc (3x), and the 
organics were pooled, passed through a phase separator and concentrated in 
vacuo. Crude product was purified using Teledyne ISCO Combi-Flash system (0-
50% EtOAc/Hex) to yield desired products.  
 
 
 
3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]azetidine-1-carboxylate (1.93). 
Yellow oil, 61%. 1HNMR  (400 MHz, CDCl3)  δ  7.98 (t, J =  1.7, 1H), 7.87 (dt, J = 
7.6, 1.3 Hz, 1H),  7.40-7.37 (m, 1H), 7.32 (t,  J = 7.7 Hz, 1H), 4.31 (t, J = 8.8 Hz, 
2H), 4.24 (dd, J = 8.7, 6.0 Hz, 2H),  4.05-3.92 (m, 1H),   1.40 (s, 9H); 13CNMR  
(100 MHz, CDCl3) δ 179.4, 167.5, 155.8, 134.9, 131.3, 130.2, 128.2, 127.4, 125.5, 
80.1, 53.2, 28.3, 25.7. 
 
 
 
tert-butyl 3-[3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]azetidine-1-
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carboxylate (1.94).  
 Yellow oil, 57%.  1HNMR  (400 MHz, CDCl3)  δ  8.36 (bs,  1H), 8.27 (d, J = 7.8 Hz, 
1H), 7.75 (t, J = 7.84 Hz, 1H),  7.63 (d, J = 7.84 Hz, 1H), 4.39 (t, J = 4.4 Hz, 2H), 
4.32 (dd, J = 8.6, 6.0 Hz, 2H), 4.06 (tt, J = 7.4, 6.0 Hz, 1H), 1.46 (s, 9H); 13CNMR 
(100 MHz, CDCl3)  179.8, 167.8, 156.1, 131.4 (q, J = 32.8 Hz), 130.7, 139.7, 128.1 
(q, J = 3.7 Hz), 127.6, 124.6 (q, J = 3.8 Hz),  123.9 (q, J = 270.7 Hz), 80.5, 53.3, 
28.5, 25.9.  
 
General Procedure for 5-(azetidin-3-yl)-3-(3-chlorophenyl)-1,2,4-oxadiazole 
hydrochloride and 5-(azetidin-3-yl)-3-[3-(trifluoromethyl)phenyl]-1,2,4-
oxadiazole hydrochloride (1.95-1.96). 
To a solution of 1.93 or 1.94 (1 eq) in 1,4-Dioxane (0.37 M) was added 4M 
HCl/Dioxane slowly. The reaction was stirred for 6 hours, at which point LCMS 
analysis indicated full conversion of starting material to desired product and a 
precipitate had formed. The precipitate was isolated via vacuum filtration, washing 
with ether and hexanes, to yield the desired product as a white solid.  
 
 
 
5-(azetidin-3-yl)-3-(3-chlorophenyl)-1,2,4-oxadiazole hydrochloride (1.95). 
White solid, 75% yield. 1HNMR  (400 MHz, DMSO)  δ   9.70 (bs, 1H), 9.43 (bs, 
1H), 8.03-7.98 (m, 2H), 7.76-7.68 (m, 1H), 7.64 (t, J = 7.8 Hz, 1H), 4.59 (m, 1H), 
4.42-4.25 (m, 4H);  13CNMR  (100 MHz, DMSO) δ  178.6, 166.6, 134.0, 131.6, 
131.4, 127.9, 126.5, 125.6,  48.2, 28.1.  
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5-(azetidin-3-yl)-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole hydrochloride 
(1.96).  
White solid, 30% yield. 1HNMR  (400 MHz, DMSO)  δ 9.63 (bs, 2H), 8.34 (d, J = 
7.8 Hz, 1H), 8.27 (s, 1H), 8.02 (d, J = 7.9 Hz), 7.87 (t, J = 7.8 Hz, 1H), 4.60-4.49 
(m, 1H), 4.41-4.29 (m, 4H); 13CNMR  (100 MHz, DMSO) δ 178.9, 166.6, 130.9, 
130.4 (q, J = 32.2), 128.4 (q, J = 3.54), 127.0, 123.7 (q, J = 270.7), 123.3 (q, J = 
3.9), 48.4, 28.2.  
 
General Procedure for 1.98-1.139.  
To a solution of substituted benzoic acid (1 eq) in DMF (0.2 M) at room temperature 
was added HATU (2 eq) and DIEA (4 eq). This mixture was stirred for 10 minutes 
before the addition of 1.95 or 1.96. The reaction was allowed to stir overnight, then 
diluted with water (1 mL) and extracted with DCM (3x2 mL). The organics were 
passed through a phase separator then purified by Gilson HPLC to yield desired 
compounds.  
 
 
 
 
[3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]azetidin-1-yl]-(3-fluoro-2-
thienyl)methanone (1.130).  
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Clear oil, 40% yield. 1HNMR  (400 MHz, CDCl3) δ 8.38 (s, 1H), 8.29 (d, J = 7.8 Hz, 
1H), 7.79, (d, J = 8.1 Hz, 1H), 7.65 (t, J = 7.8 Hz, 1H), 7.58-7.55 (m, 2H), 7.15-7.12 
(m, 1H), 4.99-4.54 (m, 4H), 4.28 (tt, J = 7.5, 6.0 Hz, 1H); 13CNMR  (100 MHz, 
CDCl3) δ 179.2, 167.9, 163.2, 136.0, 131.8 (q, J = 32.7 Hz), 131.0, 130.8, 130.8, 
129.8, 128.2 (q, J = 3.7 Hz), 127.9, 127.4, 124.7 (q, J = 3.8), 123.9 (q, J = 271 Hz), 
26.7.  
 
 
 
 
2-thienyl-[3-[3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]azetidin-1-
yl]methanone (1.134).  
Clear oil, 5%. 1HNMR  (600 MHz, CDCl3) δ 8.01 (t, J = 1.7 Hz, 1H), 7.99 (dt, J = 
4.4, 1.1 Hz, 1H), 7.51-7.48 (m, 1H), 7.44 (t, J = 7.9 Hz, 1H), 7.42 (t, J = 5.5 Hz, 
1H), 6.83 (d, J = 5.5 Hz, 1H), 4.87-4.52 (m, 4H), 4.23 (tt, J = 7.7, 6.2 Hz, 1H); 
13CNMR  (125 MHz, CDCl3) δ 179.1, 167.9, 156.0 (d, J = 222 Hz) 135.2, 131.7, 
130.4, 129.7 (d, J = 8.3 Hz), 128.3, 127.8, 125.8, 118.2 (d, J = 22.7 Hz), 115.9 (d, 
J = 12.8 Hz), 26.6, 26.5 ppm. 
 
General Procedure for the synthesis of 1.143-1.181.  
To a solution of 5-(p-tolyl)-1,3,4-oxadiazol-2-amine (1 eq) in DMF (0.05 eq) at room 
temperature was added DIEA (3 eq) and substituted acyl chloride (1.2 eq) or 
carboxylic acid (1.2 eq) and HATU (1.1 eq). The reaction was stirred overnight at 
room temperature, then diluted with water (2 mL) and extracted with DCM (3x2mL). 
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The organics were passed through a phase separator then concentrated under a 
constant stream of air and purified using Gilson HPLC to yield desired material in 2-
20% yield. 
 
 
 
4-fluoro-N-[5-(p-tolyl)-1,3,4-oxadiazol-2-yl]benzamide (1.143).  
White solid, 11% yield. 1HNMR  (600 MHz, DMSO) δ 8.16-8.09 (m, 2H), 7.86 (d, J 
= 7.9 Hz, 2H), 7.45-7.38 (m, 4H), 2.40 (s, 3H); 13CNMR (125 MHz, DMSO) δ 165.3 
(d, J = 208 Hz), 161.9, 158.1, 142.4, 131.7 (d, J = 7.5 Hz), 130.5, 129.2 (d, J = 
10.8 Hz), 126.5, 121.1, 116.2 (d, J = 18.1 Hz), 21.6.  
 
 
 
methyl 6-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]pyridine-3-carboxylate 
(1.154).   
To a solution of methyl 6-hydroxynicotinate (300 mg, 1.96 mmol) in DMF (9.8 mL) 
at 23 oC was added potassium carbonate (412 mg, 2.94 mmol) and 3-
(trifluoromethyl)benzyl bromide (359 μL, 2.35 mmol). The reaction was stirred for 5 
hours, at which point LCMS analysis indicated full conversion to desired product. 
The reaction was diluted with water (10 mL) and extracted with DCM (3x10 mL). 
The organics were washed with water (2x20 mL), then passed through a phase 
separator and concentrated in vacuo. Crude product was purified using Teledyne 
ISCO Combi-Flash system (solid loading, 12G column, 0-50% EtOAc/Hex) to yield 
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methyl 6-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]pyridine-3-carboxylate (390 
mg,1.25 mmol, 63.96% yield) as a white solid. 1HNMR (400 MHz, CDCl3) δ 8.21 (d, 
J = 2.4 Hz, 1H), 7.82 (dd, J = 9.6, 2.5 Hz, 1H), 7.56 (bs, 1H), 7.53 (d, J = 7.7 Hz, 
1H), 7.48 (d, J = 7.7 Hz, 1H), 7.44 (q, J = 7.6 Hz, 1H), 5.18 (s, 2H), 3.80 (s, 3H); 
13CNMR (100 MHz, CDCl3) δ 164.5, 162.3, 142.7, 138.9, 136.7, 131.5, 131.3 (q, J 
= 31.5 Hz), 129.6, 125.3 (q, J = 3.7 Hz), 124.9 (q, J = 3.7 Hz), 123.9 (q, J = 276 
Hz), 120.2, 110.4, 52.6, 52.2. 
 
 
 
6-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]pyridine-3-carboxylic acid (1.155). 
To a solution of methyl 6-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]pyridine-3-
carboxylate (390 mg, 1.25 mmol) in THF (6 mL) at 23 oC was added lithium 
hydroxide (6 mL, 6 mmol) and the reaction was stirred for 1 hour, at which point 
LCMS analysis indicated product formation. The organics were removed in vacuo, 
then the aqueous was acidifed with 2M HCl and extracted with ether (2x5 mL), 
DCM (2x5 mL) and EtOAc (2x10 mL). The organics were passed through a phase 
separator then concentrated in vacuo to yield 6-oxo-1-[[3-
(trifluoromethyl)phenyl]methyl]pyridine-3-carboxylic acid (122 mg,0.41 mmol, 33% 
yield) as a white solid. 1HNMR (400 MHz, DMSO) δ 8.68 (d, J = 2.4 Hz, 1H), 7.82 
(dd, J = 9.5, 2.5 Hz, 1H), 7.73 (bs, 1H), 7.65 (d, J = 7.0 Hz, 1H), 7.63-7.55 (m, 2H), 
6.46 (d, J = 9.5 Hz, 1H), 5.28 (s, 2H). 13CNMR (100 MHz, CDCl3) δ 165.3, 161.6, 
144.0, 139.4, 138.3, 131.9, 129.8, 129.2 (q, J = 31.5 Hz), 124.6 (q, J = 3.7 Hz), 
124.5 (q, J = 3.6 Hz), 124.1 (q, J = 271 Hz), 120.0, 118.9, 110.4, 51.5. 
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General Procedure for the synthesis of 1.157-1.181.  
To a solution of 6-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]pyridine-3-carboxylic 
acid (1 eq) in DCM (0.03M) was added PYCLU (2 eq) and DIEA (2 eq). The 
reaction was stirred for 15 minutes before addition of amine (1 eq) and the reaction 
was heated to 100 °C for 30 minutes using microwave irradiation. The reaction 
was quenched by addition of water (2mL) then extracted with DCM (3x4mL) and 
the organics were passed through a phase separator and concentrated under a 
stream of constant air. Crude product was purified using Gilson HPLC to yield 
desired materials in 8-47% yield.  
 
   
 
 
5-(indoline-1-carbonyl)-1-(3-(trifluoromethyl)benzyl)pyridin-2(1H)-one (1.161). 
White solid, 45% yield. 1HNMR  (400 MHz, CDCl3) δ 7.85 (d, J = 2.4 Hz, 1H), 7.62-
7.56 (m, 3H), 7.54 (d, J = 7.7, 1H), 7.50 (q, J = 7.6 Hz, 1H), 7.22 (d, J = 7.3 Hz), 
7.11 (t, J = 7.3 Hz, 1H), 7.03 (t, J = 7.3 Hz, 1H), 6.66 (d, J = 9.4 Hz, 1H), 5.22 (s, 
2H), 4.10 (t, J = 8.1 Hz, 2H), 3.12 (t, J = 8.1 Hz, 2H); 13CNMR (100 MHz, CDCl3) δ 
164.8, 162.3, 142.3, 140.2, 138.8, 136.7, 132.7, 131.9, 131.6 (q, J = 32.3 Hz), 
129.8, 127.5, 125.5 (q, J = 3.7 Hz), 125.4, 125.2 (qq, J = 3.7), 124.5, 123.9 (q, J = 
271 Hz), 120.4, 116.8, 116.2, 52.6, 50.9, 28.4. 
 
General Procedure for 1.185-1.210.  
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To a solution of 4-(3-aminophenyl)benzonitrile (1 eq) in methanol (0.2M) at room 
temperature was added corresponding aldehyde (1.6 eq) and the reaction was 
heated to 60 °C for 2 hours. After cooling to room temperature, sodium 
borohydride (2 eq) was added and the reaction was stirred an additional hour at 
room temperature, then diluted with water (5mL) and extracted with DCM (3x8mL). 
The organics were passed through a phase separator and concentrated in vacuo, 
then the resulting crude intermediate was dissolved in THF (0.2M) and to this 
solution was added pyridine (1 eq) and ethanesulfonyl chloride (1.2 eq) for 1.185-
1.208 or 2,2,2-trifluoroethylsulfonyl chloride (1.2 eq) for 1.209-1.210. The reaction 
was heated to 60 °C overnight, then cooled to room temperature and diluted with 
water (3mL) and extracted with ether (3x3mL). The organics were pooled, passed 
through a phase separator and concentrated under a constant stream of air, then 
purified using Gilson HPLC to give desired materials in 2-45% yield.  
 
 
 
 
 
N-(4'-cyano-[1,1'-biphenyl]-3-yl)-N-(thiazol-5-ylmethyl)ethanesulfonamide 
(1.194). Brown solid, 45% yield. 1HNMR  (400 MHz, CDCl3) δ 8.73 (s, 1H), 7.69 (d, 
J = 8.4 Hz, 2H), 7.58 (t, J = 7.1 Hz, 3H), 7.55-7.50 (m, 1H), 7.47 (d, J = 7.8 Hz, 
1H), 7.45 (t, J = 1.8 Hz, 1H), 7.35-7.28 (m, 1H), 5.13 (s, 2H), 3.10 (q, J = 7.4 Hz, 
2H), 1.42 (t, J = 7.4 Hz, 3H); 13CNMR (100 MHz, CDCl3) δ 154.5, 144.2, 143.3, 
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140.9, 139.3, 134.1, 132.8, 130.4, 128.6, 128.4, 127.9, 127.4, 118.8, 111.7, 53.6, 
47.6, 46.6, 8.2.  
 
 
 
2,4-difluoro-N-[2-[6-[4-(trifluoromethoxy)phenyl]pyridazin-3-
yl]oxyethyl]benzenesulfonamide (1.217).  
To a solution of 2-(6-chloropyridazin-3-yl)oxyethanamine (882 mg, 5.08 mmol) in 
DCM (25.403mL) at 23 oC was added DIEA (1.77 mL, 10.16 mmol, 2 eq) and 2,4-
difluorobenzenesulfonyl chloride (1296 mg, 6.1 mmol, 1.2 eq). The reaction was 
stirred for 2 hours at this temperature, then diluted with water (20mL) and the 
layers were separated, the aqueous was extracted with DCM (2x20mL), then the 
organics were pooled, dried over magnesium sulfate, filtered, and concentrated in 
vacuo. Crude product was purified using Teledyne ISCO Combi-Flash system 
(solid loading, 12G column, 0-60% EtOAc/Hex) to yield N-[2-(6-chloropyridazin-3-
yl)oxyethyl]-2,4-difluoro-benzenesulfonamide (763 mg, 2.18 mmol, 43% yield) as a 
tan solid. 1HNMR (400 MHz, DMSO) δ 8.31 (t, J = 5.6 Hz, 1H), 7.91-7.81 (td, J = 
8.6, 6.4 Hz, 1H), 7.75 (d, J = 9.2 Hz, 1H), 7.49-7.41 (m, 1H), 7.24 (td, J = 8.4, 2.0 
Hz, 1H), 7.13 (d, J = 9.2 Hz, 1H), 4.39 (t, J = 5.3 Hz, 2H), 3.36 (q, J = 7.0 Hz, 2H); 
13CNMR (100 MHz, DMSO) δ 166.0 (d, J = 11.8 Hz), 163.9, 163.5 (d, J = 11.7), 
160.2 (d, J = 13.5 Hz), 157.6 (d, J = 13.2), 150.8, 131.6, 131.5 (d, J = 11.3), 125.5 
(dd, J = 57.2, 3.65 Hz), 120.8, 112.2 (dd, J = 86.7, 3.41 Hz), 105.9 (t, J = 25.9 Hz), 
65.8, 41.4.  
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To a solution of N-[2-(6-chloropyridazin-3-yl)oxyethyl]-2,4-difluoro-
benzenesulfonamide (100 mg, 0.29 mmol, 1 eq) in 1,4-dioxane (0.14M) in a 2-5 
mL microwave vial was added aqueous sodium carbonate (2M, 429 μL, 0.86 
mmol, 3 eq), 4-trifluoromethoxyphenylboronic acid (71 mg, 0.34 mmol, 1.2 eq) and 
tetrakis(triphenylphosphine)palladium(0) (17 mg, 0.01 mmol, 0.05 eq). The vial 
was sealed and heated to 120 °C for 30 minutes using microwave irradiation. After 
cooling to room temperature, the reaction mixture was filtered through a plug of 
celite, washing with EtOAc (3x10mL). The layers were separated and the aqueous 
was extracted with EtOAc (3x5mL), then the organics were pooled, dried over 
magnesium sulfate, filtered, and concentrated in vacuo. Crude product was 
purified using Gilson HPLC (55-85% 0.1% aq. TFA/MeCN) to yield 2,4-difluoro-N-
[2-[6-[4-(trifluoromethoxy)phenyl]pyridazin-3-yl]oxyethyl]benzenesulfonamide (88 
mg, 0.19 mmol, 65%) as a white solid. 1HNMR (400 MHz, CDCl3) δ 8.01-7.95 (m, 
2H), 7.93 (td, J = 8.5, 6.2 Hz, 1H), 7.75 (d, J = 9.2 Hz), 7.31 (d, J = 8.3 Hz, 2H), 
6.99 (d, J = 9.2 Hz, 1H), 6.97-6.92 (m, 1H), 6.89-6.82 (m, 1H), 5.73 (t, J = 6.0 Hz, 
1H), 4.62 (t, J = 5.1 Hz, 2H), 3.55 (q, J = 5.2 Hz, 2H); 13CNMR (100 MHz, CDCl3) δ 
167.1 (d, J = 11.6 Hz), 164.6 (d, J = 11.5 Hz), 163.8, 160.9 (d, J = 12.8 Hz), 158.4 
(d, J = 12.8 Hz), 154.6, 150.5, 134.6, 132.0 (d, J = 9.9 Hz), 128.2, 127.5, 125.0 
(dd, J = 56.0, 3.65 Hz), 121.4, 120.6 (d, J = 256 Hz), 118.0, 112.1 (dd, J = 86.6, 
3.50 Hz), 105.7 (t, J = 25.4 Hz), 66.0, 42.7. 
 
General Procedure for the synthesis of 1.273-1.282. 
To a solution of p-toluoyl chloride (1 eq) in acetone (0.19M) was added potassium 
thiocyanate (1.65 eq) and the reaction was stirred for 30 minutes at room 
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temperature. Next, the corresponding amine (2 eq) was added and the reaction 
was stirred overnight, then diluted with water (2mL) and extracted with DCM 
(3x3mL). The organics were passed through a phase separator, then concentrated 
under a stream of constant air and crude product was purified using Gilson HPLC 
to yield desired material in 5-39% yield.  
 
 
N-(cyclopentylcarbamothioyl)-4-methyl-benzamide (1.281).  
Pink oil, 32% yield. 1HNMR (400 MHz, CDCl3) δ 8.33 (bs, 1H), 7.73 (d, J = 8.2 Hz, 
2H), 7.27 (d, J = 8.0 Hz, 2H), 3.36-3.27 (m, 1H), 2.40 (s, 3H), 1.99-1.88 (m, 1H), 
1.78-1.61 (m, 5H), 1.36 (d, J = 7.0 Hz, 3H); 13CNMR (100 MHz, CDCl3) δ 178.5, 
163.4, 143.9, 130.0, 129.7, 128.0, 54.9, 47.3, 30.0, 25.8, 21.7, 18.3, 15.5.  
 
General Procedure for the synthesis of 1.287-1.334. 
To a solution of (3R)-5-oxo-1,4-thiazepane-3-carboxylic acid (1 eq) in DMF (0.2M) 
was added HATU (2 eq) and DIEA (3 eq). The reaction was stirred for 15 minutes, 
then the corresponding aniline/amine nucleophile was added and the reaction was 
stirred overnight at room temperature. The reaction was then diluted with water 
(2mL) and extracted with DCM (3x2mL), then the organics were pooled, passed 
through a phase separator and concentrated in vacuo. Crude product was purified 
using Gilson HPLC to yield desired material in 5-48% yield.  
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(3R)-N-(3-chlorophenyl)-5-oxo-1,4-thiazepane-3-carboxamide (1.299).  
Yellow oil, 48%. 1HNMR (400 MHz, DMSO) δ 10.40 (s, 1H), 7.80 (t, J = 2.0 Hz, 
1H), 7.48-7.44 (m, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.17-7.13 (m, 1H), 7.13-7.09 (m, 
1H), 4.54-4.48 (m, 1H), 3.03 (dd, J = 14.4, 2.2 Hz, 1H), 2.95 (dd, J = 14.4, 8.2 Hz, 
1H), 2.90-2.73 (m, 3H), 2.72-2.68 (m, 2H); 13CNMR (100 MHz, CDCl3) δ 174.3, 
168.1, 134.0, 133.1, 130.1, 123.5, 119.1, 118.0, 57.8, 40.3, 33.9, 23.5.  
 
 
 
1-methoxy-2,3-dimethylbenzene (1.341).  
To a solution of cyclopentyl acetic acid (6.2 g, 48.4 mmol, 1 eq) was added thionyl 
chloride (16.5 mL, 226.4 mmol, 4.7 eq) and the reaction was heated to reflux for 1 
hour. After cooling to room temperature, the reaction was concentrated in vacuo, 
then the resulting residue was dissolved in DCM (242 mL, 0.2M) and placed in an 
ice bath. Next, 2,3-dimethylanisole (8.0 mL, 58 mmol, 1.2 eq) and aluminum 
chloride (6.45 g, 48 mmol, 1 eq) were added and the reaction was allowed to 
slowly warm to room temperature overnight. The reaction was quenched by 
pouring over crushed ice, then the layers were separated and the aqueous was 
extracted with DCM (3x50 mL). The organics were pooled, dried over magnesium 
sulfate, filtered, and concentrated in vacuo, then crude product was purified using 
Teledyne ISCO Combi-Flash system (liquid loading, 120g, 0-5% EtOAc/Hex) to 
yield 2-cyclopentyl-1-(4-methoxy-2,3-dimethyl-phenyl)ethanone (10.2 g, 41.2 
mmol, 85%) as a yellow oil. 1HNMR (400 MHz, CDCl3) δ 7.43 (d, J = 8.6 Hz, 1H, 
1H), 6.71 (d, J = 8.6 Hz, 1H), 3.84 (s, 3H), 2.87 (d, J = 7.2 Hz, 2H), 2.36 (s, 3H), 
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2.35-2.25 (m, 1H), 2.17 (s, 3H), 1.88-1.79 (m, 2H), 1.69-1.57 (m, 2H), 1.57-1.48 
(m, 2H), 1.22-1.10 (m, 2H); 13CNMR (100 MHz, CDCl3) δ 205.2, 159.4, 137.9, 
132.9, 127.2, 126.7, 106.6, 55.6, 48.4, 36.7, 32.7, 25.1, 17.1, 11.8.  
 
 
 
2-cyclopentyl-1-(4-methoxy-2,3-dimethyl-phenyl)prop-2-en-1-one (1.344).  
To a solution of 1-methoxy-2,3-dimethylbenzene (10.2 g, 41 mmol, 1 eq) and 
paraformaldehyde (9.3 g, 103 mmol, 2.5 eq) in acetic acid (10 mL) was added 
dimethylamine hydrochloride (15.1 g, 186 mmol, 4.5 eq) and the reaction was 
heated to 80 °C for 16 hours, at which point LCMS analysis indicated full 
conversion to Mannich intermediate. The reaction was then diluted with DMF (60 
mL, 0.69M) and the reaction was heated to 120 °C for an additional 16 hours. After 
cooling to room temperature the reaction was diluted with water (60mL) and 
extracted with DCM (3x100mL). The organics were pooled, dried over magnesium 
sulfate, filtered, and concentrated in vacuo, then crude product was purified using 
Teledyne ISCO Combi-Flash system (liquid loading, 120g, 0-5% EtOAc/Hex) to 
yield 2-cyclopentyl-1-(4-methoxy-2,3-dimethyl-phenyl)prop-2-en-1-one (10.3g, 40 
mmol, 96%) as a yellow oil. 1HNMR (400 MHz, CDCl3) δ 7.12 (d, J = 8.5 Hz, 1H), 
6.69 (d, J = 8.5 Hz, 1H), 5.78 (s, 1H), 5.53 (s, 1H), 3.83 (s, 3H), 3.10 (p, J = 8.4 
Hz), 1H), 2.23 (s, 3H), 2.16 (s, 3H), 2.03-1.92 (m, 2H), 1.79-1.68 (m, 2H), 1.49-
1.38 (m, 2H); 13CNMR (100 MHz, CDCl3) δ 201.2, 158.8, 154.2, 136.9, 132.8, 
127.4, 126.1, 124.7, 106.5, 55.6, 40.6, 31.9, 25.0, 17.2, 11.7.  
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2-cyclopentyl-5-methoxy-6,7-dimethyl-indan-1-one (1.345). 
A solution of 2-cyclopentyl-1-(4-methoxy-2,3-dimethyl-phenyl)prop-2-en-1-one 
(10.3 g, 40 mmol, 1 eq) in sulfuric acid (48 mL) was stirred for 4 hours at room 
temperature, then quenched by pouring the reaction mixture over crushed ice. The 
resulting mixture was extracted with ether (3x100 mL), then the organics were 
pooled, dried over magnesium sulfate, filtered, and concentrated in vacuo to yield 
2-cyclopentyl-5-methoxy-6,7-dimethyl-indan-1-one (8.0 g, 31.0 mmol, 78%) as a 
yellow oil in sufficient purity for further transformations. An analytical sample was 
obtained using flash chromatography. 1HNMR (400 MHz, CDCl3) δ 6.64 (s, 1H), 
3.81 (s, 3H), 3.02 (dd, J = 17.0, 7.8 Hz, 1H), 2.68 (dd, J = 17.0, 3.7 Hz, 1H), 2.62-
2.56 (m, 1H), 2.54 (s, 3H), 2.33-2.20 (m, 1H), 2.06 (s, 3H), 1.92-1.83 (m, 1H), 
1.64-1.50 (m, 3H), 1.50-1.44 (m, 2H), 1.41-1.29 (m, 1H), 1.08-0.97 (m, 1H); 
13CNMR (100 MHz, CDCl3) δ 208.0, 162.4, 154.9, 138.2, 127.7, 125.1, 104.2, 
55.4, 51.1, 41.3, 30.7, 29.6, 28.2, 25.3. 25.2, 13.7, 10.8.  
 
 
 
2-cyclopentyl-6,7-dimethyl-5-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl]methoxy]indan-1-one (1.348). 
To a solution of 2-cyclopentyl-5-methoxy-6,7-dimethyl-indan-1-one (716 mg, 2.77 
mmol, 1 eq) in Toluene (13.9 mL, 0.2M) at room temperature was added aluminum 
chloride (1.1 g, 8.31 mmol, 3 eq). The reaction was heated to 110 oC for one hour, 
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then cooled to room temperature, then was poured over crushed ice. After the ice 
had melted, the resulting solution was extracted with ether (3x75mL) and the 
organics were pooled, dried over magnesium sulfate, filtered, and concentrated in 
vacuo to yield 2-cyclopentyl-5-hydroxy-6,7-dimethyl-indan-1-one as a red/pink 
solid that was taken on without further purification.  
 
A solution of 2-cyclopentyl-5-hydroxy-6,7-dimethyl-indan-1-one (390 mg, 1.6 mmol, 
1 eq), 3-bromomethylphenylboronic acid pinacol ester (521 mg , 1.76 mmol, 1.1 eq 
eq), and cesium carbonate (576 mg, 1.76mmol, 1.1 eq) at 23 oC in DMF (7.981mL) 
was stirred overnight. The reaction was quenched by addition of water (10mL) and 
extracted with DCM (3x10mL). The organics were pooled, dried over magnesium 
sulfate, filtered, and concentrated in vacuo. Crude product was purified using 
Teledyne ISCO Combi-Flash system (solid loading, 12G column, 0-40% 
EtOAc/Hex) to yield 2-cyclopentyl-6,7-dimethyl-5-[[3-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl]methoxy]indan-1-one (537 mg,1.17 mmol, 73% yield) as 
a bright red oil. 1HNMR (400 MHz, CDCl3) δ 7.87 (bs, 1H), 7.81 (d, J = 7.3 Hz, 1H), 
7.58 (d, J = 7.8 Hz, 1H), 7.44 (t, J = 7.5 Hz, 1H), 6.76 (s, 1H), 5.13 (s, 2H), 3.12-
3.01 (m, 1H), 2.76-2.66 (m, 2H), 2.62 (s, 3H), 2.39-2.28 (m, 1H), 2.19 (s, 3H), 
1.99-1.89 (m, 1H), 1.69-1.49 (m, 6H), 1.37 (s, 12H), 1.13-1.02 (m, 1H); 13CNMR 
(100 MHz, CDCl3) δ 208.5, 161.7, 155.0, 138.8, 136.1, 134.6, 133.7, 130.3, 128.3, 
128.2, 125.8, 105.7, 84.1, 70.3, 51.4, 41.5, 30.9, 29.8, 28.3, 25.5, 25.4, 25.0, 14.1, 
11.4.  
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methyl 5-[3-[(2-cyclopentyl-6,7-dimethyl-1-oxo-indan-5-yl)oxymethyl]phenyl]-
2-hydroxy-benzoate (1.350). 
To a solution of 2-cyclopentyl-6,7-dimethyl-5-[[3-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl]methoxy]indan-1-one (2.2 g, 4.76 mmol, 1 eq) in a 
mixture of MeCN (18 mL) and Water (9 mL) was added methyl 5-bromosalicylate 
(1.2 g, 5.23 mmol, 1.1 eq), sodium carbonate (1.02 g, 9.52 mmol, 2 eq), and 
dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(ii) dichloromethane 
adduct (195 mg, 0.24 mmol, 0.05 eq). The reaction was heated to 100 oC for 1 
hour, then cooled to room temperature then filtered through a celite, washing with 
EtOAc (3x20 mL) and the resulting filtrates were concentrated in vacuo. Crude 
product was purified using Teledyne ISCO Combi-Flash system (lquid loading, 
24G column, 0-30% EtOAc/Hex) to yield methyl 5-[3-[(2-cyclopentyl-6,7-dimethyl-
1-oxo-indan-5-yl)oxymethyl]phenyl]-2-hydroxy-benzoate (1.5 g, 3.06 mmol, 64 % 
yield) as a sticky pink solid. 1HNMR (400 MHz, CDCl3) δ 10.79 (s, 1H), 8.09 (d, J = 
1.6 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.62 (s, 1H), 7.54 (d, J = 7.3 Hz, 1H), 7.47 (t, 
J = 7.4 Hz), 7.42 (d, J = 7.3 Hz), 7.07 (d, J = 8.6 Hz, 1H), 6.80 (s, 1H), 5.18 (s, 2H), 
3.98 (s, 3H), 3.13-3.02 (m, 1H), 2.78-2.66 (m, 2H), 2.63 (s, 3H), 2.40-2.28 (m, 1H0, 
2.22 (s, 3H), 1.99-1.89 (m, 1H), 1.69-1.48 (m, 5H), 1.46-1.34 (m, 1H), 1.14-1.02 
(m, 1H); 13CNMR (100 MHz, CDCl3) δ 208.5, 170.6, 161.6, 161.3, 155.0, 140.4, 
138.9, 137.5, 134.5, 132.1, 129.3, 128.3, 126.4, 126.0, 125.7, 125.5, 18.3, 112.7, 
105.7, 70.2, 52.5, 51.4, 41.5, 30.9, 29.8, 28.3, 25.5, 25.4, 14.1, 11.4. 
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methyl 2-(2-tert-butoxy-2-oxo-ethoxy)-5-[3-[(2-cyclopentyl-6,7-dimethyl-1-
oxo-indan-5-yl)oxymethyl]phenyl]benzoate (1.351). 
To a solution of methyl 5-[3-[(2-cyclopentyl-6,7-dimethyl-1-oxo-indan-5-
yl)oxymethyl]phenyl]-2-hydroxy-benzoate (300 mg, 0.62 mmol, 1 eq) and cesium 
carbonate (800 mg, 2.44 mmol, 3.9 eq) in DMF (3.10 mL, 0.2M) at 23 oC  was 
added tert-butyl bromoacetate (0.23 mL, 1.55mmol, 2.5 eq). The reaction was 
stirred for 54 hours at room temperature, then diluted with water (30mL) and 
extracted with DCM (3x10mL). The organics were pooled, washed with water 
(2x15mL), and passed through a phase separator, then crude product was purified 
using Teledyne ISCO Combi-Flash system (solid loading, 12G column, 0-25% 
EtOAc/Hex) to yield methyl 2-(2-tert-butoxy-2-oxo-ethoxy)-5-[3-[(2-cyclopentyl-6,7-
dimethyl-1-oxo-indan-5-yl)oxymethyl]phenyl]benzoate (332 mg, 0.55 mmol, 89% 
yield) as a pink foam. 1HNMR (400 MHz, CDCl3) δ 8.09 (d, J = 2.3 Hz, 1H), 8.08 
(dd, J = 8.6, 2.4 Hz, 1H), 7.62 (bs, 1H), 7.54 (d, J = 7.5 Hz, 1H), 7.45 (t, J = 7.5 Hz, 
1H), 7.41 (d, J = 7.5 Hz, 1H), 6.93 (d, J = 8.6 Hz, 1H), 6.79 (s, 1H), 5.17 (s, 2H), 
4.65 (s, 2H), 3.93 (s, 3H), 3.11-3.01 (m, 1H), 2.76-2.64 (m, 2H), 2.62 (s, 3H), 2.38-
2.25 (m, 1H), 2.21 (s, 3H), 1.97-1.86 (m, 1H), 167-1.51 (m, 5H), 1.49 (s, 10H), 
1.43-1.35 (m, 1H), 1.13-1.01 (m, 1H); 13CNMR (100 MHz, CDCl3) δ 208.4, 167.5, 
166.4, 161.6, 140.1, 138.8, 137.5, 134.0, 131.7, 130.6, 129.3, 128.3, 126.5, 126.1, 
125.7, 125.6, 121.2, 114.2, 105.7, 82.6, 70.1, 66.8, 52.3, 51.3, 41.4, 30.9, 29.8, 
28.3, 28.1, 25.5, 25.3, 14.0, 11.4. 
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To a solution of methyl 2-(2-tert-butoxy-2-oxo-ethoxy)-5-[3-[(2-cyclopentyl-6,7-
dimethyl-1-oxo-indan-5-yl)oxymethyl]phenyl]benzoate (332 mg, 0.55 mmol) in 
DCM (2.5 mL) at 23 oC was added trifluoroacetic acid (2.5 mL). The reaction was 
stirred for 1 hour, then the organics were removed in vacuo. The resulting residue 
was diluted with water (10mL) and extracted with DCM (3x15mL). The organics 
were passed through a phase separator and concentrated in vacuo to yield 2-[4-[3-
[(2-cyclopentyl-6,7-dimethyl-1-oxo-indan-5-yl)oxymethyl]phenyl]-2-
methoxycarbonyl-phenoxy]acetic acid (271 mg,0.50 mmol, 90% yield) as an off-
white solid. 1HNMR (400 MHz, DMSO) δ 7.96 (d, J = 2.4 Hz, 1H), 7.81 (dd, J = 8.7, 
2.4 Hz), 1H), 7.75 (bs, 1H), 7.61 (d, J = 7.5 Hz, 1H), 7.48 (t, J = 7.6 Hz, 1H), 7.44 
(d, J = 7.6 Hz, 1H), 7.12 (d, J = 8.8 Hz, 1H), 7.01 (s, 1H), 5.23 (s, 2H), 4.83 (s, 2H), 
3.83 (s, 3H), 3.04 (dd, J = 16.9, 7.6 Hz, 1H), 2.66-2.54 (m, 2H), 2.50 (s, 3H), 2.21-
2.12 (m, 1H), 2.10 (s, 3H), 1.85-1.76 (m, 1H), 1.61-1.53 (m, 1H), 1.53-1.41 (m, 
4H), 1.36-1.25 (m, 1H), 1.06-.95 (m, 1H); 13CNMR (100 MHz, CDCl3) δ 207.1, 
169.8, 166.0, 160.9, 156.4, 154.7, 138.9, 137.6, 137.3, 132.3, 131.2, 129.2, 128.8, 
127.3, 126.2, 125.8, 125.3, 124.7, 120.9, 114.2, 106.2, 69.5, 65.2, 52.0, 50.6, 40.8, 
30.2, 29.2, 27.9, 25.0, 24.7, 13.4, 10.9. 
 
 
 
tert-butyl N-tert-butoxycarbonyl-N-(2-methoxy-4-nitro-phenyl)carbamate 
(1.353). 
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To a solution of 2-methoxy-4-nitroaniline (3000 mg, 17.8 mmol) and 4-
dimethylaminopyridine (1.07 g, 8.92 mmol, 0.5 eq) in THF (60 mL) at 23 oC was 
added di-tert-butyl dicarbonate (8.2 g, 37.47 mmol, 2.5 eq). The reaction was 
stirred for 5 hours then quenched by addition of saturated ammonium chloride 
(20mL), the layers were separated, and the aqueous was extracted with ether 
(3x25mL). The organics were pooled, dried over magnesium sulfate, filtered, and 
concentrated in vacuo to yield (5.4 g,15 mmol, 82% yield) as a yellow foam that 
was taken on without further purification. 
 
 
 
tert-butyl N-(4-amino-2-methoxy-phenyl)-N-tert-butoxycarbonyl-carbamate 
(1.354). 
To a solution of tert-butyl N-tert-butoxycarbonyl-N-(2-methoxy-4-nitro-
phenyl)carbamate (4.44 g, 12.03 mmol) in Ethanol (60 mL) at 23 oC was added 
palladium on activated carbon (443 mg) and the reaction was stirred under 
hydrogen atmosphere overnight. The reaction was filtered through a plug of celite 
then concentrated in vacuo to yield tert-butyl N-(4-amino-2-methoxy-phenyl)-N-tert-
butoxycarbonyl-carbamate (3.9 g,11 mmol, 9577% yield) as a brown foam that 
was taken on without further purification. 
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tert-butyl N-tert-butoxycarbonyl-N-[2-methoxy-4-(pyridine-2-
carbonylamino)phenyl]carbamate (1.356). 
A solution of tert-butyl N-(4-amino-2-methoxy-phenyl)-N-tert-butoxycarbonyl-
carbamate (3.5 g, 10.3 mmol, 1 eq) in DCE (20 mL) at room temperature was 
added N,N-diisopropylethylamine (6.3 mL, 36 mmol, 3.5 eq) and picolinoyl chloride 
hydrochloride (2.2 g, 12 mmol, 1.2 eq). The reaction was heated to 80 oC for 5 
hours, then the reaction was cooled to room temperature then diluted with water 
(50 mL) and extracted with DCM (3x50 mL). The organics were pooled, dried over 
magnesium sulfate, filtered, and concentrated in vacuo, then crude product was 
purified using Teledyne ISCO Combi-Flash system (solid loading, 40G column, 0-
60% EtOAc/Hex) to yield tert-butyl N-tert-butoxycarbonyl-N-[2-methoxy-4-
(pyridine-2-carbonylamino)phenyl]carbamate (640 mg,1.44 mmol, 14% yield) along 
with residual starting material. 1HNMR (400 MHz, CDCl3) δ 10.07 (bs, 1H), 8.59 
(dq, J = 4.8, 0.7 Hz, 1H), 8.26 (dt, J = 4.4, 0.9 Hz, 1H), 7.91 (td, J = 7.7, 1.7 Hz, 
1H), 7.75 (d, J = 2.1 Hz, 1H), 7.46 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 7.10 (dd, J = 8.4, 
2.1 Hz, 1H), 7.04 (d, J = 8.4 Hz, 1H), 3.85 (s, 3H), 1.38 (s, 18H); 13CNMR (100 
MHz, CDCl3) δ 162.1, 155.0, 151.9, 149.7, 148.1, 138.4, 137.9, 129.2, 126.7, 
124.7, 122.4, 111.0, 103.1, 82.2, 55.7, 28.0. 
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N-(4-amino-3-methoxy-phenyl)pyridine-2-carboxamide (1.357) 
To a solution of tert-butyl N-tert-butoxycarbonyl-N-[2-methoxy-4-(pyridine-2-
carbonylamino)phenyl]carbamate (805 mg, 1.82 mmol) in DCM (9 mL) was added 
trifluoroacetic acid (9 mL) and the reaction was stirred for 1 hour, at which point 
LCMS analysis indicated full conversion to desired product. The organics were 
concentrated in vacuo then the residue was quenched by addition of saturated 
sodium bicarbonate, and the resulting yellow mixture was extracted with DCM 
(3x15mL). The organics were pooled, dried over magnesium sulfate, filtered, and 
concentrated in vacuo to yield N-(4-amino-3-methoxy-phenyl)pyridine-2-
carboxamide (287 mg, 1.18 mmol, 65% yield) as a waxy yellow solid. 1HNMR (400 
MHz, CDCl3) δ 9.86 (s, 1H), 8.56 (d, J = 4.6 Hz, 1H0, 8.26 (d, J = 7.8 Hz, 1H), 7.86 
(td, J = 7.7, 1.6 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.45-7.37 (m, 1H), 6.99 (dd, J = 
8.3, 2.2 Hz, 1H), 6.69 (d, J = 8.3 Hz, 1H), 3.87 (s, 3H), 3.66 (bs, 2H); 13CNMR (100 
MHz, CDCl3) δ 161.6, 150.2, 148.0, 147.4, 137.7, 133.1, 129.6, 126.6, 122.2, 
114.8, 112.5, 103.7, 55.6.  
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N-[4-[(2-chloro-4-nitro-benzoyl)amino]-3-methoxy-phenyl]pyridine-2-
carboxamide (1.359).  
To a solution of N-(4-amino-3-methoxy-phenyl)pyridine-2-carboxamide (1.35 g, 5.7 
mmol, 1 eq) in DCM (29 mL, 0.2M) was added DIEA  (2 mL, 11.5 mmol, 2 eq) and 
2-chloro-4-nitrobenzoyl chloride (1.5 g, 6.88 mmol, 1.2 eq) dropwise. The reaction 
was stirred overnight at room temperature, then quenched by addition of water (30 
mL) and the layers were separated and the aqueous layer was extracted with DCM 
(2x30 mL). The organic layers were pooled, dried over magnesium sulfate, filtered, 
and concentrated in vacuo to yield N-[4-[(2-chloro-4-nitro-benzoyl)amino]-3-
methoxy-phenyl]pyridine-2-carboxamide (2.26 g,5.3 mmol, 92% yield) as a brown 
foam. Product was taken on without further purification. An analytically pure 
sample was obtained using Gilson HPLC. 1HNMR (400 MHz, DMSO) δ 10.67 (s, 
1H), 10.00 (s, 1H), 8.76 (d, J = 4.6 Hz, 1H), 8.38 (d, J = 1.8 Hz, 1H), 8.28 (dd, J = 
8.4, 1.8 Hz, 1H), 8.18 (d, J = 7.7 Hz, 1H), 8.10 (t, J = 7.4 Hz, 1H), 7.88 (d, J = 8.7 
Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.73-7.66 (m, 1H), 7.61 (dd, J = 8.7, 1.4 Hz, 1H), 
3.84 (s, 3H); 13CNMR (100 MHz, DMSO) δ 163.6, 162.3, 151.0, 149.8, 148.4, 
148.2, 142.6, 138.2, 136.8, 131.2, 130.1, 127.0, 124.4, 123.6, 122.3, 122.3, 122.1, 
111.7, 104.1, 55.7.  
 
 
 
N-[4-[(4-amino-2-chloro-benzoyl)amino]-3-methoxy-phenyl]pyridine-2-
carboxamide (1.360). 
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To a solution of N-[4-[(2-chloro-4-nitro-benzoyl)amino]-3-methoxy-phenyl]pyridine-
2-carboxamide (1.3 g, 3.0 mmol, 1 eq) in ethanol (15 mL) at room temperature was 
added acetic acid (7.5 mL, 131 mmol, 44 eq) and iron (631 mg, 11.3 mmol, 3.8 
eq). The reaction was heated to 100 oC for 2 hours, at which point LCMS analysis 
indicated full conversion of starting material, so the reaction was cooled to room 
temperature and basified with 1M NaOH. The resulting dark red solution was 
extracted with EtOAc (3x80 mL) and the organics were pooled and concentrated in 
vacuo to yield a brown solid that was taken on without further purification assuming 
quantitative yield. 
 
 
 
 
 
 
2-[2-[3-chloro-4-[[2-methoxy-4-(pyridine-2-
carbonylamino)phenyl]carbamoyl]anilino]-2-oxo-ethoxy]acetic acid (1.362).  
To a solution of N-[4-[(4-amino-2-chloro-benzoyl)amino]-3-methoxy-
phenyl]pyridine-2-carboxamide (1.2 g, 3.0 mmol, 1 eq) was added diglycolic 
anhydride (522 mg, 4.5 mmol, 1.5 eq) and the reaction mixture was heated to 60 
°C overnight. After cooling, the resulting precipitate was isolated via vacuum 
filtration to yield 2-[2-[3-chloro-4-[[2-methoxy-4-(pyridine-2-
carbonylamino)phenyl]carbamoyl]anilino]-2-oxo-ethoxy]acetic acid (354 mg, 0.69 
mmol, 23% yield) as an orange solid. 1HNMR (400 MHz, DMSO) δ 10.64 (s, 1H), 
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10.27 (s, 1H), 9.49 (s, 1H), 8.75 (d, J = 4.2 Hz, 1H), 8.18 (d, J = 7.7 Hz, 1H), 8.08 
(t, J = 7.0 Hz, 1H), 7.93 (s, 1H), 7.87 (d, J = 8.6 Hz, 1H), 7.77 (s, 1H), 7.71-7.65 
(m, 2H), 7.61-7.55 (m, 2H), 4.23 (s, 4H), 3.84 (s, 3H); 13CNMR (100 MHz, DMSO) 
δ 171.7, 168.6, 164.3, 162.3, 150.8, 149.8, 148.4, 140.6, 138.2, 135.9, 131.1, 
130.3, 130.0, 127.0, 126.2, 122.7, 122.3, 119.9, 117.7, 111.7, 104.1, 70.3, 68.0, 
55.8.  
 
General Procedure for the synthesis of 1.352-1.360.  
To a solution of 2-[4-[3-[(2-cyclopentyl-6,7-dimethyl-1-oxo-indan-5-
yl)oxymethyl]phenyl]-2-methoxycarbonyl-phenoxy]acetic acid (45 mg, 0.08 mmol, 1 
eq) in DMF (0.5 mL, 0.17M) was added HATU (63 mg, 0.17 mmol, 2 eq) and DIEA 
(43.3 μL, 0.25 mmol, 3 eq) and the mixture was stirred for 30 minutes at room 
temperature. Next, the corresponding monoprotected N-boc diamine (0.12 mmol, 
1.5 eq) was added and the reaction was stirred overnight, then diluted with water 
(2 mL) and extracted with DCM (3x2 mL). The organics were passed through a 
phase separator and concentrated under a stream of constant air to yield a red oil 
that was taken on without further purification assuming quantitative yield.  
 
General Procedure for the synthesis of 1.361-1.369.  
To a solution of 1.352-1.360 (0.083 mmol, 1 eq) in THF (0.25 mL, 0.33M) at room 
temperature was added 1M aqueous LiOH (0.25 mL, 0.25 mmol, 3 eq) and the 
reaction was stirred overnight. The organics were removed in vacuo, then the 
aqueous was acidified with 1M HCl, then extracted with DCM (3x4 mL) and the 
  
130  
organics were passed through a phase separator and concentrated in vacuo and 
taken on for the next reaction without further purification.  
 
The resulting residue was diluted in 1,4-dioxane (0.5 mL, 0.17M) at room 
temperature was added 4M HCl in 1,4-dioxane (0.5 mL, 2 mmol, 24 eq) and the 
reaction was stirred overnight. The organics were then concentrated in vacuo to 
yield crude 1.361-1.369 that were taken on without further purification assuming 
quantitative yield.  
 
General Procedure for the synthesis of 1.370-1.378. 
To a solution of 2-[2-[3-chloro-4-[[2-methoxy-4-(pyridine-2-
carbonylamino)phenyl]carbamoyl]anilino]-2-oxo-ethoxy]acetic acid (36.5 mg, 0.07 
mmol, 1 eq) in DMF (0.50 mL) was added HATU (27 mg, 0.07 mmol, 1 eq) and 
DIEA (12.4 µL, 0.07 mmol, 1 eq) and the mixture was stirred for 30 minutes. In 
separate vials, 1.361-1.369 were dissolved in DMF (0.50 mL) and DIEA (40 µL, 
0.23 mmol, 3.2 eq) was added. The second solution was added to the first, and the 
reaction was stirred overnight at room temperature, then diluted with water (5 mL) 
and extracted with DCM (3x5 mL) and the organics were passed through a phase 
separator and concentrated in vacuo. Crude product was purified using Gilson 
HPLC (60-100% 0.1% aq. TFA/MeCN), then fractions containing desired materials 
were pooled, the TFA salt quenched by addition of saturated sodium bicarbonate 
(5 mL), then extracted with DCM (3x5 mL). The organics were passed through a 
phase separator and concentrated in vacuo to yield 1.370-1.378 as their 
corresponding sodium salts. Due to the size of these molecules and the high 
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flexibility that could complicate NMRs, desired materials were characterized by 
LCMS analysis. Yields correspond to the yield over the final 4 steps.  
 
[2-[2-[2-[[2-[2-[3-chloro-4-[[2-methoxy-4-(pyridine-2-
carbonylamino)phenyl]carbamoyl]anilino]-2-oxo-
ethoxy]acetyl]amino]ethylamino]-2-oxo-ethoxy]-5-[3-[(2-cyclopentyl-6,7-
dimethyl-1-oxo-indan-5-yl)oxymethyl]phenyl]benzoyl]oxysodium 
 (1.370).  
2% yield. LRMS calculated for C58H58ClN6O12 [M+H]+: 1065.4, found: 1065.2 
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[2-[2-[3-[[2-[2-[3-chloro-4-[[2-methoxy-4-(pyridine-2-
carbonylamino)phenyl]carbamoyl]anilino]-2-oxo-
ethoxy]acetyl]amino]propylamino]-2-oxo-ethoxy]-5-[3-[(2-cyclopentyl-6,7-
dimethyl-1-oxo-indan-5-yl)oxymethyl]phenyl]benzoyl]oxysodium (1.371). 
10% yield. LRMS calculated for C59H60ClN6O12 [M+H]+: 1079.4, found: 1079.2. 
 
 
 
 
 
 
 
 
 
[2-[2-[4-[[2-[2-[3-chloro-4-[[2-methoxy-4-(pyridine-2-
carbonylamino)phenyl]carbamoyl]anilino]-2-oxo-
ethoxy]acetyl]amino]butylamino]-2-oxo-ethoxy]-5-[3-[(2-cyclopentyl-6,7-
dimethyl-1-oxo-indan-5-yl)oxymethyl]phenyl]benzoyl]oxysodium (1.372). 
8% yield. LRMS calculated for C60H62ClN6O12 [M+H]+: 1092.4, found: 1093.2. 
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[2-[2-[5-[[2-[2-[3-chloro-4-[[2-methoxy-4-(pyridine-2-
carbonylamino)phenyl]carbamoyl]anilino]-2-oxo-
ethoxy]acetyl]amino]pentylamino]-2-oxo-ethoxy]-5-[3-[(2-cyclopentyl-6,7-
dimethyl-1-oxo-indan-5-yl)oxymethyl]phenyl]benzoyl]oxysodium (1.373). 
8% yield. LRMS calculated for C61H64ClN6O12 [M+H]+: 1107.4, found: 1107.3. 
 
[2-[2-[6-[[2-[2-[3-chloro-4-[[2-methoxy-4-(pyridine-2-
carbonylamino)phenyl]carbamoyl]anilino]-2-oxo-
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ethoxy]acetyl]amino]hexylamino]-2-oxo-ethoxy]-5-[3-[(2-cyclopentyl-6,7-
dimethyl-1-oxo-indan-5-yl)oxymethyl]phenyl]benzoyl]oxysodium (1.374). 
12% yield. LRMS calculated for C62H66ClN6O12 [M+H]+: 1121.4, found: 1121.2. 
 
 
 
 
[2-[2-[7-[[2-[2-[3-chloro-4-[[2-methoxy-4-(pyridine-2-
carbonylamino)phenyl]carbamoyl]anilino]-2-oxo-
ethoxy]acetyl]amino]heptylamino]-2-oxo-ethoxy]-5-[3-[(2-cyclopentyl-6,7-
dimethyl-1-oxo-indan-5-yl)oxymethyl]phenyl]benzoyl]oxysodium (1.375). 
8% yield. LRMS calculated for C63H68ClN6O12 [M+H]+: 1135.5, found: 1135.3. 
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[2-[2-[8-[[2-[2-[3-chloro-4-[[2-methoxy-4-(pyridine-2-
carbonylamino)phenyl]carbamoyl]anilino]-2-oxo-
ethoxy]acetyl]amino]octylamino]-2-oxo-ethoxy]-5-[3-[(2-cyclopentyl-6,7-
dimethyl-1-oxo-indan-5-yl)oxymethyl]phenyl]benzoyl]oxysodium (1.377).  
6% yield. LRMS calculated for C63H68ClN6O12 [M+H]+: 1149.5, found: 1149.3 
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[2-[2-[10-[[2-[2-[3-chloro-4-[[2-methoxy-4-(pyridine-2-
carbonylamino)phenyl]carbamoyl]anilino]-2-oxo-
ethoxy]acetyl]amino]decylamino]-2-oxo-ethoxy]-5-[3-[(2-cyclopentyl-6,7-
dimethyl-1-oxo-indan-5-yl)oxymethyl]phenyl]benzoyl]oxysodium (1.378). 
2% yield. LRMS calculated for C64H70ClN6O12 [M+H]+: 1177.5, found: 1177.5. 
  
137  
 
 
 
 
 
 
 
 
 
 
 
 
[2-[2-[12-[[2-[2-[3-chloro-4-[[2-methoxy-4-(pyridine-2-
carbonylamino)phenyl]carbamoyl]anilino]-2-oxo-
ethoxy]acetyl]amino]dodecylamino]-2-oxo-ethoxy]-5-[3-[(2-cyclopentyl-6,7-
dimethyl-1-oxo-indan-5-yl)oxymethyl]phenyl]benzoyl]oxysodium (1.379). 
4% yield. LRMS calculated for C64H70ClN6O12 [M+H]+: 1205.5, found: 1205.3. 
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Total Synthesis of Epi- And Pericoannosin A 
 
Introduction 
Natural Products In Medicine 
Before the age of modern medicine, therapeutics were derived from natural 
sources, such as plants and animals. For example, salicylic acid containing fauna, 
such as willow and other plants rich in this natural product, have been known to be 
used since the time of ancient civilizations. The father of medicine, Hippocrates, 
mentions tea derived from salicylate containing plants as a means for treating 
fevers, and it was common in medicine throughout the Middle Ages124,125. Other 
famous natural product derived medicines include the Penicillin class of antibiotics, 
derived from the mold Penicillum126, taxol, a microtubule inhibitors used in 
chemotherapies, was derived from the Pacific Yew127, and the statins, which are 
used for the treatment of high cholesterol and were isolated from the fungus 
Aspergillus terreus128 (Figure 2.1). Natural products comprised 34% of the drugs 
approved by the US Food and Drug Administration (FDA) from 1981-2010129.  
Figure 2.1. Structure and medicinal uses of several natural products.   
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However, the use of natural products in drug discovery has waned 
considerably in recent years, especially in comparison to the last century130. This is 
for a number of reasons, including the fact that natural products can have complex 
structures that can make process scale synthesis difficult and/or expensive131. They 
can also exhibit complex pharmacology that can make it difficult to determine what 
proteins it is targeting and predict undesired side effects132,133. Additionally, natural 
products are not designed for use in human biology, which means they can have 
undesirable pharmacokinetic properties134,135 that can be difficult to ameliorate 
without a good understanding of the molecules minimum pharmacophore, the 
portions of the molecule necessary for activity. Determination of the minimum 
pharmacophore for a complex natural product is not a trivial task136,137.  
For these reasons, recent drug discovery efforts have focused on the use of 
large compound libraries in HTS screens that can be screened against a single 
protein target, which has the advantage of accessing chemical matter that 
definitively interacts with the desired molecular target138. However, the success of 
these campaigns is heavily reliant on a strong understanding of the biological 
processes that cause a disease state and understanding of the role of one’s 
molecular target in this disease state139-141. A recent example of the importance of 
this understanding is the recent failure of a number of beta-secretase 1 (BACE1) 
inhibitors in clinical trials, which were efforts to prevent the formation of amyloid 
plaques that are associated with Alzheimer’s disease (AD)142-144. Many of these 
trials failed due to a lack of efficacy in phase II and/or III, meaning that there was an 
insufficient understanding of the role of BACE1 in AD. The discovery of natural 
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product derived medicines often follows a more phenotypic process, in which it is 
discovered that an organism can elicit a biological effect, which means that one only 
has to find the molecule(s) that contribute to this effect. Additionally, HTS libraries 
can lack in the realm of chemical diversity, which is associated with higher rates of 
success in HTS screening efforts145,165. These caveats highlight the importance of 
natural products for the discovery of novel medicines.  
Natural Products from Periconia sp. F-31 
The medicinal plant graviola (Annona muricata) is found in numerous tropical 
areas throughout the world, including parts of the Americas, Asia, and Africa. 
Various parts of this flowering tree have been used in a number of traditional 
medicines for the treatment of inflammation, rheumatism, diabetes, hypertension, 
and parasitic infection147-149. Living in this plant is an endophytic fungus, Periconia 
sp. F-31, from which in vitro assays displayed antiviral, antitumor, and anti-
inflammatory activities150. Analysis of these metabolites revealed a number of hybrid 
polyketide synthase (PKS)/non-ribosomal peptide synthetase derived compounds. 
The first family of natural products discovered were the periconiasins, which are 
metabolites form the cytochalasan family of natural products151-153. These 
compounds exhibited potent and selective cytotoxicity against HCT-8, a colon 
cancer cell line, and BGC-823, a gastric cancer cell line151-153. Five of these natural 
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products were synthesized in 2016, using a biomimetic strategy derived from the 
proposed biosynthetic pathway (Figure 2.3)154.  
 
A similar compound, Pericoannosin A, was discovered from isolation efforts 
in this species and was discovered to have a unique hexahydr-1H-isochromen-5-
isobutylpyrrolidin-2-one skeleton hypothesized to be derived from a common 
biosynthetic intermediate to the periconiasins (Figure 2.3, 2.4)153. This was 
proposed to be derived from a similar pathway to the Periconiasins, but resulting 
from a slightly different sequence of cyclizations to arrive at this unique skeleton. 
Figure 2.2. Structures of Periconiasins A-F isolated from fungus Periconia Sp. F-31.    
Figure 2.3. Structures of biosynthesis for the formation of the periconiasins and 
pericoannosins. 
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This cyclization sequence seems to be non-enzyme 
mediated, indicated by the discovery of Pericoannosin 
B, which is epimeric at every stereocenter besides the 
one derived from L-leucine. This unusual skeleton 
combined with the discovery of a weak anti-HIV activity 
of 69.6 µM along with no observable cytotoxicity led to a 
strong interest in developing a synthetic route for the synthesis of this natural 
product.  
Previous Total Synthesis of Pericoannosin A 
In 2017, Kalesse et al. reported their total synthesis of Pericoannosin A in a 
15 step (18 steps from known compounds) longest linear sequence, with 27 total 
synthetic steps155. Their retrosynthesis was predicated on formation of the unique 
lactol moiety last, which could be formed from an aldol-oxidation sequence to form 
the necessary 1,3 dicarbonyl species. The protected lactam necessary for the aldol 
addition was readily available from Boc-L-leucine using known procedures. The 
aldehyde necessary for the aldol reaction could be synthesized from a homologation 
sequence, which was done after an asymmetric Diels-Alder cycloaddition to set the 
desired stereo- and regiochemistry of the cyclohexene ring. The Diels-Alder 
precursor was synthesized by a Horner-Wadsworth-Emmons (HWE) reaction of 
oxazolidinone 2.12 onto an aldehyde derived from the oxidative cleavage of 2.11, 
which was accessed via an aldol reaction with commercially available tiglic 
Figure 2.4. Structure of  
the natural product 
Pericoannosin A.  
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aldehyde.  
 
 In the forward sense, the total synthesis began with an Evan’s aldol addition 
of oxazolidinone 2.8, available in 3 known steps from glycolic acid mediated by 
dibutylboron trilfate, followed by silyl protection of the resulting alcohol in 71% overall 
yield over the two steps (Scheme 2.1). Next, PMB-deprotection with DDQ followed 
by reductive cleavage of the Evan’s auxiliary yielded vicinal diol 2.11 in 72% overall 
yield. Periodate cleavage of the 1,2-diol yielded the aldehyde necessary for HWE 
addition with phosphonate 2.12, a known compound synthesized in 2 steps by  
Scheme 2.1. Synthesis of intermediate 2.16 in the reported synthesis of Pericoannosin A.     
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addition of (S)-4-benzyl-2-oxazolidinone to bromo acetylbromide followed by an 
Arbuzov reaction, which went in 84% over the two steps. The Diels-Alder 
cycloaddition of this intermediate with isoprene mediated by diethylaluminum 
chloride went in 66% yield as a single, desired diastereomer, along with 11% of an 
inseparable impurity that was identified as a Michael addition adduct with an ethyl 
group derived from the Lewis Acid. Reductive removal of the auxiliary with lithium 
borohydride yielded the primary alcohol, which allowed separation and isolation of 
the pure Diels-Alder adduct. Homologation of this alcohol was performed by Appel 
reaction with iodine, then displacement of the halide with potassium cyanide in 78% 
overall yield. DIBAL reduction of the resulting nitrile yielded the aldol precursor in 
98% yield from 2.16.  
The lactam aldol partner was synthesized readily from Boc-L-leucine in a 
known procedure (Scheme 2.2). First, the amino acid was coupled with Meldrum’s 
acid using EDCI and DMAP, followed by reductive removal of the carbonyl using 
sodium borohydride and acetic acid. Finally, refluxing in toluene resulted in the 
collapse of Meldrum’s acid into a ketene intermediate, along with release of carbon 
dioxide and acetone. The Boc-protected amine then attacks the central, more 
electrophilic carbon of the ketene to form the 5-membered lactam. However, the 
Boc-lactam was found to be unproductive in the desired aldol reaction due to “acid-
Scheme 2.2. Synthesis of enolate precursor 2.19 for aldol addition to 2.16.     
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mediated elimination” of the silyl-ether, though at exactly what step is unclear. Thus, 
the Boc group was swapped for a Teoc protecting group by TFA deprotection of the 
amide, then reprotection using n-BuLi and Teoc-O-p-nitrophenol, in 77% yield. 
 
The aldol condensation was performed using lithium hexamethyldisilizane 
(LHMDS) as the base, yielding a mixture of 4 inconsequential diastereomers in 83% 
yield (Scheme 2.3). IBX oxidation of the β-hydroxy amide to the 1,3 dicarbonyl 
Scheme 2.3. End game synthesis of Pericoannosin A in an 18 LLS and 27 overall step 
sequence. 
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yielded the desired material in 54%, with a yield of 79% brsm. Cyclization of this 
intermediate using triethylamine trihydrofluoride under dilute conditions gave lactol 
2.22 in 81% yield, with a d.r. of 2:1. Finally, cleavage of the Teoc-protecting group 
and equilibration with an excess of TBAF yielded the natural product in a final yield 
of 75%, and in 5% overall yield for the total synthesis.  
First Retrosynthesis of Pericoannosin A 
Our first retrosynthesis of Pericoannosin A was done before the synthesis 
Scheme 2.4. Our retrosynthetic analysis of Pericoannosin A, coincidentally utilizing common 
intermediate 2.16. 
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was published, and it is interesting to note the similarities and differences in the two 
retrosyntheses (Scheme 2.4). For our retrosynthesis, the last step would be 
cyclization to form the lactam, which would occur after a cyclization to yield the lactol 
moiety. This would then be separated into two fragments that would come together 
in an aldol reaction, azide 2.23 and aldehyde 2.16, an intermediate that is common 
to both routes. The azide is accessible through known chemistry from Boc-L-
leucine155, and the aldehyde is accessible through a homologation sequence from 
an aldehyde. The southern portion of the molecule would be synthesized through a 
Weinreb ketone synthesis, followed by an asymmetric reduction and silyl protection, 
which are all possible from known intermediate 2.25, which is synthesized by an 
asymmetric Diels-Alder of isoprene with commercially available aldehyde 2.26.  
First Generation Synthesis of Pericoannosin A  
The organocatalyzed Diels-Alder cycloaddition of 2.26 with isoprene reported 
by Hayashi et al with commercial organocatalyst 2.32 went smoothly, yielding the 
desired adduct in similar yield and enantioselectivity (90% yield, 94% ee) to the 
literature report157 (Scheme 2.5). Excitingly, this reaction also scaled nicely, with 
yield ranging from 75-90% to yield multigram quantities of the Diels-Alder adduct. 
With this material in hand, reduction with sodium borohydride went smoothly to yield 
the primary alcohol in 85% yield. At this stage, it was envisioned that a non-silyl 
protecting group would be used to allow for orthogonal deprotection in the presence 
of the TBS-silyl ether that would be introduced later. Protecting groups that are 
cleaved under acidic conditions (i.e-MOM) were avoided due to the lability of silyl 
protecting groups under acidic conditions. Thus, it was decided that a PMB-ether  
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would be most desirable as the protecting group for the primary alcohol. 
Unfortunately, protection under extremely mild conditions, using the 
trifluoroacetimidate and catalytic amounts various lanthanide Lewis-Acids, resulted 
in degradation of the enantiomeric purity of the product. This result was somewhat 
surprising and disappointing, but it was figured that a mono-deprotection of the bis-
silyl protected molecule could be performed at a later stage, so the primary alcohol 
Scheme 2.5. Failed synthesis of intermediate 2.31 through an attempted Weinreb ketone 
synthesis. 
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was protected as the TBS-ether using TBSCl and imidazole, yielding the protected 
alcohol in 92% yield.  
Conversion of the ethyl ester to the Weinreb amide using isopropyl 
magnesium chloride went smoothly, yielding the amide in 71% yield with no 
evidence of alpha-epimerization of the carbonyl. Unfortunately, addition of an 
organometallic reagent derived from the respective vinyl group was unproductive. 
Addition using the vinyl lithium reagent derived from the vinyl bromide and tBuLi 
resulted in no desired product, only basic elimination of the methoxy group from the 
Weinreb amide, a common side reaction for very basic nucleophiles158. The use of 
a commercial Grignard reagent resulted in a minute amount of conversion to the 
ketone, but revealed that the commercial reagent was a mixture of E and Z isomers.  
To circumvent this roadblock, we decided to reverse the nucleophile and 
electrophile; instead of nucleophilic attack of the vinyl group onto the core scaffold, 
convert the cyclohexene into a nucleophile and use an electrophile to form the 
Scheme 2.6. Synthesis of 2.37, an intermediate common to our and the published synthesis. 
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desired vinyl group (Scheme 2.6). To accomplish this, the ethyl ester was converted 
to a HWE reagent using lithiated ethyl ethylphosphonate, which proceeded in 89% 
yield. Due to the presence of methyl epimers and keto-enol tautomers, it was difficult 
to ascertain if any alpha epimerization had occurred. To our delight, using a slight 
excess of the phosphonate to help prevent vinylogous aldol chemistry, the HWE of 
this phosphonate with acetaldehyde using barium hydroxide as the base went 
smoothly to afford the α,β unstaturated carbonyl, which was confirmed to be the 
desired E olefin isomer by 1D nOe (Appendix B).  
Asymmetric reduction of this enone was attempted using a number of 
conditions. Initially, a Corey-Bakshi-Shibata (CBS) reduction was envisioned159-161. 
However, this reduction was plagued by alkene hydroboration and little reduction 
product. It was then found that the Felkin-Anh model of nucleophilic attack would 
theoretically give the desired alcohol stereocenter162-164. This was first attempted 
using DIBAL at -78 °C for 1 hour, which gave only a moderate yield of the desired 
product, but, excitingly, as a single diastereomer. Mosher ester analysis of this 
reduction product revealed that the Felkin-Anh model did indeed predict the 
stereochemical outcome of the reaction. Reaction optimization revealed that the 
reaction was very rapid, with complete consumption of starting materials being 
observed within 5-20 minutes, depending on scale.  
Next, protection of the allylic alcohol with TBSOTf under standard conditions 
gave the desired bis-silyl protected product. To our surprise, it was fairly difficult to 
perform mono-deprotection of this product. It seems that the allylic silyl-ether is more 
labile than one would expect a secondary TBS-protected alcohol to be, perhaps due 
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to it being allylic or due to the relatively high steric strain it is under being located 
between the cyclohexene ring and the dimethyl vinyl group. However, it was found 
that catalytic camphor sulfonic acid (CSA) in methanol at 0 °C allowed for sufficiently 
selective mono-deprotection to yield the primary alcohol in variable yields of 40-
50%. Due to the difficulty in deprotecting the bis-TBS ether, the primary alcohol 
protecting group was changed to a triethylsilyl (TES) protecting group, which is more 
labile than a TBS group and it was hypothesized that this would improve the 
efficiency of this synthetic step. Indeed, stirring the starting material with 0.2 
equivalents of pyridinium p-toluenesulfonate (PPTS) in a 1:1 mixture of DCM and 
methanol for 30 minutes allowed for isolation of the pure primary alcohol in 72% 
yield in a 1 gram scale reaction.  
At this point in the synthesis, the total synthesis of this natural product was 
published, revealing the similarities in our routes. Though we knew that future work 
would be necessary to differentiate our routes in the future, we were fortunate to be 
able to use optimized conditions that were published to help push toward late 
intermediates to try out the novel chemistries that our synthesis contained. Using 
the published conditions, the primary alcohol was homologated using Appel 
conditions, followed by displacement with potassium cyanide in DMSO. 
Unfortunately, the yields of the published could not be replicated (48 and 66%, 
respectively, versus 78% over the two steps in the literature report), but we were 
able to push sufficient quantities of material forward for further work. DIBAL 
reduction of the resulting nitrile yielded known aldehyde 2.16 in 53% yield, which 
matched the published material, additionally confirming the stereochemistry of the 
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carbonyl reduction. 
The synthesis of 2.23 was achieved according to the route described by 
Avery, et al156. Briefly, Boc-L-leucinol was oxidized using standard Parikh-Doering 
conditions to give the desired aldehyde in 87% yield, which was then homologated 
in an HWE olefination using triethyl ethylphosphonate and sodium 
hexamethyldisilazide (NHMDS) and hydrogenated under standard conditions to give 
2.38 in good yields. Next, saponification followed by Boc-deprotection using HCl in 
dioxanes formed a white solid that could be isolated using air free filtration (product 
may form a hydrate that is more soluble in ether than the parent compound). Azide 
formation using the sulfuric acid salt of imidazole sulfonylazide165 gave 2.40 in a 
moderate yield, which was followed by imide formation under standard conditions 
with R-ispropyl oxazolidinone to form desired intermediate 2.23 in a good yielding 7 
step sequence.  
 
Scheme 2.7. Synthesis of compound through a rapid, seven step sequence reported by Avery 
et al.  
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With intermediates 2.16 and 2.23 in hand, the aldol condensation was 
attempted using standard Evan’s aldol conditions. Forming the boron enolate with 
dibutyl boron triflate, the desired aldol product could be obtained in moderate yields 
of 40-65%. With this product in hand, attempts to reduce the azide and cyclize to 
the lactam were attempted, with the vision of a final step formation and equilibration 
to simultaneously form the lactol and epimerize to the thermodynamically favored 
natural product. Unfortunately, numerous methods for reducing the azide produced 
either very little (SnCl2, Staudinger reduction-PBu3 or PPh3, 5% yield) or no (Lindlar 
catalyst, Zn/NH4Cl) product. This is hypothesized to be due to steric reasons, as the 
beta-hydroxy ketone will be rigidified by an intramolecular hydrogen bond. This 
results in the azide being blocked by the TBS silyl ether or the vinyl group on one  
side, and the carbonyl or isopropyl group of the oxazolidinone.  
Scheme 2.8. Synthesis of 2.41 and failed lactam synthesis through azide reduction. 
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To circumvent this obstacle in the synthesis, it was decided that the lactol 
would be formed first, which would remove much of the steric bulk surrounding the 
azide and allow for the desired reactions to occur. In the event, the beta-keto amide 
was oxidized using 4 equivalents of 2-ioxodybenoic acid (IBX) in DMSO to yield the 
1,3 diketone in 78% yield. Due to the presence of diastereomers and keto-enol 
tautomers, this product was not characterized further, but pushed onto the next step.  
 
 
Cyclization of intermediate 2.43 to the lactol was accomplished using a large 
excess of triethylamine trihydrofluoride in THF, with stirring for 54 hours. This yielded 
a mixture of 2 diastereomers,that were taken on for the final cyclization to yield the 
natural product. In the event, the Staudinger reduction of azide 2.44 was performed 
Scheme 2.9. Unsuccessful attempts at the final steps for the synthesis of Pericoannosin A. 
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using resin-bound triphenylphosphine, to simplify the workup, in a mixture of THF 
and water, first, at room temperature overnight, then at 60 °C for 8 hours, which 
allowed for full conversion of starting materials. Isolation of this product using 
column chromatography revealed an unknown impurity that could not be separated 
after several columns. However, it was thought that this route, with some 
optimization, would be sufficiently robust, combined with an improved synthetic 
scheme, for finishing the molecule and publication. 
Second Generation Route for the Formal Total Synthesis of Pericoannosin A 
While the first generation route towards the synthesis of Pericoannosin A was 
successful in bringing up late stage intermediates for the synthesis, there was 
significant room for improvement. The end of the synthesis could not be changed in 
a facile manner and was already efficient, so this part of the scheme was left 
untouched. One area of the synthesis that was found to be inefficient was the 
homologation sequence starting from the aldehyde. Ignoring the formation of the 
ketone, the homologation requires 6 synthetic steps, including a protection-
deprotection sequence, and two reduction transformations (reduction of the 
aldehyde, reduction of the nitrile) to get to the desired aldehyde. This leaves a lot of 
room for improvement, and is where our efforts were first focused for optimization 
of the route.  Routes for optimization were hypothesized from the aldehyde to get to 
the homologated aldehyde. This route would need to be able to withstand fairly 
aggressive reaction conditions in the lithated phosphonate addition and DIBAL 
reduction of the enone. Additionally, it would need to be more efficient than the 
previous 6 step synthesis. To this end, it was hypothesized that an olefination 
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reaction of the aldehyde would be sufficiently 
orthogonal such that it could be run 
chemoselectively, not touching the ester (Scheme 
2.10). Additionally, this terminal alkene would be 
inert to the reaction conditions that are intermediary 
to the formation of the homologated aldehyde. 
Finally, the alkene is a versatile functional handle, 
and could be transformed in a facile manner to the aldehyde using a selective 
hydroboration-oxidation, followed by an oxidation of the resulting primary alcohol. 
Selective hydroborations of terminal alkenes over more substituted alkenes is well 
precedented166, and can be carried out using bulky boron reagents, such as 9-BBN, 
to only react with the desired alkene, along with reacting solely in an anti-
Markovnikov fashion.  
 Starting from the Diels-Alder adduct used in the first generation route, 
olefination was first attempted using potassium t-butoxide and 
methytriphenylphosphonium bromide in THF, which gave the desired product in a 
moderate yield of 52%, but only 4:1 d.r. It was thought that these reaction conditions 
were too strongly basic, causing equilibration at the alpha position of the ester, which 
was confirmed by thermodynamic equilibration with DBU in toluene to yield the 
desired alkene as a single diastereomer. Thus, a non-basic Wittig olefination was 
attempted, which utilized trimethylsilyl (TMS) diazomethane and Wilkinson’s catalyst 
to form a carbene that reacts with triphenylphosphine to form an intermediate that 
can react with isopropanol to give an ylide without addition of any base. This reaction 
Scheme 2.10. Revised 
retrosynthesis toward 
intermediate 2.16. 
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proceeded smoothly to give the Wittig olefination product, albeit in moderate yields 
of 50-60%, but with a d.r. of >20:1 by NMR. While we were excited to be able to 
obtain the desired product without epimerization of the formed stereocenters, further 
optimization was done due the moderate yields and relative expense of TMS 
diazomethane and Wilkinson’s catalyst that could potentially prohibit large scale 
synthesis of the desired intermediate.  
 Wittig olefination was next explored using different bases to form the ylide, 
LHMDS and KHMDS, for which an interesting salt effect was observed. Using 
KHMDS to form the ylide results in the formation of KBr, which has relatively low 
solubility in THF, and thus it was thought that the potassium would be unable to 
activate the ester for deprotonation, thus preventing epimerization and potential 
decomposition of the starting material. Lithium bromide, on the other hand, is very 
soluble in THF, and it was thought that the free lithium ion could potentially be 
detrimental to the reaction. However, the exact opposite was observed. While both 
olefinations proceeded in an improved yield of 65%, the d.r. using KHMDS was 
drastically lower, 10:1, than the olefination using LHMDS, which produced the 
desired material in >20:1 d.r. We were delighted to find, upon scaling up this reaction 
using LHMDS as the base, that we were able to obtain the desired product in 75% 
yield, with little to no impact on the enantiopurity of this intermediate.  
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Conditionsa Yield d.r. 
Rh(PPh3)3Cl, iPrOH, PPh3, 
TMSCHN2 
65% >20:1 
CH3PPh3Br, KOtBu 55% 4:1 
CH3PPh3Br, KHMDS 59% 10:1 
CH3PPh3Br, LHMDS 73% >20:1 
CH3PPh3Br, LHMDSb 75% >20:2 
 
 Fortunately, the next several steps in the sequence proceeded in a similar 
manner to the initial route with minimal optimization (Scheme 2.11). Stirring the  
Wittig product with excess lithated ethyl ethylphosphonate producted the β-
ketophosphonate in 81% yield, which was then reacted with acetaldehyde in the 
Scheme 2.11. Second generation synthesis of aldehyde 2.16. 
aReactions were conducted on 100 mg (0.5 mmol) scales. bReaction conducted 
on a 1 g (5 mmol) scale. 
Table 2.1. Conditions explored for Wittig olefination of Diels 
Alder adduct 2.25 (Scheme 2.11). 
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presence of barium hydroxide octahydrate to yield the enone in 81% yield. 
Reduction of the enone using DIBAL at -78 °C for 15 minutes in toluene proceeded 
in slightly lower yields than the first route. The undesired allylic alcohol epimer was 
also observed as a minor side product, but the two diastereomers were fortunately 
easily separable via column chromatography, enabling the synthesis of the allylic 
alcohol in 83% yield. TBS protection of this alcohol proceeded in 89% yield using 
TBSOTf and 2,6-lutidine in DCM. Selective hydroboration of the terminal alkene 
using a slight excess of 9-borabicyclo(3.3.1)nonane (9-BBN) in THF, followed by 
oxidation using hydrogen peroxide with 2M NaOH, yielded the desired primary 
alcohol in 81% yield. Oxidation of this alcohol using Dess-Martin Periodinane (DMP) 
in DCM buffered with sodium bicarbonate, to neutralize the acetic acid byproducts 
and protect the very sensitive allylic silyl ether, proceeded smoothly to give the 
known aldehyde in 73% yield.  
Aldol Optimization and Attempted Completion of Synthesis  
At this point in the synthesis, it became apparent that the initial Evan’s aldol 
conditions using the boron enolate derived from dibutylboron triflate was not tenable 
for the completion of the synthesis. Even in the initial route, the yields of this reaction 
were inconsistent, either giving no desired product with some decomposition of 
starting materials, or about 45% yield. Either of these cases were not ideal for the 
completion of the synthesis, especially when the aldol was attempted using a 
number of different Evan’s auxiliaries (Bn, Ph, iPr) and conditions (LHMDS, TiCl4, 
Bu2BOTf) with no major improvements in the yield of the reaction.  
A model system for this aldol was developed utilizing isoveraldehyde, which 
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was thought would be a good mimic for the steric bulk around the aldehyde used in 
the synthesis. Utilizing the boron enolate derived from oxazolidinone 2.23, no 
productive yield of desired product was observed, even upon using a new bottle of 
the Lewis acid and freshly distilled base. Using the lithium enolate, however, 
resulted in good conversion to the aldol condensation product, which we thought 
was curious as these conditions did not work in the actual system. From here, we 
hypothesized that the issues plaguing this aldol reaction may be due to the large 
steric bulk surrounding the aldehyde from the Southern allylic alcohol and alkene. 
Our first attempt to ameliorate this was utilizing NHMDS as the base, as it was 
hypothesized that the sodium salt would be unable to form a closed transition state, 
and that the open transition state may allow production of product. However, these 
conditions also failed to yield any desired product. Because it would take significant 
retooling and optimization of the synthetic route to alter the sterics of the aldehyde 
used in the aldol reaction, we hypothesized that lowering the sterics around the 
nucleophile in the aldol could allow for productive reaction to occur. 
 To lower the steric bulk around of the nucleophile, we decided to focus on the 
two requirements that are necessary for the moiety attached to the carbonyl of the 
azide: it must be sufficiently activating to allow for the formation of an enolate, but 
also labile enough to function as a good leaving group upon reduction of the azide 
to allow formation of the lactam. An ideal candidate for this is the use of an ester, 
which has an acidic alpha proton for enolate formation and could be easily formed 
from the already known acid (2.40). Synthesis of the methyl ester was achieved by 
addition of TMS diazomethane, which gave the desired material in 92% yield 
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(Scheme 2.12). Next, aldol reaction mediated by LHMDS proceeded in a moderate 
yield of 47%, but with good recovery of starting material, which resulted in a yield of 
76% based on recovered starting (brsm). Interestingly, no additional methyl ester  
 
 
 
 
 
 
 
 
 
 
was 
recovered, which indicated to us that this material was decomposing in some way 
before it was capable of participating in the aldol reaction. Analysis of the LCMS 
reports from this reaction indicated the presence of a dimer derived from a formal 
Claisen condensation of the methyl ester, which is known to occur with ester derived 
enolates at too high of temperatures. Lowering of the temperature to -98 °C showed 
no improvement in yield. We then thought that the formation of this byproduct could 
be the result of an improper order of addition, as we were initially adding the base 
to a solution of ester, which results in a small population of enolate in a large pool 
of unchanged ester and could facilitate this condensation reaction. Unfortunately, 
Scheme 2.12. Synthesis of enolate precursor 2.51 and subsequent aldol reaction. 
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adding a solution of ester to a solution of LHMDS resulted in no significant change 
in yield. Surprisingly, addition of 3 equivalents of enolate was also ineffective in 
improving the yield in this reaction. Switching the base from LHMDS to lithium 
diisopropyl amide (LDA) resulted in an aldol with similar efficacy in producing the 
desired product, but recovery of only trace amounts of starting aldehyde. This is 
presumably due to the increased basicity of diisopropylamine compared to 
hexamethyldisilizane resulting in decomposition of the sensitive starting aldehyde.  
Several groups have reported that this formal Claisen condensation can be 
mediated not through a direct nucleophilic attack of an ester enolate onto an ester, 
but instead can occur by first formation of a ketene by decomposition of the lithium 
enolate with release of the methoxide anion167-169. However, prevention of this 
decomposition is typically ameliorated by lowering of the reaction temperature, 
which was already shown to be ineffective. Additionally, warm temperatures are 
typically needed for this ketene formation to occur, so it is most likely a result of a 
direct Claisen condensation that occurs concurrently or immediately after enolate 
formation169. Another means of preventing this mechanism of decomposition is to 
utilize a tert-butyl ester, which is more thermally stable than less sterically 
encumbered esters, but due to the poor electrophilicity of tert-butyl esters, it was 
hypothesized that this method would complicate the future lactam formation step. 
Nonetheless, the high recovery of unreacted starting material along with the relative 
ease of synthesis of the methyl ester portion of the reaction made this a useful 
synthetic step.  
Next, the aldol product, which was isolated as a mixture of 4 diastereomers, 
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was oxidized using IBX in DMSO to form the β-keto ester in 43% yield, with a yield 
of 57% brsm. Cyclization to the lactol with triethylamine trihydrofluoride proceeded 
in a good yield of 86%. Unfortunately, cyclization of this material to the natural 
product proved non-trivial. Staudinger reduction in toluene resulted in good 
conversion to the amine in 1 hour, but proved ineffective at enacting the desired 
cyclization. Isolation of this intermediate followed by stirring in methanol with 
potassium carbonate resulted in no change in starting material, while heating to 
reflux resulted in decomposition of starting material and little product formation. This 
was hypothesized to be due to the sensitivity of the lactol species, so we decided to 
rearrange the order of the final steps (Scheme 2.13). Cyclization of the aldol product 
under standard Staudinger conditions in THF smoothly converted to the lactam, as 
a mixture of 4 diastereomers, in 4-5 hours at 60 °C in 91% yield. There was no 
observation of the secondary amine intermediate by LCMS, meaning that lactam 
Scheme 2.13. End game synthesis of Pericoannosin A.  
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formation proceeded rapidly after completion of the reduction. IBX oxidation of the 
resulting material proceeded in 53% yield (64% brsm), which was followed by 
cyclization under the same conditions as before to yield 2.53 as a mixture of 2 
diastereomers in 69% yield. At this point, equilibration using the conditions in the 
published synthesis was attempted to determine if our route was viable for producing 
the desired product. However, the use of TBAF in THF resulted in no appreciable 
change in the ratio of diastereomers. This is likely due to the fact that the Teoc 
protecting group may acidify the alpha proton of the amide, allowing for TBAF to 
equilibrate this position. With the remaining material, separation of the 
diastereomers by preparative TLC was attempted, which was unsuccessful in 
producing pure natural product.  
Summary and Future Directions 
In summary, this work represents both a formal total synthesis of 
Pericoannosin A that is a marked improvement over the published work, and a total 
synthesis of a mixture of epi- and Pericoannosin A. Arrival at common intermediate 
2.16 in an 8 longest linear and total steps in 18.3% yield stands as a large 
improvement over the published work, which arrives at this intermediate in 14 
longest linear step sequence and 16 overall steps, with poor atom economy. The 
use of an organocatalyzed asymmetric Diels-Alder cyclization sets 2 stereocenters 
that allow for the creation of the allylic stereocenter by structural induction, whereas 
the published synthesis utilizes two separate Evan’s oxazolidinone steps to 
establish all 3 stereocenters in 2.16. The high yield and low step count of this formal 
synthesis make these chemistries ideal for the future synthesis of Pericoannosin A, 
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or for similarly structured natural products.  
 This work has also established different reactions for the total synthesis of 
Pericoannosin A. An ester aldol followed by lactam cyclization allowed preparation 
of the Eastern lactam of the natural product. Unfortunately, the desired product was 
isolated as a mixture of two diastereomers that were very difficult to separate by 
flash chromatography and prep TLC. Future directions for this synthesis include 
exploring the separation of these diastereomers by reverse phase 
chromatography/HPLC or by supercritical fluid chromatography (SFC), which can 
utilize chiral columns for an improved separation170-171. Additionally, one could also 
explore ways of equilibrating the two diastereomers to the desired material. One 
method could potentially be a kinetic protonation, in which the enolate could be 
formed and quenched at cryogenic temperatures172. The proton would most likely 
preferentially come in opposite of the isobutyl group of the lactam due to sterics. 
However, the enolate formation would most likely be complicated due to the similar 
pKas of the lactam nitrogen and the alpha proton. Alternatively, according to the 
literature report, the product is also the thermodynamically favored product, so 
thermodynamic equilibration conditions using base could theoretically be used as 
well.   
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Experimental Methods 
 
General Synthetic Methods and Instrumentation 
All reagents and solvents were commercial grade and used as received. All 
reactions were carried out employing standard chemical technique under air, unless 
otherwise noted. Thin layer chromatography (TLC) was performed on glass-backed 
silica gel of 250 μm thickness. Visualization was accomplished with UV light and/or 
the use of KMnO4 or p-anisaldehyde stain. Analytical HPLC 113 was performed on 
an Agilent 1200 LCMS with UV detection at 215 and 254 nm and electrospray 
ionization. MS parameters were as follows: capillary voltage: 3000V, nebulizer 
pressure: 40 psi, drying gas flow: 11 L/min, drying gas temperature: 350 °C. 
Samples were separated on an internal column (Thermo Accucore C18 2.1 x 30 
mm, 2.6 μm) before ionization with the following solvent gradient: 7% to 95% MeCN 
in H2O (0.1% TFA) over 1.6 min, hold at 95% MeCN for 0.35 min, 1.5 mL/min flow, 
45 °C. Chromatography on silica gel was performed using Teledyne ISCO pre-
packed silica gel columns using gradients of EtOAc/Hexanes or DCM/MeOH. 1H 
and 13C NMR spectra were recorded on Bruker DRX-400 (400 MHz) or AV-II 600 
(600 MHz) instrument and chemical shifts are reported in ppm relative to residual 
solvent. 
 
 
 
ethyl (1S,6S)-6-formyl-3-methyl-cyclohex-3-ene-1-carboxylate (2.25). 
To a 100 mL round-bottom flask at 4 oC containing ethyl (E)-4-oxobut-2-enoate (3.53 
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mL, 28.1 mmol, 1 eq) and [bis[3,5-bis(trifluoromethyl)phenyl]-[(2S)-pyrrolidin-1-ium-
2-yl]methoxy]-trimethyl-silane perchlorate (981 mg, 1.4 mmol, 0.05 eq) in water (30 
mL) was added isoprene (8.43 mL, 84 mmol, 3 eq) with stirring. After 48 hours, the 
reaction mixture was quenched with saturated sodium bicarbonate (20 mL), then 
extracted with ether (3x75 mL), and the organic layers were dried over magnesium 
sulfate, filtered, and concentrated in vacuo onto silica gel. Crude product was 
purified using Teledyne ISCO Combi-Flash system (solid loading, 40G column, 0-
25% Hex/EtOAc) to yield ethyl (1S,6S)-6-formyl-3-methyl-cyclohex-3-ene-1-
carboxylate (5.2 g, 26.4 mmol, 94% yield) as a clear oil. 1H-NMR (400 MHz, CDCl3) 
δ 9.67 (s, 1H), 5.38 (bs, 1H), 4.19-4.07 (m, 2H), 2.91-2.76 (m, 2H), 2.37-2.24 (m, 
2H), 2.14-2.01 (m, 1H), 1.64 (s, 3H), 1.27-1.17 (m, 3H) ppm; 13C-NMR (100 MHz, 
CDCl3) δ 202.8, 174.5, 133.0, 118.4, 60.9, 47.4, 39.8, 31.5, 24.3, 23.3, 14.3 ppm; 
ESI-HRMS: m/z calc for C11H19O3 [M+H]+: 197.1172, found: 197.1175; [α]D
20 = 
+58.2 (c 1.0, CHCl3); Rf = 0.24 (5% EtOAc/Hex). 
 
 
 
ethyl (1S,6R)-3-methyl-6-vinyl-cyclohex-3-ene-1-carboxylate (2.45). 
To a suspension of methyltriphenylphosphonium bromide (2.01 g, 5.61 mmol, 1.1 
eq) in THF (17 mL) at 0 °C was added LHMDS (1M in THF, 5.35 mL, 5.35 mmol, 
1.05 eq) dropwise. The reaction was stirred for 40 minutes at this temperature, 
then cooled to -78 °C and a solution of ethyl (1S,6S)-6-formyl-3-methyl-cyclohex-3-
ene-1-carboxylate (1 g, 5.10 mmol, 1 eq) was added slowly. The cooling bath was 
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removed and the reaction was stirred for 10 minutes at this temperature before a 
solution of saturated NH4Cl (30 mL) and ether (30 mL) were added. The layers 
were separated and the aqueous was extracted with ether (3x30 mL), then the 
organics were pooled, dried over magnesium sulfate, filtered, and concentrated in 
vacuo. Crude product was purified by column chromatography (EtOAc/Hex, 0-
20%) to yield ethyl (1S,6R)-3-methyl-6-vinyl-cyclohex-3-ene-1-carboxylate (751 
mg, 3.87 mmol, 75%) as a clear oil in >20:1 d.r. 1H-NMR (400 MHz, CDCl3) δ 
5.75-5.66 (m, 1H), 5.38 (m, 1H), 5.06 (dd, J = 17.1, 1.5 Hz, 1H), 4.97 (dd, J = 10.2, 
1.7 Hz, 1H),  4.11 (qd, J = 7.1, 1.4 Hz, 2H), 2.49-2.41 (m, 2H), 2.32-2.26 (m, 1H), 
2.15-2.09 (m, 2H, 1.95-1.87 (m, 1H), 1.67 (bs, 3H), 1.24 (t, J = 7.2 Hz, 3H) ppm; 
13C-NMR (100 MHz, CDCl3) δ 175.4, 140.8, 132.1, 119.8, 115.2, 60.2, 45.9, 40.9, 
32.8, 31.2, 23.3, 14.5; ESI-HRMS: m/z calc for C12H18O2 [M+H]+: 195.1380, found: 
195.1381; [α]D
20 = +53.6 (c 0.65, CHCl3); Rf = 0.48 (Hex:EtOAc 20:1). 
 
 
 
 
2-diethoxyphosphoryl-1-[(1S,6R)-3-methyl-6-vinyl-cyclohex-3-en-1-yl]propan-
1-one (2.46). 
To a solution of diethyl ethylphosphonate (1.28 g, 7.72 mmol, 3 eq) in THF (12.9 
mL) at -78 oC was added n-BuLi (1.77M in Hex, 3.68 mL, 7.46 mmol) dropwise. 
The reaction was stirred for 1 hour at this temperature, then ethyl (1S,6R)-3-
methyl-6-vinyl-cyclohex-3-ene-1-carboxylate (500 mg, 2.57 mmol, 1 eq) in THF 
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(3.2 mL) was added slowly and the reaction was stirred an additional 1.5 hours at 
the same temperature. The reaction was quenched by addition of saturated NH4Cl 
(30 mL), then allowed to warm to room temperature and the mixture was extracted 
with ether (3x60 mL). The organics were dried over magnesium sulfate, filtered, 
and then concentrated in vacuo and crude product was purified using column 
chromatography (0-50% EtOAc/Hex) to yield 2-diethoxyphosphoryl-1-[(1S,6R)-3-
methyl-6-vinyl-cyclohex-3-en-1-yl]propan-1-one (740 mg , 2.35 mmol, 91% yield) 
as a clear oil as a ~3:1 mixture of methyl diastereomers. 
Analytical data are given for the mixture of diastereomers (signals are described 
as major (mj) and minor (mn) where it can be determined, otherwise given as a 
mix (mix)). 1H-NMR (400 MHz, CDCl3): 5.64 (m, 1.36H, mix), 5.33 (m, 0.33H, mn), 
5.27 (m, 1H, mj), 4.99 (d, J = 17.2 Hz, 0.35H, mn), 4.93 (d, J = 17.1 Hz, 1H, mj), 
4.88 (d, J = 10.2 Hz, 1.37H, mix), 4.05 (sep, J = 7.2 Hz, 5.7H, mix), 3.25 (qd, J = 
26.0, 7.1 Hz, 0.40H, mn), 3.18 (qd, J = 26.5, 6.9 Hz, 1H, mj), 2.99 (td, J = 19.9, 5.5 
Hz, 1.23H, mix), 2.53-2.43 (m, 0.32H, mn), 2.33-2.22 (m, 1.24H, mix), 2.22-2.14 
(m, 1H, mj), 2.14-1.82 (m, 4.94H, mix), 1.59 (bs, 3.85H, mix), 1.26 (q, J = 7.3, 9H, 
mix), 1.17 (dd, J = 17.5, 7.0 Hz, 3.44H, mix), 0.85 (t, J = 7.2 Hz, 0.22H, mn) ppm; 
13C-NMR (100 MHz, CDCl3) δ 209.9 (d, J = 3.9 Hz, mj), 208.5 (d, J = 4.0 Hz, mn), 
145.5 (mn), 141.1 (mn), 104.4 (mj), 132.8 (mj), 131.5 (mn), 120.5 (mn), 118.9 (mj), 
115.9 (mj), 115.0 (mn), 62.7 (d, J = 6.8 Hz, mj), 62.6 (d, J = 6.9 Hz, mn), 62.5 (d, J 
= 6.8 Hz, mj), 62.4 (d, J = 6.8 Hz, mn), 53.3 (mj), 51.8 (mn), 49.7 (mj), 48.4 (mj), 
46.6 (mn), 45.3 (mn), 43.1 (mj), 39.0 (mn), 33.3 (mn), 32.2 (mj), 31.8 (mj), 30.8 
(mn), 23.3 (mj), 23.3 (mn), 16.5 (d, J = 5.3 Hz, mj), 16.4 (d, J = 5.8 Hz, mj), 11.5 
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(d, J = 6.5 Hz, mn), 9.8 (d, J = 6.1 Hz, mj) ppm; ESI-HRMS: m/z calc for 
C16H27O4P [M+H]+: 315.1720, found: 315.1720; Rf = 0.27 (Hex:EtOAc 2:1). 
 
 
 
 
(E)-2-methyl-1-[(1S,6R)-3-methyl-6-vinyl-cyclohex-3-en-1-yl]but-2-en-1-one 
(2.47). 
To a solution of 2-diethoxyphosphoryl-1-[(1S,6R)-3-methyl-6-vinyl-cyclohex-3-en-
1-yl]propan-1-one (1.2 g, 3.84 mmol, 1.2 eq) in THF (16 mL) at 0 oC was added 
barium hydroxide octahydrate (1.01 g, 3.2 mmol, 1 eq) and acetaldehyde (180 μL, 
3.2 mmol, 1 eq) at 0 oC. The reaction was warmed to room temperature overnight, 
then diluted with ether (60 mL) and filtered. The organics were removed in vacuo, 
then crude product was purified using column chromatography (0-60% EtOAc/Hex, 
high gradient used to recover excess starting material) to yield (E)-2-methyl-1-
[(1S,6R)-3-methyl-6-vinyl-cyclohex-3-en-1-yl]but-2-en-1-one (528 mg, 2.58 mmol, 
81% yield) as a clear oil. Olefin geometry was confirmed by 1D nOE analysis. 1H-
NMR (400 MHz, CDCl3) δ 6.70 (q, J = 6.4 Hz, 1H), 5.55 (m, 1H), 5.35 (m, 1H), 
4.92 (d, J = 17.1 Hz, 1H), 4.83 (dd, J = 10.9, 1.0 Hz, 1H), 3.27 (td, J = 10.7, 5.3 
Hz, 1H), 2.50-2.41 (m, 1H), 2.17-2.07 (m, 2H), 1.95-1.87 (m, 2H), 1.83 (d, J = 6.9 
Hz, 3H), 1.72 (s, 3H), 1.62 (s, 3H) ppm; 13C-NMR (100 MHz, CDCl3) δ 205.2, 
141.0, 139.4, 136.9, 132.8, 119.8, 114.8, 44.9, 40.8, 34.5, 31.4, 23.3, 14.9, 11.2 
ppm; ESI-HRMS: m/z calc for C14H20O [M+H]+: 205.1587, found: 205.1587; [α]D
20 
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= +63.8 (c 1.14, CHCl3); Rf = 0.348 (Hex:EtOAc 50:1); 
 
 
 
 
 
(E,1S)-2-methyl-1-[(1S,6R)-3-methyl-6-vinyl-cyclohex-3-en-1-yl]but-2-en-1-ol 
(2.48).  
To a solution of (E)-2-methyl-1-[(1S,6R)-3-methyl-6-vinyl-cyclohex-3-en-1-yl]but-2-
en-1-one (528 mg, 2.58 mmol, 1 eq) in Toluene (10.6 mL) at -78 oC was added 
DIBAL (1M in toluene, 3.51 mL, 3.51 mmol, 1.34 eq) dropwise, turning the reaction 
yellow. The mixture was stirred for 5-15 minutes (monitored by TLC), then 
quenched by addition of methanol (3.5 mL) and saturated Rochelle's salt (20 mL), 
then allowed to warm to room temperature and diluted further with Rochelle's salt 
(75 mL) and ether (75 mL). The mixture was stirred vigorously at room 
temperature for 2 hours, forming two distinct layers, then the organics were 
separated and the aqueous was extracted with ether (3x50mL). The organics were 
pooled, dried over magnesium sulfate, filtered, and concentrated in vacuo, then 
crude product was purified using column chromatography (0-20% EtOAc/Hex) to 
yield (E,1S)-2-methyl-1-[(1S,6R)-3-methyl-6-vinyl-cyclohex-3-en-1-yl]but-2-en-1-ol 
(424 mg, 2.06 mmol, 80% yield) as a clear oil. 1H-NMR (400 MHz, CDCl3) δ 5.95 
(ddd, J = 17.5, 10.1, 8.0 Hz, 1H), 5.39 (q, J = 6.44 Hz, 1H), 5.32 (m, 1H), 5.11 (d, J 
= 17.2 Hz, 1H),  4.99 (dd, J = 10.4, 0.8 Hz, 1H), 3.87 (d, J = 8.8 Hz, 1H), 2.43 (p, J 
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= 7.3 Hz, 1H), 2.15 (m, 1H), 2.01-1.89 (m, 2H), 1.82-1.72 (m, 2H), 1.63-1.55 (m, 
9H), 1.53-1.43 (m, 1H) ppm; 13C-NMR (100 MHz, CDCl3) δ 144.1, 136.7, 132.6, 
122.9, 119.3, 114.0, 80.8, 41.2, 39.9, 30.7, 23.8, 13.2, 10.7 ppm; ESI-HRMS: m/z 
calc for C14H21 [M+H]+[-H2O]: 189.1638, found: 189.1640; [α]D
20 = +24.2 (c 1.21, 
CHCl3); Rf = 0.296 (20:1 Hex:EtOAc); 
 
Mosher ester analysis was performed as described by Hoye, et al.173 Briefly, to a 
solution of (E,1S)-2-methyl-1-[(1S,6R)-3-methyl-6-vinyl-cyclohex-3-en-1-yl]but-2-
en-1-ol (10 mg, 0.05 mmol) and (R)-(-)-alpha-methoxy-alpha-trifluoromethyl acetic 
acid {(R)-Mosher’s acid} (35.18 mg, 0.15 mmol, 3.1 eq) in DCM (0.75 mL) at 23 oC 
was added 1,3-dicyclohexylcarbodiimide (31.0 mg, 0.15 mmol, 3.1 eq) and 4-
dimethylaminopyridine (18.4 mg, 0.15 mmol, 3.1 eq). The reaction was stirred 
overnight at room temperature, then diluted with DCM (1 mL) and filtered 
through a plug of celite, washing with DCM (3x2 mL). The solvent was removed in 
vacuo, then crude product was purified using silica gel chromatography (0-10% 
EtOAc/Hex) to yield [(E,1S)-2-methyl-1-[(1S,6R)-3-methyl-6-vinyl-cyclohex-3-en-1-
yl]but-2-enyl] (2R)-3,3,3-trifluoro-2-methoxy-2-phenyl-propanoate (20 mg, 0.047 
mmol, 98% yield) as a clear oil. 1H-NMR (400 MHz, CDCl3) δ 7.53-7.45 (m, 2H), 
7.40-7.36 (m, 3H), 5.80 (ddd, J = 17.3, 10.1, 7.6 Hz, 1H), 5.58 (qd, J = 6.8, 1.1 Hz, 
1H), 5.34 (m, 1H), 5.30 (d, J = 9.9 Hz, 1H), 4.99 (td, J = 17.1, 1.4 Hz, 1H), 4.94 (m, 
1H), 3.54 (d, J = 1.0 Hz, 3H), 3.20 (m, 1H), 2.38-2.32 (m, 1H), 2.25-2.16 (m, 1H), 
2.04-1.99 (m, 1H), 1.99-1.89 (m, 4H), 1.77-1.70 (m, 2H), 1.62-1.59 (m, 3H), 1.59-
1.57 (m, 3H), 1.37 (s, 3H), 1.36-1.17 (m, 5H)  
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The S-Mosher ester product was synthesized in an analogous fashion using (S)-(-
)-alpha-methoxy-alpha-trifluoromethyl acetic acid (16 mg, 0.038 mmol, 78%). 1H-
NMR (400 MHz, CDCl3) δ 7.52-7.47 (m, 2H), 7.42-7.35 (m, 3H), 5.75 (ddd, J = 
17.2, 10.4, 7.5 Hz, 1H), 5.65 (qd, J = 6.7, 1.1 Hz, 1H), 5.37-5.31 (m, 2H), 4.89-4.87 
(m, 1H), 4.87-4.82 (m, 1H), 3.53 (d, J = 1.1 Hz, 3H), 2.22-2.12 (m, 1H), 2.12-2.06 
(m, 1H), 2.01-1.91 (m, 2H), 1.89-1.83 (m, 1H), 1.65 (dd, J = 6.8, 0.8 Hz, 3H), 1.57 
(s, 3H), 1.56 (d, J = 9.4 Hz, 3H). 
 
 
 
 
2-[(1R,6S)-6-[(E,1S)-1-[tert-butyl(dimethyl)silyl]oxy-2-methyl-but-2-enyl]-4-
methyl-cyclohex-3-en-1-yl]ethanol (2.49).  
To a solution of (E,1S)-2-methyl-1-[(1S,6R)-3-methyl-6-vinyl-cyclohex-3-en-1-
yl]but-2-en-1-ol (101 mg, 0.49 mmol, 1 eq) in DCM (2.45 mL) at -78 oC was added 
2,6-lutidine (0.29 mL, 2.45 mmol, 2 eq) and tert-butyldimethylsilyl 
trifluoromethylsulfonate (0.21 mL, 0.93 mmol, 1.5 eq). This was then warmed to 
0ºC for 30 minutes, at which point TLC analysis confirmed formation of desired 
product. The reaction was quenched by addition of water (5 mL) and the aqueous 
was extracted with DCM (3x5 mL). The organics were pooled, passed through a 
phase separator, and concentrated in vacuo, then crude product was purified 
using column chromatography (100% Hex) to yield tert-butyl-dimethyl-[(E,1S)-2-
methyl-1-[(1S,6R)-3-methyl-6-vinyl-cyclohex-3-en-1-yl]but-2-enoxy]silane (141 mg, 
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0.44 mmol, 90% yield) as a clear oil. 1H-NMR (400 MHz, CDCl3) δ 5.89 (ddd, J = 
17.3, 10.2, 7.2 Hz, 1H), 5.34-5.26 (m, 2H), 5.02 (d, J = 17.3 Hz, 1H), 4.95 (d, J = 
10.3 Hz, 1H), 3.86 (d, J = 9.6 Hz, 1H), 2.73-2.66 (m, 1H), 2.24-2.14 (m, 1H), 1.96-
1.85 (m, 2H), 1.79-1.70 (m, 1H), 1.58 (d, J = 6.7 Hz, 3H), 1.56-1.51 (m, 6H), 0.87 
(s, 10H), 0.01 (s, 3H), -0.06 (s, 3H) ppm; 13C-NMR (100 MHz, CDCl3) δ 143.7, 
137.7, 132.3, 122.2, 118.9, 112.9, 79.6, 41.2, 35.4, 28.0, 26.3, 26.1, 25.9, 24.2, 
18.4, 13.2, 10.8, -2.7, -4.3, -5.1 ppm; ESI-HRMS: No peaks corresponding to 
desired material were observed by HRMS. [α]D
20 = -14.50 (c 1.03, CHCl3); Rf = 
0.826 (100% Hexanes). 
 
 
 
 
2-[(1R,6S)-6-[(E,1S)-1-[tert-butyl(dimethyl)silyl]oxy-2-methyl-but-2-enyl]-4-
methyl-cyclohex-3-en-1-yl]ethanol (2.50).  
To a solution of tert-butyl-dimethyl-[(E,1S)-2-methyl-1-[(1S,6R)-3-methyl-6-vinyl-
cyclohex-3-en-1-yl]but-2-enoxy]silane (272 mg, 0.85 mmol) in THF (4.24 mL) at 0 
°C was added 9-BBN solution (0.5M in THF, 3.39 mL, 1.7 mmol) dropwise. The 
reaction was warmed to room temperature and stirred for 30 minutes, at which 
point TLC analysis indicated consumption of starting materials. The reaction was 
again cooled to 0 °C and a premixed solution of hydrogen peroxide (30 wt%, 1.11 
mL, 10.87 mmol) and aqueous sodium hydroxide (2M, 1.24 mL, 2.47 mmol) was 
added slowly. The reaction was warmed to room temperature and stirred for 1.5 
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hours, then diluted with brine (10 mL) and extracted with ether (3x15 mL). The 
organics were pooled, dried over magnesium sulfate, filtered, and concentrated in 
vacuo, then crude product was purified using column chromatography (0-20% 
EtOAc/Hex) to yield 2-[(1R,6S)-6-[(E,1S)-1-[tert-butyl(dimethyl)silyl]oxy-2-methyl-
but-2-enyl]-4-methyl-cyclohex-3-en-1-yl]ethanol (234 mg, 0.69 mmol, 81% yield) 
as a clear oil. 1H-NMR (400 MHz, CDCl3) δ 5.30-5.23 (m, 2H), 3.80 (d, J = 10.0 
Hz, 1H), 3.72-3.63 (m, 2H), 2.21-2.12 (m, 2H), 1.94-1.85 (m, 1H), 1.76-1.65 (m, 
2H), 1.65-1.61 (m, 1H), 1.59-1.52 (m, 9H), 1.50 (s, 3H), 0.85 (s, 9H), 0.00 (s, 3H), -
0.07 (s, 3H) ppm; 13C-NMR (100 MHz, CDCl3) δ 137.8, 131.6, 122.3, 118.9, 79.8, 
61.8, 39.9, 37.0, 27.4, 26.5, 24.1, 18.4, 13.1, 10.5, -4.3, -5.1 ppm; ESI-HRMS: m/z 
calc for C20H38O2Si [M+Na]+: 361.2533, found: 361.2539; [α]D
20 = -13.60 (c 0.75, 
CHCl3); Rf = 0.478 (15% Hexanes/EtOAc); 
 
 
 
 
2-[(1R,6S)-6-[(E,1S)-1-[tert-butyl(dimethyl)silyl]oxy-2-methyl-but-2-enyl]-4-
methyl-cyclohex-3-en-1-yl]acetaldehyde (2.16). 
To a solution of 2-[(1R,6S)-6-[(E,1S)-1-[tert-butyl(dimethyl)silyl]oxy-2-methyl-but-2-
enyl]-4-methyl-cyclohex-3-en-1-yl]ethanol (88 mg, 0.26 mmol, 1 eq) in DCM (1.73 
mL) at 0 oC was added sodium bicarbonate (131 mg, 1.56 mmol, 6 eq) and Dess-
Martin Periodinane (165 mg, 0.39 mmol, 1.5 eq). The reaction was warmed to 
room temperature and stirred for 1.5 hours, at which point TLC analysis indicated 
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full consumption of starting materials and formation of a more non-polar spot. The 
reaction was diluted with water (2 mL) and extracted with EtOAc (3x4 mL) and the 
organics were passed through a phase separator and concentrated in vacuo. 
Crude product was purified using Teledyne ISCO Combi-Flash system (solid 
loading, 0-15% EtOAc/Hex) to yield 2-[(1R,6S)-6-[(E,1S)-1-[tert-
butyl(dimethyl)silyl]oxy-2-methyl-but-2-enyl]-4-methyl-cyclohex-3-en-1-
yl]acetaldehyde (64 mg, 0.19 mmol, 73% yield) as a clear oil.  
1H-NMR (400 MHz, CDCl3) δ 9.50 (t, J = 2.0 Hz, 1H), 5.24-5.19 (m, 2H), 3.88 (d, J 
= 9.9 Hz, 1H), 2.85-2.77 (m, 1H), 2.33-2.24 (m, 1H), 2.10 (ddd, J = 16.3, 9.0, 2.2 
Hz, 1H), 1.92 (ddd, J = 16.3, 5.4, 1.7 Hz, 1H), 1.77-1.59 (m, 4H), 1.53-1.49 (m, 
6H), 1.45 (dd, J = 6.6, 0.9 Hz, 4H), 1.00 (s, 9H), 0.09 (s, 3H), 0.02 (s, 3H); 13C-
NMR (100 MHz, CDCl3) δ 200.9, 137.9, 131.5, 122.6, 118.9, 79.9, 48.3, 40.2, 
27.5, 26.2, 25.0, 24.1, 18.5, 13.0, 10.5, -4.2, -5.0 ppm; ESI-HRMS: m/z calc for 
C20H36O2Si [M+Na]+: 359.2377, found: 359.2380; [α]D
20 = -21 (c 1.0, CHCl3), lit: -
31.5; Rf = 0.46 (5% EtOAc/Hex) 
Analytical data are in accordance with the literature. 
 
 
methyl (4R)-4-azido-6-methyl-heptanoate (2.51). 
To a solution of (4R)-4-azido-6-methyl-heptanoic acid (383 mg, 2.07 mmol, 1 eq) in 
a mixture of DCM (5 mL) and Methanol (0.51 mL) at 0 oC was added 
(trimethylsilyl)diazomethane (2M in ether, 2.07 mL, 4.14 mmol, 2 eq) dropwise. The 
reaction was warmed to room temperature and stirred for 30 minutes, then 
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concentrated in vacuo onto silica gel and crude product was purified using Teledyne 
ISCO Combi-Flash system (solid loading, 4G column, 0-20% EtOAc/Hex) to yield 
methyl (4R)-4-azido-6-methyl-heptanoate (369 mg,1.85mmol, 90% yield) as a clear 
oil. 1H-NMR (400 MHz, CDCl3) δ 3.68 (s, 3H), 3.35 (sep, J = 4.8 Hz, 1H), 2.53-2.36 
(m, 2H), 1.94-1.83 (m, 1H), 1.82-1.66 (m, 2H), 1.50 (ddd, J = 14.1, 8.6, 5.9 Hz, 1H), 
1.30 (ddd, J = 13.8, 8.4, 5 Hz, 1H), 0.93 (dd, J = 6.6, 1.0 Hz, 6H); 13C-NMR (100 
MHz, CDCl3) δ 173.6, 60.3, 51.9, 43.5, 30.7, 30.0, 25.2, 23.0, 22.2; ESI-HRMS: m/z 
calc for C9H18NO2 [M+Na]+: 222.1213, found: 222.1212; [α]D
20 = +16.7 (c 0.71, 
CHCl3); Rf = 0.38 (20:1 Hex/EtOAc). 
 
 
 
 
 
(5S)-3-[2-[(1R,6S)-6-[(E,1S)-1-[tert-butyl(dimethyl)silyl]oxy-2-methyl-but-2-
enyl]-4-methyl-cyclohex-3-en-1-yl]-1-hydroxy-ethyl]-5-isobutyl-pyrrolidin-2-
one (2.53). 
To a solution of lithium bis(trimethylsilyl)amide (1M in THF, 121 µL, 0.65 mmol, 1.6 
eq) in THF (4.18 mL) at -78 oC was added a solution of methyl (4R)-4-azido-6-
methyl-heptanoate (121 mg, 0.61mmol, 1.5 eq) in THF (0.84 mL) dropwise. The 
resulting mixture was stirred for 1 hour at this temperature, then a solution of 2-
[(1R,6S)-6-[(E,1S)-1-[tert-butyl(dimethyl)silyl]oxy-2-methyl-but-2-enyl]-4-methyl-
cyclohex-3-en-1-yl]acetaldehyde (136 mg, 0.40 mmol, 1 eq) in THF (1.26 mL) was 
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added dropwise and the reaction was stirred an additional 2 hours at this 
temperature, then quenched by addition of saturated ammonium chloride (5 mL). 
The reaction was allowed to warm to room temperature, then diluted with water 
(5mL) to dissolve remaining salts and extracted with EtOAc (3x15 mL). The 
organics were pooled, dried over magnesium sulfate, filtered, and concentrated in 
vacuo. Crude product was purified using Teledyne ISCO Combi-Flash system 
(solid loading, 4G column, 0-15% EtOAc/Hex) to yield 103 mg of an inseparable 
mixture of desired product and starting ester Claisen condensation product, along 
with 54 mg of desired starting material. ESI-HRMS: m/z calc for C29H53N3O4Si 
[M+Na]+: 558.3698, found: 558.3708; Rf = 0.49, 0.54 (10% EtOAc/Hex). 
 
Glassware was not dried for this reaction. To a solution of crude methyl (4S)-4-
azido-2-[2-[(1R,6S)-6-[(E,1S)-1-[tert-butyl(dimethyl)silyl]oxy-2-methyl-but-2-enyl]-4-
methyl-cyclohex-3-en-1-yl]-1-hydroxy-ethyl]-6-methyl-heptanoate (32 mg, 0.06 
mmol, 1 eq) in a mixture of THF (1.2 mL) and Water (0.40 mL) was added 
triphenylphosphine (47 mg, 0.18 mmol, 3 eq). The reaction was heated to 60 oC 
for 5 hours at which point full conversion to the desired product was observed. 
After cooling to room temperature, the remaining triphenylphosphine was oxidized 
by addition of 3% hydrogen peroxide (3 mL) and diluted with ether (3 mL). The 
layers were separated and the aqueous was extracted with ether (3x5 mL), then 
the organics were passed through a phase separator and concentrated in vacuo. 
Crude product was purified using Teledyne ISCO Combi-Flash system (solid 
loading, 4G column, 0-60% EtOAc/Hex). to yield (5S)-3-[2-[(1R,6S)-6-[(E,1S)-1-
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[tert-butyl(dimethyl)silyl]oxy-2-methyl-but-2-enyl]-4-methyl-cyclohex-3-en-1-yl]-1-
hydroxy-ethyl]-5-isobutyl-pyrrolidin-2-one (26 mg, 0.054 mmol, 43% yield over 2 
steps, 70% brsm from the first reaction) as an oily solid. Characterization was 
performed on the most polar diastereomer. 1H-NMR (400 MHz, CDCl3) δ 5.76 (s, 
1H), 5.30-5.25 (m, 2H), 3.81 (d, J = 6.7 Hz, 1H), 3.70-3.63 (m, 1H), 2.57 (td, J = 
5.7, 1.8 Hz, 1H), 2.44-2.36 (m, 1H), 2.25-2.18 (m, 2H), 1.98-1.93 (m, 1H), 1.91-
1.83 (m, 1H), 1.74-1.70 (m, 2H), 1.63-1.61 (m, 1H), 1.60-1.57 (m, 6H), 1.52-1.50 
(m, 3H), 1.50-1.47 (m, 2H), 1.43-1.39 (m, 1H), 1.39-1.34 (m, 1H), 1.32-1.27 (m, 
2H), 0.92 (dd, J = 4.4, 0.9 Hz, 6H), 0.85 (s, 9H), 0.00 (s, 3H), -0.08 (s, 3H); 13C-
NMR (100 MHz, CDCl3) δ 178.5, 137.8, 131.5, 122.4, 118.9, 79.6, 67.8, 50.8; 
46.4, 45.6, 39.2, 38.4, 27.2, 27.0, 26.6, 26.2, 26.1, 26.1, 25.5, 24.1, 23.2, 23.2, 
22.4, 18.4, 13.2, 10.6, -4.3, -5.1; ESI-HRMS: m/z calc for C22H36NO2 [M+Na]+: 
500.3530, found: 500.3542; [α]D
20 = -14.7 (c 0.57, CHCl3); Rf = 0.30, 0.40, 0.86, 
0.90 (50% EtOAc/Hex).  
 
 
 
 
 
(5S)-3-[2-[(1R,6S)-6-[(E,1S)-1-[tert-butyl(dimethyl)silyl]oxy-2-methyl-but-2-
enyl]-4-methyl-cyclohex-3-en-1-yl]acetyl]-5-isobutyl-pyrrolidin-2-one (2.54). 
Glassware was not dried for this reaction. To a solution of (5S)-3-[2-[(1R,6S)-6-
[(E,1S)-1-[tert-butyl(dimethyl)silyl]oxy-2-methyl-but-2-enyl]-4-methyl-cyclohex-3-
  
180  
en-1-yl]-1-hydroxy-ethyl]-5-isobutyl-pyrrolidin-2-one (40 mg, 0.08 mmol, 1 eq) in 
DMSO (0.80 mL) at room temperature was added 2-iodoxybenzoic acid (94 mg, 
0.33 mmol, 4 eq) and the reaction was stirred for 1.25 hours. The reaction was 
quenched by addition of saturated sodium bicarbonate (5 mL), then diluted with 
EtOAc (5 mL). The layers were separated and the aqueous was extracted with 
EtOAc (3x5 mL) and the organics were passed through a phase separator. Crude 
product was purified using Teledyne ISCO Combi-Flash system (solid loading, 4G 
column, 0-100% EtOAc/Hex) to yield (5S)-3-[2-[(1R,6S)-6-[(E,1S)-1-[tert-
butyl(dimethyl)silyl]oxy-2-methyl-but-2-enyl]-4-methyl-cyclohex-3-en-1-yl]acetyl]-5-
isobutyl-pyrrolidin-2-one (21 mg, 0.044 mmol, 53% yield, 64% brsm) as a white 
solid. Due to the presence of keto-enol tautomers, the product was not further 
characterized. Rf = 0.32 (20% EtOAc/Hex). 
 
 
 
 
 
Pericoannosin A and Epi-Pericoannosin A (2.7, 2.55). 
To a solution of (5S)-3-[2-[(1R,6S)-6-[(E,1S)-1-[tert-butyl(dimethyl)silyl]oxy-2-
methyl-but-2-enyl]-4-methyl-cyclohex-3-en-1-yl]acetyl]-5-isobutyl-pyrrolidin-2-one 
(21 mg, 0.04 mmol) in THF (1.5 mL) at 23 oC in a 10 mL plastic conical tube was 
added triethylamine trihydrofluoride (1.5 mL, 9.2 mmol). The reaction was stirred 
for 60 hours at this temperature, then quenched by addition of saturated sodium 
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bicarbonate (50 mL) and diluted with ether (35 mL). The layers were separated 
and the aqueous was extracted with ether (3x35 mL), then the organics were 
pooled, washed with brine (30mL), dried over magnesium sulfate, filtered, and 
concentrated in vacuo. Crude product was purified using Teledyne ISCO Combi-
Flash system (solid loading, 4G column, 0-35% EtOAc/Hex) to yield 2.7 and 2.54 
(11 mg,0.030 mmol, 69% yield) as a 3:1 mixture of diastereomers, with the desired 
being the major product.  
For NMR analysis, “min” corresponds to minor peaks, “mix” corresponds to signals 
that cannot be distinguished from the two diastereomers. 
1H-NMR (600 MHz, (CD3)2CO) δ 7.16 (bs, 1H), 6.67 (d, J = 2.2, 1H), 5.58 (m, 
0.31H, min), 5.43-5.38 (m, 1H), 5.38-5.36 (m, 0.34H, min), 5.36-5.33 (m, 1H), 
4.03-4.00 (m, 0.16H, min), 3.99 (d, J = 10.1 Hz, 1H), 3.81 (t, J = 9.7 Hz, 0.32H, 
min), 3.70-3.63 (m, 1H), 3.61-3.57 (m, 0.30H, min), 2.90-2.84 (m, 0.33H, min), 
2.56 (t, J  = 9.8 Hz, 1H), 2.39-2.33 (m, 1H), 2.29-2.19 (m, 0.37H, min), 2.17-2.11 
(m, 0.35H, min), 2.01-1.95 (m, 1H), 1.89-1.82 (m, 1H, mix), 1.82-1.79 (m, 1H, mix), 
1.78-1.72 (m, 2H, mix), 1.72-1.66 (m, 1H), 1.67-1.64 (m, 3H), 1.62-1.59 (m, 6H, 
mix), 1.58-1.57 (m, 2H, mix), 1.54-1.47 (m, 2H), 1.39-1.23 (m, 4H, mix), 1.20 (td, J 
= 12.5, 1.8 Hz, 1H), 0.95-0.89 (m, 8H, mix); 13C-NMR (150 MHz, (CD3)2CO) δ  
178.9, 171.9 (min), 159.4 (min), 159.3 (min), 135.4, 134.5 (min), 133.8, 133.3 
(min), 124.8 (min), 124.8 (min), 122.9, 120.9, 120.9 (min), 82.1, 50.8, 50.7 (min), 
49.7, 49.4 (min), 49.1 (min), 48.1 (min), 47.3, 41.0, 40.9 (min), 38.8, 38.5 (min), 
34.3 (min), 34.2 (min), 33.4, 33.3 (min), 33.0, 32.7 (min), 32.7 (min), 31.9 (min), 
31.5 (min), 31.5 (min), 30.9, 30.8, 30.3 (min), 25.6, 25.5 (min), 23.9, 23.8 (min), 
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23.2 (min), 23.2 (min), 23.2, 22.9, 22.8 (min), 13.2 (min), 13.1, 11.3, 10.9 (min), 
10.9 (min). ESI-HRMS: m/z calc for C20H38O2Si [M+Na]+: 384.2509, found: 
361.2514. Rf = 0.28 (33% EtOAc/Hex).  
Analytical data of major peaks correspond with the literature data (Figures 2.5, 2.6 
and Tables 2.2, 2.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
183  
NMR Comparison of Diastereomer Mixture with Authentic Sample 
 
 
 
 
Table 2.2: Comparison of 1H-NMR data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. 
Natural Sample 
δH mult (J in Hz) 
Synthetic 
Sample 
δH mult (J in Hz) 
1   
2 2.56, t (10.2) 2.56, t (9.8) 
3   
4 1.66, dd (12.6, 3.6) 1.72-1.66, mix 
 
1.20, dd (12.6, 
11.2) 
1.20, td (12.5, 
1.8) 
5 1.82, m 1.82-1.79, m 
6 
1.99, m 2.01-1.95, m 
1.61, nd 1.60-1.59, m 
7 5.35, bs 5.36-5.33, m 
8   
9 
1.60, nd 1.60-1.59, m 
1.50, m 1.54-1.47, m 
10 1.37, m 1.39-1.23, m 
11 3.99, d (10.2) 3.99 (d, 10.1) 
12   
13 5.41, m 5.43-5.38, m 
14 1.58, nd 1.58-1.57, m 
15 
2.36, m 2.39-2.33, m 
1.80, m 1.82-1.79, m 
16 3.67, m 3.70-3.63, m 
17 
1.51, m 1.54-1.47, m 
1.31, m 1.39-1.23, m 
18 1.77, m 1.78-1.72, m 
19 0.93, d (7.2) 0.95-0.89, m 
20 0.92, d (7.2) 0.95-0.89, m 
21 1.59, s 1.59-1.58, m 
22 1.60, s 1.60-1.59, m 
NH nd 7.16, bs 
OH 6.67, d, (2.4) 6.67, d, (2.2) 
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Dai, J. et al., authentic sample (600 MHz) 
 
This work, synthetic sample (600 MHz) 
Figure 2.5: Comparison of 1H-NMR data in acetone-d6. 
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Table 2.3: Comparison of 13C-NMR (using ONLY major peaks from synthetic 
work). 
 
   
No. Natural Sample 
Synthetic 
Sample 
1 178.8 178.9 
2 49.7 49.7 
3 97.5 97.5 
4 40.9 41 
5 30.9 30.9 
6 33.4 33.4 
7 120.9 120.9 
8 133.7 133.8 
9 33.0 33.0 
10 38.8 38.8 
11 82.1 82.1 
12 135.4 135.4 
13 122.9 122.9 
14 13.0 13.1 
15 30.8 30.8 
16 50.8 50.8 
17 47.3 47.3 
18 25.6 25.6 
19 22.9 22.9 
20 23.1 23.2 
21 23.9 23.9 
22 11.2 11.3 
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Dai, J. et al., authentic sample (150 MHz) 
 
 
This work, synthetic sample (150 MHz) 
Figure 2.6: Comparison of 13C-NMR data in acetone-d6. 
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Appendix A 
 
Relevant Spectra for Chapter 1 
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Mosher Ester Analysis 
 
  
   Δδ
SR(=δS-δR) 
 S R ppm 
Hz (400 
MHz) 
5 5.3366 5.3016 0.03500 14.000 
6 1.5599 1.5552 0.00465 1.86 
4 1.6418 1.6516 -0.00985 -3.94 
1 5.7457 5.8070 -0.06130 -24.52 
2 4.8436 4.9411 -0.09753 -39.01 
3 4.8776 4.9883 -0.11068 -44.27 
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